US20100227767A1 - Stochastic confinement to detect, manipulate, and utilize molecules and organisms - Google Patents
Stochastic confinement to detect, manipulate, and utilize molecules and organisms Download PDFInfo
- Publication number
- US20100227767A1 US20100227767A1 US12/670,739 US67073908A US2010227767A1 US 20100227767 A1 US20100227767 A1 US 20100227767A1 US 67073908 A US67073908 A US 67073908A US 2010227767 A1 US2010227767 A1 US 2010227767A1
- Authority
- US
- United States
- Prior art keywords
- bacteria
- plugs
- plug
- sample
- amplification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 claims abstract description 345
- 241000894006 Bacteria Species 0.000 claims abstract description 303
- 230000003115 biocidal effect Effects 0.000 claims description 90
- 239000000126 substance Substances 0.000 claims description 87
- 230000001580 bacterial effect Effects 0.000 claims description 79
- 239000012530 fluid Substances 0.000 claims description 63
- 230000001018 virulence Effects 0.000 claims description 60
- 230000012010 growth Effects 0.000 claims description 46
- 238000012216 screening Methods 0.000 claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 241000894007 species Species 0.000 claims description 28
- 238000003752 polymerase chain reaction Methods 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 20
- 239000001301 oxygen Substances 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 239000002689 soil Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 230000002934 lysing effect Effects 0.000 claims description 3
- 230000008093 supporting effect Effects 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims 1
- 238000006911 enzymatic reaction Methods 0.000 claims 1
- 230000003321 amplification Effects 0.000 abstract description 166
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 166
- 238000001514 detection method Methods 0.000 abstract description 140
- 230000000694 effects Effects 0.000 abstract description 42
- 238000005516 engineering process Methods 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 description 216
- 239000002245 particle Substances 0.000 description 167
- 239000000523 sample Substances 0.000 description 120
- 230000008569 process Effects 0.000 description 98
- 102000004190 Enzymes Human genes 0.000 description 89
- 108090000790 Enzymes Proteins 0.000 description 89
- 229940088598 enzyme Drugs 0.000 description 89
- 239000011324 bead Substances 0.000 description 80
- 230000007246 mechanism Effects 0.000 description 77
- 238000006243 chemical reaction Methods 0.000 description 72
- 210000004369 blood Anatomy 0.000 description 59
- 239000008280 blood Substances 0.000 description 59
- 238000012360 testing method Methods 0.000 description 50
- 239000003242 anti bacterial agent Substances 0.000 description 47
- 230000006870 function Effects 0.000 description 47
- 230000003213 activating effect Effects 0.000 description 46
- 229940088710 antibiotic agent Drugs 0.000 description 40
- 239000000463 material Substances 0.000 description 40
- 238000003556 assay Methods 0.000 description 39
- 238000004519 manufacturing process Methods 0.000 description 39
- 239000003112 inhibitor Substances 0.000 description 37
- 108020004414 DNA Proteins 0.000 description 35
- 230000002401 inhibitory effect Effects 0.000 description 35
- 230000008859 change Effects 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 32
- 239000003814 drug Substances 0.000 description 31
- 239000000243 solution Substances 0.000 description 31
- 108090000190 Thrombin Proteins 0.000 description 30
- 239000000047 product Substances 0.000 description 30
- 229960004072 thrombin Drugs 0.000 description 30
- 229940079593 drug Drugs 0.000 description 29
- 208000015181 infectious disease Diseases 0.000 description 29
- 244000005700 microbiome Species 0.000 description 28
- 230000001605 fetal effect Effects 0.000 description 27
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 24
- 230000004913 activation Effects 0.000 description 24
- 239000012491 analyte Substances 0.000 description 24
- 230000027455 binding Effects 0.000 description 24
- 229960002682 cefoxitin Drugs 0.000 description 24
- 108010071241 Factor XIIa Proteins 0.000 description 23
- 108010059993 Vancomycin Proteins 0.000 description 23
- 230000004044 response Effects 0.000 description 23
- 229960003165 vancomycin Drugs 0.000 description 23
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 23
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 23
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 22
- 230000005291 magnetic effect Effects 0.000 description 21
- 239000000758 substrate Substances 0.000 description 21
- 239000007850 fluorescent dye Substances 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 230000001965 increasing effect Effects 0.000 description 19
- 108060005987 Kallikrein Proteins 0.000 description 18
- 102000001399 Kallikrein Human genes 0.000 description 18
- 230000008901 benefit Effects 0.000 description 18
- 239000010410 layer Substances 0.000 description 18
- 239000003153 chemical reaction reagent Substances 0.000 description 17
- 238000003776 cleavage reaction Methods 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 229960000723 ampicillin Drugs 0.000 description 16
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 15
- 241000700605 Viruses Species 0.000 description 15
- 238000011534 incubation Methods 0.000 description 15
- 210000002381 plasma Anatomy 0.000 description 15
- 230000007017 scission Effects 0.000 description 15
- 230000035945 sensitivity Effects 0.000 description 15
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 14
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 14
- 230000023555 blood coagulation Effects 0.000 description 14
- 238000012512 characterization method Methods 0.000 description 14
- 230000002068 genetic effect Effects 0.000 description 14
- -1 homo serine lactones Chemical class 0.000 description 14
- 230000002452 interceptive effect Effects 0.000 description 14
- 230000000813 microbial effect Effects 0.000 description 14
- 230000006399 behavior Effects 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 239000003642 reactive oxygen metabolite Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 208000035143 Bacterial infection Diseases 0.000 description 12
- 108010080865 Factor XII Proteins 0.000 description 12
- 102000000429 Factor XII Human genes 0.000 description 12
- 238000013459 approach Methods 0.000 description 12
- 208000022362 bacterial infectious disease Diseases 0.000 description 12
- 238000009640 blood culture Methods 0.000 description 12
- 230000007423 decrease Effects 0.000 description 12
- 239000002184 metal Substances 0.000 description 12
- 229910052751 metal Inorganic materials 0.000 description 12
- 150000003384 small molecules Chemical class 0.000 description 12
- 101710194146 Ecotin Proteins 0.000 description 11
- 239000004809 Teflon Substances 0.000 description 11
- 229920006362 Teflon® Polymers 0.000 description 11
- 229960003276 erythromycin Drugs 0.000 description 11
- 230000008774 maternal effect Effects 0.000 description 11
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 11
- 230000035899 viability Effects 0.000 description 11
- 108010080805 Factor XIa Proteins 0.000 description 10
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 10
- 102000035195 Peptidases Human genes 0.000 description 10
- 108091005804 Peptidases Proteins 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000012258 culturing Methods 0.000 description 10
- 238000011990 functional testing Methods 0.000 description 10
- 229960003376 levofloxacin Drugs 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 238000012544 monitoring process Methods 0.000 description 10
- 230000003287 optical effect Effects 0.000 description 10
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 10
- 229960001019 oxacillin Drugs 0.000 description 10
- 244000052769 pathogen Species 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 230000007923 virulence factor Effects 0.000 description 10
- 239000000304 virulence factor Substances 0.000 description 10
- 102000004039 Caspase-9 Human genes 0.000 description 9
- 108090000566 Caspase-9 Proteins 0.000 description 9
- 102000010911 Enzyme Precursors Human genes 0.000 description 9
- 108010062466 Enzyme Precursors Proteins 0.000 description 9
- 108010094028 Prothrombin Proteins 0.000 description 9
- 102100027378 Prothrombin Human genes 0.000 description 9
- 230000015271 coagulation Effects 0.000 description 9
- 238000005345 coagulation Methods 0.000 description 9
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 229940039716 prothrombin Drugs 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 8
- 208000026350 Inborn Genetic disease Diseases 0.000 description 8
- 206010040047 Sepsis Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000016361 genetic disease Diseases 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 238000011533 pre-incubation Methods 0.000 description 8
- 239000013049 sediment Substances 0.000 description 8
- 239000003053 toxin Substances 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 229920001817 Agar Polymers 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 150000001768 cations Chemical class 0.000 description 7
- 238000000354 decomposition reaction Methods 0.000 description 7
- 239000004205 dimethyl polysiloxane Substances 0.000 description 7
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000007789 gas Substances 0.000 description 7
- 230000023597 hemostasis Effects 0.000 description 7
- 229940006607 hirudin Drugs 0.000 description 7
- 230000000977 initiatory effect Effects 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 7
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 7
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 7
- 239000004810 polytetrafluoroethylene Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 230000018612 quorum sensing Effects 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- 102000003952 Caspase 3 Human genes 0.000 description 6
- 108090000397 Caspase 3 Proteins 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 108010074860 Factor Xa Proteins 0.000 description 6
- 241000233866 Fungi Species 0.000 description 6
- 102000007625 Hirudins Human genes 0.000 description 6
- 108010007267 Hirudins Proteins 0.000 description 6
- 239000012480 LAL reagent Substances 0.000 description 6
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 6
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 239000012190 activator Substances 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 235000010419 agar Nutrition 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000013000 chemical inhibitor Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 6
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical group C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000009545 invasion Effects 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 238000004088 simulation Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241000193738 Bacillus anthracis Species 0.000 description 5
- 208000031729 Bacteremia Diseases 0.000 description 5
- 206010053567 Coagulopathies Diseases 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 108010074864 Factor XI Proteins 0.000 description 5
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 5
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 5
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000004520 agglutination Effects 0.000 description 5
- 239000003570 air Substances 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 238000003491 array Methods 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000035602 clotting Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 230000007613 environmental effect Effects 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 230000005298 paramagnetic effect Effects 0.000 description 5
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- BZRWWAYVITZYRZ-UHFFFAOYSA-N 3-[4-[(5-bromopyridin-2-yl)diazenyl]-3-hydroxy-N-propylanilino]propane-1-sulfonic acid Chemical compound OC1=CC(N(CCCS(O)(=O)=O)CCC)=CC=C1N=NC1=CC=C(Br)C=N1 BZRWWAYVITZYRZ-UHFFFAOYSA-N 0.000 description 4
- 108010039627 Aprotinin Proteins 0.000 description 4
- 108010074105 Factor Va Proteins 0.000 description 4
- 108010014173 Factor X Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 4
- 241000244206 Nematoda Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 108090000113 Plasma Kallikrein Proteins 0.000 description 4
- 241000187747 Streptomyces Species 0.000 description 4
- 229960004405 aprotinin Drugs 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 229910001919 chlorite Inorganic materials 0.000 description 4
- 229910052619 chlorite group Inorganic materials 0.000 description 4
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 4
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical group [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 229960000633 dextran sulfate Drugs 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000003100 immobilizing effect Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical group C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
- 229940126181 ion channel inhibitor Drugs 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 229960003085 meticillin Drugs 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000006053 organic reaction Methods 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000009897 systematic effect Effects 0.000 description 4
- 201000008827 tuberculosis Diseases 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- 206010000234 Abortion spontaneous Diseases 0.000 description 3
- 108090000935 Antithrombin III Proteins 0.000 description 3
- 241000203069 Archaea Species 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108030002440 Catalase peroxidases Proteins 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 3
- 108010065152 Coagulase Proteins 0.000 description 3
- 241000588722 Escherichia Species 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 108010014172 Factor V Proteins 0.000 description 3
- 108010061932 Factor VIIIa Proteins 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 description 3
- 108700016172 Glutathione peroxidases Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 101150005343 INHA gene Proteins 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- ZBWVMVMSUCUFMR-UHFFFAOYSA-L O=[Cl+2]=O.[O-]S(=O)(=O)SSS([O-])(=O)=O Chemical compound O=[Cl+2]=O.[O-]S(=O)(=O)SSS([O-])(=O)=O ZBWVMVMSUCUFMR-UHFFFAOYSA-L 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 206010034133 Pathogen resistance Diseases 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 102000002262 Thromboplastin Human genes 0.000 description 3
- 208000004006 Tick-borne encephalitis Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000003592 biomimetic effect Effects 0.000 description 3
- 239000003114 blood coagulation factor Substances 0.000 description 3
- 239000008364 bulk solution Substances 0.000 description 3
- 229940105657 catalase Drugs 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- ZVWJBRCEGQIZJJ-UHFFFAOYSA-N chlorous acid sulfurothioic O-acid Chemical compound OCl=O.OS(O)(=O)=S ZVWJBRCEGQIZJJ-UHFFFAOYSA-N 0.000 description 3
- 238000004320 controlled atmosphere Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000000432 density-gradient centrifugation Methods 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 230000014670 detection of bacterium Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000007877 drug screening Methods 0.000 description 3
- 239000003344 environmental pollutant Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000002532 enzyme inhibitor Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 3
- 239000013505 freshwater Substances 0.000 description 3
- 238000002825 functional assay Methods 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 208000015994 miscarriage Diseases 0.000 description 3
- 239000002070 nanowire Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 230000003534 oscillatory effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000003793 prenatal diagnosis Methods 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000008261 resistance mechanism Effects 0.000 description 3
- 239000011435 rock Substances 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 208000000995 spontaneous abortion Diseases 0.000 description 3
- 210000004215 spore Anatomy 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- BVIYGXUQVXBHQS-IUYQGCFVSA-N (2R,4S)-2-methyltetrahydrofuran-2,3,3,4-tetrol Chemical compound C[C@@]1(O)OC[C@H](O)C1(O)O BVIYGXUQVXBHQS-IUYQGCFVSA-N 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 2
- 208000003829 American Hemorrhagic Fever Diseases 0.000 description 2
- 102100022977 Antithrombin-III Human genes 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000193752 Bacillus circulans Species 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 241000722910 Burkholderia mallei Species 0.000 description 2
- 241001136175 Burkholderia pseudomallei Species 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000193155 Clostridium botulinum Species 0.000 description 2
- 241000223205 Coccidioides immitis Species 0.000 description 2
- 241001522757 Coccidioides posadasii Species 0.000 description 2
- 108010048049 Factor IXa Proteins 0.000 description 2
- 108010001103 Glutathione oxidase Proteins 0.000 description 2
- 241000893570 Hendra henipavirus Species 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 241000239205 Merostomata Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- YPIFWBVSZYZCCY-UHFFFAOYSA-N OCl=O.I Chemical compound OCl=O.I YPIFWBVSZYZCCY-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000736032 Sabia <angiosperm> Species 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000006851 antioxidant defense Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- OFZCIYFFPZCNJE-UHFFFAOYSA-N carisoprodol Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC(C)C OFZCIYFFPZCNJE-UHFFFAOYSA-N 0.000 description 2
- 238000010868 cell confinement Methods 0.000 description 2
- 230000010267 cellular communication Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000006249 magnetic particle Substances 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000003936 merozoite Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002923 metal particle Substances 0.000 description 2
- 229910052750 molybdenum Inorganic materials 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000006174 pH buffer Substances 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002810 primary assay Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000006479 redox reaction Methods 0.000 description 2
- 238000005067 remediation Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 238000003239 susceptibility assay Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000006150 trypticase soy agar Substances 0.000 description 2
- 231100000747 viability assay Toxicity 0.000 description 2
- 238000003026 viability measurement method Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 150000003952 β-lactams Chemical class 0.000 description 2
- URNKXHHGSVKUKV-HJOGWXRNSA-N (2s)-n-[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-2-[(4-methyl-2-oxochromen-7-yl)amino]pentanoyl]amino]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide Chemical compound C([C@@H](C(=O)NC(=O)[C@H](CCCN=C(N)N)NC1=CC=2OC(=O)C=C(C=2C=C1)C)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 URNKXHHGSVKUKV-HJOGWXRNSA-N 0.000 description 1
- UYYRDZGZGNYVBA-VPXCCNNISA-N (2s,3r,4s,5r,6r)-2-[2-chloro-4-[3-(3-chloro-4-hydroxyphenyl)-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(Cl)C(O)=CC=2)C=C1Cl UYYRDZGZGNYVBA-VPXCCNNISA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 101150091518 APAF1 gene Proteins 0.000 description 1
- 241000224422 Acanthamoeba Species 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000607528 Aeromonas hydrophila Species 0.000 description 1
- 241000120516 African horse sickness virus Species 0.000 description 1
- 241000701386 African swine fever virus Species 0.000 description 1
- 241001222053 Akabane virus Species 0.000 description 1
- 241001492267 Alcelaphine gammaherpesvirus 1 Species 0.000 description 1
- 241000004176 Alphacoronavirus Species 0.000 description 1
- 241000544678 Anisakis sp. Species 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 241000244185 Ascaris lumbricoides Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000711404 Avian avulavirus 1 Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241001323415 Bhanja virus Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 241000120506 Bluetongue virus Species 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 241000589567 Brucella abortus Species 0.000 description 1
- 241001148106 Brucella melitensis Species 0.000 description 1
- 241001148111 Brucella suis Species 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- 241001137864 Camelpox virus Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 description 1
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 description 1
- JFPVXVDWJQMJEE-QMTHXVAHSA-N Cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)C(=NOC)C1=CC=CO1 JFPVXVDWJQMJEE-QMTHXVAHSA-N 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 241001529572 Chaceon affinis Species 0.000 description 1
- 241001502567 Chikungunya virus Species 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241000710777 Classical swine fever virus Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000606678 Coxiella burnetii Species 0.000 description 1
- 241000150230 Crimean-Congo hemorrhagic fever orthonairovirus Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000223936 Cryptosporidium parvum Species 0.000 description 1
- 241000016605 Cyclospora cayetanensis Species 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- 241001137876 Diphyllobothrium Species 0.000 description 1
- JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 description 1
- 241000149824 Dugbe orthonairovirus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101150099213 ERN2 gene Proteins 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241000605314 Ehrlichia Species 0.000 description 1
- 241000605310 Ehrlichia chaffeensis Species 0.000 description 1
- 241000606675 Ehrlichia ruminantium Species 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000690783 Eustrongylides Species 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- YPZRHBJKEMOYQH-UYBVJOGSSA-N FADH2 Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C(NC(=O)NC2=O)=C2NC2=C1C=C(C)C(C)=C2 YPZRHBJKEMOYQH-UYBVJOGSSA-N 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 241000190598 Flexal mammarenavirus Species 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000713109 Germiston virus Species 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 241001112691 Goatpox virus Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 101000591286 Homo sapiens Myocardin-related transcription factor A Proteins 0.000 description 1
- 206010020429 Human ehrlichiosis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241000531220 Issyk-Kul virus Species 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000178324 Koutango virus Species 0.000 description 1
- 208000003140 Kyasanur forest disease Diseases 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 101710173438 Late L2 mu core protein Proteins 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 241000710769 Louping ill virus Species 0.000 description 1
- 241000609846 Lumpy skin disease virus Species 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000608292 Mayaro virus Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001643857 Menangle virus Species 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241000700627 Monkeypox virus Species 0.000 description 1
- 241000868135 Mucambo virus Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 241000710908 Murray Valley encephalitis virus Species 0.000 description 1
- 201000005805 Murray valley encephalitis Diseases 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000204025 Mycoplasma capricolum Species 0.000 description 1
- 241000202936 Mycoplasma mycoides Species 0.000 description 1
- 102100034099 Myocardin-related transcription factor A Human genes 0.000 description 1
- 241000863434 Myxococcales Species 0.000 description 1
- MNLRQHMNZILYPY-MDMHTWEWSA-N N-acetyl-alpha-D-muramic acid Chemical compound OC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@@H]1NC(C)=O MNLRQHMNZILYPY-MDMHTWEWSA-N 0.000 description 1
- CDOJPCSDOXYJJF-KSKNGZLJSA-N N-acetyl-beta-D-glucosaminyl-(1->4)-N-acetyl-beta-D-glucosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CDOJPCSDOXYJJF-KSKNGZLJSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241001501625 Nanophyetus Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 208000011448 Omsk hemorrhagic fever Diseases 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000283283 Orcinus orca Species 0.000 description 1
- 241000250439 Oropouche virus Species 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 241000120522 Orungo virus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000012807 PCR reagent Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 241000760727 Peronosclerospora philippinensis Species 0.000 description 1
- 241000682645 Phakopsora pachyrhizi Species 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 240000009188 Phyllostachys vivax Species 0.000 description 1
- 241000711965 Piry virus Species 0.000 description 1
- 241000751100 Pityopus Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 102000003827 Plasma Kallikrein Human genes 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
- 241000158500 Platanus racemosa Species 0.000 description 1
- 241000606999 Plesiomonas shigelloides Species 0.000 description 1
- 241000723784 Plum pox virus Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000710884 Powassan virus Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000588768 Providencia Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 241000589771 Ralstonia solanacearum Species 0.000 description 1
- 241000606697 Rickettsia prowazekii Species 0.000 description 1
- 241000606695 Rickettsia rickettsii Species 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- 241000711897 Rinderpest morbillivirus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 101100177159 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HAC1 gene Proteins 0.000 description 1
- 101000775071 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Peroxiredoxin AHP1 Proteins 0.000 description 1
- 241000831652 Salinivibrio sharmensis Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 241000710961 Semliki Forest virus Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000700665 Sheeppox virus Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 239000000589 Siderophore Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241001428894 Small ruminant morbillivirus Species 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000907333 Spondweni virus Species 0.000 description 1
- 241001149963 Sporothrix schenckii Species 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 241000709710 Swine vesicular disease virus Species 0.000 description 1
- 241000827175 Synchytrium endobioticum Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 241000243774 Trichinella Species 0.000 description 1
- 241001489145 Trichuris trichiura Species 0.000 description 1
- 108010069584 Type III Secretion Systems Proteins 0.000 description 1
- 208000034892 Typhoid carrier Diseases 0.000 description 1
- 241000726423 Variola major virus Species 0.000 description 1
- 241000519618 Variola minor virus Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000602423 Vibrio cholerae O1 Species 0.000 description 1
- 241000936820 Vibrio cholerae non-O1 Species 0.000 description 1
- 206010047400 Vibrio infections Diseases 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 241000607265 Vibrio vulnificus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000589652 Xanthomonas oryzae Species 0.000 description 1
- 241000204362 Xylella fastidiosa Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000005844 autocatalytic reaction Methods 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 210000004666 bacterial spore Anatomy 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000032770 biofilm formation Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 1
- 229940056450 brucella abortus Drugs 0.000 description 1
- 229940038698 brucella melitensis Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229940074375 burkholderia mallei Drugs 0.000 description 1
- 108090001015 cancer procoagulant Proteins 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960003012 cefamandole Drugs 0.000 description 1
- OLVCFLKTBJRLHI-AXAPSJFSSA-N cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 description 1
- 229960004350 cefapirin Drugs 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960004489 cefonicid Drugs 0.000 description 1
- DYAIAHUQIPBDIP-AXAPSJFSSA-N cefonicid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS(O)(=O)=O DYAIAHUQIPBDIP-AXAPSJFSSA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004292 ceforanide Drugs 0.000 description 1
- SLAYUXIURFNXPG-CRAIPNDOSA-N ceforanide Chemical compound NCC1=CC=CC=C1CC(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)CC(O)=O)CS[C@@H]21 SLAYUXIURFNXPG-CRAIPNDOSA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960001242 cefotiam Drugs 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- SYLKGLMBLAAGSC-QLVMHMETSA-N cefsulodin Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S(O)(=O)=O)[C@H]2SC1 SYLKGLMBLAAGSC-QLVMHMETSA-N 0.000 description 1
- 229960003202 cefsulodin Drugs 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 238000012824 chemical production Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002361 compost Substances 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000005292 diamagnetic effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011066 ex-situ storage Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940118764 francisella tularensis Drugs 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 229940085435 giardia lamblia Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229960000433 latamoxef Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 101150008979 mecA gene Proteins 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 229940087515 mefoxin Drugs 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 230000003547 miosis Effects 0.000 description 1
- 239000003604 miotic agent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000021232 nutrient availability Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 230000010399 physical interaction Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 210000003281 pleural cavity Anatomy 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108010028105 prolyl-phenylalanyl-arginine-4-methylcoumaryl-7-amide Proteins 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229960003351 prussian blue Drugs 0.000 description 1
- 239000013225 prussian blue Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000007845 reactive nitrogen species Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000002824 redox indicator Substances 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000017702 response to host Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940046939 rickettsia prowazekii Drugs 0.000 description 1
- 229940075118 rickettsia rickettsii Drugs 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000002174 soft lithography Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000003046 sporozoite Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 201000000627 variola minor Diseases 0.000 description 1
- 208000014016 variola minor infection Diseases 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
- C12M35/08—Chemical, biochemical or biological means, e.g. plasma jet, co-culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
- C12M1/14—Apparatus for enzymology or microbiology with means providing thin layers or with multi-level trays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/34—Internal compartments or partitions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/01—Drops
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P39/00—Processes involving microorganisms of different genera in the same process, simultaneously
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
Definitions
- the broth in the blood culture bottle is the first step in creating an environment in which bacteria will grow. It contains all the nutrients that bacteria need to grow. If the physician expects anaerobic bacteria to grow, oxygen will be kept out of the blood culture bottle; if aerobes are expected, oxygen will be allowed in the bottle.
- the bottles are placed in an incubator and kept at body temperature. They are watched daily for signs of growth, including cloudiness or a color change in the broth, gas bubbles, or clumps of bacteria.
- the laboratory does a gram stain and a subculture.
- a drop of blood is removed from the bottle and placed on a microscope slide. The blood is allowed to dry and then is stained with purple and red stains and examined under the microscope. If bacteria are seen, the color of stain they picked up (purple or red), their shape (such as round or rectangular), and their size provide valuable clues as to what type of microorganism they are and what antibiotics might work best.
- To do the subculture a drop of blood is placed on a culture plate, spread over the surface, and placed in an incubator.
- the laboratory looks for bacteria by doing gram stains and subcultures. These steps are repeated daily for the first several days and periodically after that.
- An early report known as a preliminary report, is usually available after one day. This report will tell if any bacteria have been found yet, and if so, the results of the gram stain.
- the next preliminary report may include a description of the bacteria growing on the subculture.
- the laboratory notifies the physician immediately when an organism is found and as soon as sensitivity tests are complete. Sensitivity tests may be complete before the bacteria are completely identified.
- the final report may not be available for five to seven days. If bacteria are found, the report will include its complete identification and a list of the antibiotics to which the bacteria is sensitive.
- What is needed is a faster and better method of detecting organisms, including improving the accuracy and decreasing the man-hours associated with standard blood culturing, and shortening the time necessary to detect and identify an effective antibiotic regimen to treat bacterial infections.
- a method of detecting an organism comprises flowing at least two plugs in a carrier fluid through a microchannel; introducing a sample optionally comprising the organism into the first and second plugs; and analyzing the at least two plugs for the detectable signal.
- Each plug comprises a plug fluid that is substantially immiscible with the carrier fluid and the organism produces a detectable signal.
- a method of detecting bacteria in a patient comprises flowing at least two plugs in a carrier fluid through a microchannel; introducing a patient sample optionally comprising bacteria into the at least two plugs; and analyzing the at least two plugs for the detectable signal.
- Each plug comprises a plug fluid that is substantially immiscible with the carrier fluid and the bacteria produce a detectable signal.
- a method of detecting bacteria comprises flowing at least two plugs in a carrier fluid through a microchannel; introducing a sample optionally comprising bacteria into the first and second plugs, wherein the bacteria produce a detectable signal; and analyzing the plugs for the detectable signal.
- Each plug comprises a plug fluid substantially immiscible with the carrier fluid.
- the first plug comprises a means for detecting a first species of bacteria and the second plug comprises a means for detecting a second species of bacteria different from the first species of bacteria.
- a method of detecting bacteria comprising flowing at least two plugs in a carrier fluid through a microchannel; introducing a sample optionally comprising bacteria into the first and second plugs; and detecting the presence of bacteria bound beads.
- Each plug comprises a plug fluid substantially immiscible with the carrier fluid.
- the first plug comprises a first antibody bound bead, the first antibody bound bead comprising a first bead and a first antibody that binds to a first bacteria.
- the second plug comprises a second antibody bound bead, the second antibody bound bead comprising a second bead and a second antibody that binds to a second bacteria different than the first bacteria.
- the bacteria bind to the antibody bound beads to form bacteria bound beads.
- a method of screening for antibiotic activity comprises flowing at least two plugs in a carrier fluid through a microchannel.
- Each plug comprises a plug fluid substantially immiscible with the carrier fluid and an antibody bound bead, the antibody bound bead comprising a bead and an antibody that binds bacteria; introducing a sample which comprises bacteria into the first and second plugs; and detecting the presence of either antibody bound beads or bacteria bound beads.
- the first plug comprises a first antibiotic candidate and the second plug comprises a second antibiotic candidate.
- the bacteria bind to the antibody bound beads to form bacteria bound beads.
- a method of screening for antibiotic activity comprising flowing at least two plugs in a carrier fluid through a microchannel; introducing a sample which comprises bacteria into the first and second plugs; detecting the presence of either antibody bound beads or bacteria bound beads.
- Each plug comprises a plug fluid substantially immiscible with the carrier fluid and an antibody bound bead, the antibody bound bead comprising a bead and an antibody that binds bacteria.
- the first plug comprises a first antibiotic candidate and the second plug comprises a second antibiotic candidate.
- the bacteria bind to the antibody bound beads to form bacteria bound beads.
- a method of screening for antibiotic activity comprising flowing at least two plugs in a carrier fluid through a microchannel; introducing a sample which comprises bacteria into the first and second plugs; and detecting the presence of bacterial growth.
- Each plug comprises a plug fluid immiscible with the carrier fluid and media capable of supporting bacterial growth.
- the first plug comprises a first antibiotic candidate and the second plug comprises a second antibiotic candidate.
- a method of detecting molecules comprising providing a first set of molecules that constitute an autocatalytic loop, capable of amplification of one of the components; providing a second set of molecules that modulate the autocatalytic loop when the autocatalytic loop reacts with the target molecules; and analyzing for the presence of the target molecules.
- FIG. 1 illustrates a method of detecting bacteria using stochastic confinement of bacteria into plugs reduces detection time.
- FIG. 2 illustrates a method for screening many antibiotics against a bacterial sample using a combination stochastic confinement with microfluidic hybrid and/or cartridge methods.
- (a) A schematic drawing illustrating the formation of plugs of bacteria, viability indicator, and antibiotic from a preformed array of plugs of different antibiotics.
- (b) An illustrative graph of fluorescence intensity of the control plugs with no antibiotic (+, blank1, positive control) and vancomycin (A, VCM, negative control).
- An illustrative bar graph shows the results of the antibiotic screen against the Methicillin Resistant S. aureus (MRSA), indicating that this strain of MRSA was resistant to four antibiotics, but sensitive to two.
- MRSA Methicillin Resistant S. aureus
- An illustrative chart shows the agreement between the susceptibility profiles (S, sensitive and R, resistant) of MRSA determined by the plug-based microfluidic screen and the control susceptibility screen using Mueller Hinton plates.
- FIG. 3 illustrates detecting active and inactive particles.
- FIG. 4 illustrates stochastic confinement of particles by (a) encapsulation in droplets, (b) placement in pores of a membrane, and (c) confinement on materials with restricted transport.
- FIG. 5 is an illustrative method for analyte detection.
- particles stochastically confined into plugs which undergo two-stage amplification on chip to give a macroscale readout (b) particles confined on membranes which translate their activity to a signal seen by the naked eye on an upper layer; (c) particles trapped in a gel with amplification cascades incorporated localize the output signal over the active particle.
- FIG. 6 is an illustrative method used to identify the minimal inhibitory concentration (MIC) of cefoxitin (CFX) for Methicillin Sensitive S. aureus (MSSA) and Methacillin Resistant S. aureus (MRSA).
- CFX cefoxitin
- MSSA Methicillin Sensitive S. aureus
- MRSA Methacillin Resistant S. aureus
- FIG. 6 is an illustrative method used to identify the minimal inhibitory concentration (MIC) of cefoxitin (CFX) for Methicillin Sensitive S. aureus (MSSA) and Methacillin Resistant S. aureus (MRSA).
- MSSA Methicillin Sensitive S. aureus
- MRSA Methacillin Resistant S. aureus
- FIG. 7 is an illustrative combination of stochastic confinement with the plug-based microfluidic assay used to determine susceptibility of bacteria to an antibiotic in a natural matrix, blood plasma.
- (a) a schematic drawing illustrating formation of plugs of bacteria, viability indicator, antibiotic, and plasma/LB mixture;
- (b and c) Images and linescans of four representative plugs made from a 1:1 blood plasma/LB sample inoculated with MRSA without (left) and with (right) the addition of AMP;
- (d and e) Images and linescans of four representative plugs made from a 1:1 blood plasma/LB sample inoculated with MSSA without (left) and with (right) the addition of AMP
- FIG. 8 is an illustrative schematic description of a test strip with amplification system.
- FIG. 9 is an illustrative schematic drawing of a test strip with both detection region and control “timer” region.
- FIG. 10 is an illustrative chemical amplification process involving a one-step positive feedback.
- FIG. 11 is an illustrative chemical amplification process involving a two-step positive feedback.
- FIG. 12 is an illustrative chemical amplification process with a cascade of two positive feedback loops.
- FIG. 13 is an illustrative two-step amplification cascade involving blood coagulation enzymes.
- FIG. 14 is a graph of time to get response versus amount of input obtained by simulation.
- FIG. 15 is a graph of blood clotting time varied with size of patch of tissue factor.
- FIG. 16 is an illustrative example of combining amplification cascades with stochastic confinement.
- FIG. 17 is an illustrative example of selective detection of particles by using stochastic confinement.
- organism refers to any organisms or microorganism, including bacteria, yeast, fungi, viruses, protists (protozoan, micro-algae), archaebacteria, and eukaryotes.
- organism refers to living matter and viruses comprising nucleic acid that can be detected and identified by the methods of the invention.
- Organisms include, but are not limited to, bacteria, archaea, prokaryotes, eukaryotes, viruses, protozoa, mycoplasma, fungi, and nematodes. Different organisms can be different strains, different varieties, different species, different genera, different families, different orders, different classes, different phyla, and/or different kingdoms.
- Organisms may be isolated from environmental sources including soil extracts, marine sediments, freshwater sediments, hot springs, ice shelves, extraterrestrial samples, crevices of rocks, clouds, attached to particulates from aqueous environments, involved in symbiotic relationships with multicellular organisms. Examples of such organisms include, but are not limited to Streptomyces species and uncharacterized/unknown species from natural sources.
- Organisms included genetically engineered organisms.
- organisms include bacterial pathogens such as: Aeromonas hydrophila and other species (spp.); Bacillus anthracis; Bacillus cereus ; Botulinum neurotoxin producing species of Clostridium; Brucella abortus; Brucella melitensis; Brucella suis; Burkholderia mallei (formally Pseudomonas mallei ); Burkholderia pseudomallei (formerly Pseudomonas pseudomallei ); Campylobacter jejuni; Chlamydia psittaci; Clostridium botulinum; Clostridium botulinum; Clostridium perfringens; Coccidioides immitis; Coccidioides posadasii; Cowdria ruminantium (Heartwater); Coxiella burnetii ; Enterovirulent Escherichia coli group (EEC Group) such as Escherichia coli -enterotoxigenic (ETEC)
- viruses such as: African horse sickness virus; African swine fever virus; Akabane virus; Avian influenza virus (highly pathogenic); Bhanja virus; Blue tongue virus (Exotic); Camel pox virus; Cercopithecine herpesvirus 1; Chikungunya virus; Classical swine fever virus; Coronavirus (SARS); Crimean-Congo hemorrhagic fever virus; Dengue viruses; Dugbe virus; Ebola viruses; Encephalitic viruses such as Eastern equine encephalitis virus, Japanese encephalitis virus, Murray Valley encephalitis, and Venezuelan equine encephalitis virus; Equine morbillivirus; Flexal virus; Foot and mouth disease virus; Germiston virus; Goat pox virus; Hantaan or other Hanta viruses; Hendra virus; Issyk-kul virus; Koutango virus; Lassa fever virus; Louping ill virus; Lumpy skin disease virus; Lymphocytic choriomeningit
- organisms include parasitic protozoa and worms, such as: Acanthamoeba and other free-living amoebae; Anisakis sp. and other related worms Ascaris lumbricoides and Trichuris trichiura; Cryptosporidium parvum; Cyclospora cayetanensis; Diphyllobothrium spp.; Entamoeba histolytica; Eustrongylides sp.; Giardia lamblia; Nanophyetus spp.; Shistosoma spp.; Toxoplasma gondii; Filarial nematodes and Trichinella .
- analytes include allergens such as plant pollen and wheat gluten.
- organisms include fungi such as: Aspergillus spp.; Blastomyces dermatitidis; Candida; Coccidioides immitis; Coccidioides posadasii; Cryptococcus neoformans; Histoplasma capsulatum ; Maize rust; Rice blast; Rice brown spot disease; Rye blast; Sporothrix schenckii ; and wheat fungus.
- fungi such as: Aspergillus spp.; Blastomyces dermatitidis; Candida; Coccidioides immitis; Coccidioides posadasii; Cryptococcus neoformans; Histoplasma capsulatum ; Maize rust; Rice blast; Rice brown spot disease; Rye blast; Sporothrix schenckii ; and wheat fungus.
- organisms include worms such as C. Elegans and pathogenic worms nematodes.
- Particle refers to an organism, molecule, cell, a viral particle, spore, and the like.
- Patient sample refers to a sample obtained from a patient or person and includes blood, feces, urine, saliva or other bodily fluid, preferably blood. Food samples may also be analyzed.
- Sample refers to any sample potentially comprising an organism. Environments for finding organisms include, but are not limited to geothermal and hydrothermal fields, acidic soils, sulfotara and boiling mud pots, pools, hot-springs and geysers where the enzymes are neutral to alkaline, marine actinomycetes, metazoan, endo and ectosymbionts, tropical soil, temperate soil, arid soil, compost piles, manure piles, marine sediments, freshwater sediments, water concentrates, hypersaline and super-cooled sea ice, arctic tundra, Sargosso sea, open ocean pelagic, marine snow, microbial mats (such as whale falls, springs and hydrothermal vents), insect and nematode gut microbial communities, plant endophytes, epiphytic water samples, industrial sites and ex situ enrichments.
- the enzymes are neutral to alkaline, marine actinomycetes, metazoan, endo and ectosy
- a sample may be isolated from eukaryotes, prokaryotes, myxobacteria (epothilone), air, water, sediment, soil or rock, a plant sample, a food sample, a gut sample, a salivary sample, a blood sample, a sweat sample, a urine sample, a spinal fluid sample, a tissue sample, a vaginal swab, a stool sample, an amniotic fluid sample and/or a buccal mouthwash sample.
- eukaryotes prokaryotes, myxobacteria (epothilone)
- air water, sediment, soil or rock
- a plant sample a food sample, a gut sample, a salivary sample, a blood sample, a sweat sample, a urine sample, a spinal fluid sample, a tissue sample, a vaginal swab, a stool sample, an amniotic fluid sample and/or a buccal mouthwash sample.
- Microfluidics is an attractive platform for rapid single-cell functional analysis.
- Plugs for example, droplets of aqueous solution surrounded by a fluorinated carrier fluid, provide a simple platform for manipulating samples with no dispersion or losses to interfaces.
- Microfluidic plug-based assays provide the ability to reduce detection time by confining bacterium into nanoliter-sized plugs. This confinement, referred to as “stochastic confinement” decreases detection time by confining the sample into plugs that either have a single bacterium, or are empty. This approach increases the effective concentration of the bacterium, and allows released molecules to accumulate in the plug. Such stochastic trapping is commonly used for single-cell analysis in microfluidic devices, (M. Y.
- Microfluidics also enables simultaneous execution of numerous assays of bacterial function from a single bacterial sample in the same experiment, which is especially useful for rapid antibiotic susceptibility screening.
- gel microdroplets had been utilized for susceptibility screening.
- Microfluidic technology offers two advantages over traditional bacterial detection and drug screening methods: 1) stochastic confinement of single cells from dilute samples concentrates the bacteria, eliminates the need for pre-incubation, and reduces detection time; 2) each assay can be performed by using an individual bacterium, enabling hundreds of assays to be performed using a single, low density bacterial sample without pre-incubation. This technology will reduce the time needed to diagnose bacterial infections and enable patient-specific antibiotic regimens. This technology also has the advantage of separating objects into individual and separate volumes of fluid by forming plugs. A further advantage is that by using techniques such as the hybrid method to perform high throughput screening of multiple reagents and conditions using only a small volume sample.
- microfluidic technology including descriptions of uses, applications and techniques for plug-based methods of analysis, manipulation of plugs, hybrid plug merging, cartridge formation, use and handling, and holding component and loading component handling, use and formation, use of markers and fluid handling include U.S. Pat. No. 7,029,091; U.S.
- Approaches that may be used for bacterial detection include: 1) the use of cartridges (cartridges pre-loaded with reagents for different detection methods/growth media/antibiotics may be used to detect and identify bacteria); 2) the hybrid method to test many antibiotics/substrates/detection growth conditions or culturing conditions at different concentrations; and 3) screening/sorting.
- microfluidic on-chip approaches may be used to preconcentrate a sample before detection.
- One method is to flow the initial sample through a device which contains a structure (such as a filter) that would collect all of the objects (cells, particles, molecules or proteins bound to particles) needed to be detected.
- the structure traps the objects (through size exclusion such as a filter or through specific chemical or physical interactions with the objects) but enables the aqueous fluid in which the objects are suspended to pass through the structure.
- the objects may be resuspended by another aqueous flow such that the volume of aqueous fluid used to resuspend the objects is less than the volume in which the objects were originally suspended.
- the resuspended objects, now at a higher concentration, may then be loaded into plugs or droplets for further concentration due to stochastic confinement.
- concentration techniques may be used such as centrifugation, attaching magnetic beads to the particles of interest, or having surfaces which selectively bind to the target and then release the target at a later time.
- concentration techniques such as centrifugation, attaching magnetic beads to the particles of interest, or having surfaces which selectively bind to the target and then release the target at a later time.
- the experiments may be done by slowly flowing plugs into a tube, incubating them as they flow (with heating/cooling for PCR if need be along the way), flowing them by the detector, and then dumping them. This may address the “storage of 1,000,000 plugs” problem.
- the 1,000,000 plugs problem with stochastic confinement refers to the fact that to concentrate a sample 1,000,000 fold, 999,999 empty plugs must be formed for every 1,000,000 fold concentrated plug.
- One approach to this problem is do some initial screening using a less sophisticated method (such as flow cytometry or optical scanning) to sort plugs into occupied/unoccupied groups. These simple tests would not provide a detailed characterization of the object in the plug, but would rapidly determine whether or not the plug is occupied by an object. Then the advantage of stochastic confinement can still be realized by running more tests to rapidly characterize the occupied plugs.
- a possible method for encapsulating large numbers of cells is similar to sequential merging of reagents to plugs flowing in a 1D microfluidic channel (straight channel).
- the cells are introduced into a 2D channel (width of channel much larger than width of cell), and the cells flow through regions in which various reagents are applied to the cells.
- the 2D channel should be approximately similar in height to the cells such that the cells flowing through the device form a monolayer.
- plugs may or may not be encoded. If the plugs are not encoded, plugs may be analyzed for those that respond for more complex tests like susceptibility tests. Plugs may be encoded by position, or by an internal marker (for example a fluorescent marker of different colors) if not encoded. The same tests may be done by performing multiple non-encoded tests in parallel.
- microorganisms including bacteria, viruses, mold, and yeast
- bacteria can cause blood infections.
- the bacteria group can be further broken down into aerobes and anaerobes.
- Most aerobes do not need oxygen to live. They can grow with oxygen (aerobic microbes) or without oxygen (anaerobic microbes).
- the physician determines what group of microorganisms is likely to be causing the infection and then orders one or more specific types of blood culture, including aerobic, anaerobic, viral, or fungal (for yeasts and molds). Each specific type of culture is handled differently by the laboratory. Most blood cultures test for both aerobic and anaerobic microbes. Fungal, viral, and mycobacterial blood cultures can also be done, but are less common.
- the physician must also decide how many blood cultures should be done. One culture is rarely enough, but two to three are usually adequate. Four cultures are occasionally required. Some factors influencing this decision are the specific microorganisms the physician expects to find based on the person's symptoms or previous culture results, and whether or not the person has had recent antibiotic therapy.
- the time at which the cultures are to be drawn is another decision made by the physician.
- intermittent bacteremia microorganisms enter the blood at various time intervals. Blood drawn randomly may miss the microorganisms. Since microorganisms enter the blood 30-90 minutes before the person's fever spikes, collecting the culture just after the fever spike offers the best likelihood of finding the microorganism.
- the second and third cultures may be collected at the same time, but from different places on the person, or spaced at 30-minute or one-hour intervals, as the physician chooses.
- continuous bacteremia such as infective endocarditis, microorganisms are always in the blood and the timing of culture collection is less important. Blood cultures should always be collected before antibiotic treatment has begun.
- Bacteria are the most common microorganisms found in blood infections. Laboratory analysis of a bacterial blood culture differs slightly from that of a fungal culture and significantly from that of a viral culture.
- Blood is drawn from a person and put directly into a blood culture bottle containing a nutritional broth. After the laboratory receives the blood culture bottle, several processes must be completed: providing an environment for the bacteria to grow; detecting the growth when it occurs; identifying the bacteria that grow; testing the bacteria against certain antibiotics to determine which antibiotic will be effective.
- feces Other patient samples that may be collected include feces, urine or saliva. The latter would be useful for assessing oral health. Tears may be collected for diagnosing eye infections. Interstitial fluid (also referred to as tissue fluid or intercellular fluid) may be collected and use to diagnose infections in the pleural space around the lungs.
- bacterial infections include, but are not limited to those listed in Table 1.
- alamarBlue® To monitor the presence and metabolically active bacteria in plugs, a fluorescent viability indicator alamarBlue® was added to the cultures.
- the active ingredient of alamarBlue is the fluorescent redox indicator resazurin.
- Resazurin is reduced by electron receptors used in cellular metabolic activity, such as NADH and FADH, to produce the fluorescent molecule resofurin. Therefore, fluorescence intensity in a plug is correlated with the presence and metabolic activity of a cell, in this case, a bacterium. Because resazurin indicates cell viability, resazurin-based assays have been used previously in antibiotic testing. (S.
- Resazurin may be used to detect both the presence of a live bacterium and the response of bacteria to drugs, such as antibiotics. Stochastic confinement decreases detection time because in a plug that has the bacterium, the bacterium is at an effectively higher concentration than in the starting solution, and the signal-to-noise required for detection is reached sooner since the product of reduction of resazurin accumulates in the plug more rapidly.
- the detection time was proportional to plug volume. Detection time was defined as the time at which the increase in fluorescence intensity reached a maximum.
- detection time increased with the log of plug volume ( FIG. 1 c ), implying that bacteria were dividing exponentially inside the plugs. This result is similar to previous estimates that detection time decreases by about 1.5 h for every order of magnitude increase in cell density.
- Plugs may allow one to concentrate such samples and perform analysis. For example, a sample containing small amounts of DNA of interest in the presence of an excess of other DNA may be amplified. Amplification may be detected if plugs are made small enough that some plugs contain single DNA molecules of interest, and other plugs contain no DNA molecules of interest. This separation into plugs effectively creates plugs with higher DNA of interest concentration than in the original sample. Amplification of DNA in those plugs, for example by PCR, may lead to higher signal than amplification of the original sample.
- bacteria in plugs by a similar method may create a high local concentration of bacteria (1 per very small plug), making them easier to detect. For some bacteria that use quorum sensing, this may be a method to activate and detect them. Such bacteria may be inactive/non-pathogenic and difficult to detect at low concentrations due to lack of activity, but at a high concentration of bacteria, the concentration of a signaling molecule increases, activating the bacteria. If a single bacterium is localized in a plug, the signaling molecule produced by a bacterium cannot diffuse away and its concentration will rapidly increase, triggering activation of the bacterium, making it possible for detection. In addition, plugs may be used to localize cells and bacteria by creating gels or matrixes inside plugs.
- Bacteria and other species may be collected and concentrated into plugs by putting air through a plug fluid such as water, and then using that plug fluid to generate plugs. For example, by making smaller plugs from the initial plug, some of the newly formed smaller plugs will contain sample while other plugs will not contain the sample, but only buffer, for example. This results in concentrated sample containing plugs because some of the plugs do not contain any of the sample.
- a plug fluid such as water
- This method is not limited to liquid samples.
- Microorganisms and other particulate matter can be detected in gaseous samples, such as samples of air taken at airports or along train routes.
- gaseous samples such as samples of air taken at airports or along train routes.
- airborne particles there are numerous methods for collecting airborne particles in water, for example, as described in U.S. Pat. Nos. 7,201,878, 7,243,560, and 5,855,652 all incorporated by reference herein in their entirety. After collecting the airborne particulate matter in water, these samples can then be added directly to the fluorinated oil carrier fluid to form plugs.
- PCR techniques are disclosed in the following published US patent applications and International patent applications: US 2008/0166793 A1, WO 08/069,884 A2, US 2005/0019792 A1, WO 07/081,386 A2, WO 07/081,387 A1, WO 07/133,710 A2, WO 07/081,385 A2, WO 08/063,227 A2, US 2007/0195127 A1, WO 07/089,541 A2, WO 07030501 A2, US 2007/0052781 A1, WO 06096571 A2, US 2006/0078893 A1, US 2006/0078888 A1, US 2007/0184489 A1, US 2007/0092914 A1, US 2005/0221339 A1, US 2007/0003442 A1, US 2006/0163385 A1, US 2005/0172476 A1, US 2008/0003142 A1, and US 2008/0014589 A1, all of which are incorporated by reference herein in their entirety.
- PCR polymerase chain reactions
- the plug-based microfluidic platform may be used to setup a huge number of reaction centers in nano- or pico-liter volume scale, extending into the femtoliter and microliter scales.
- various conditions of reactions and samples may be incorporated, split, and merged in a microfluidic device.
- a sample comprising 1% of DNA of interest in the presence of 99% of background DNA would need to be amplified enough to harvest and use.
- amplification of 1% of DNA by a factor of 100 only increases the total amount of DNA by a factor of 2, resulting in detection difficulties.
- highly amplified PCR products of target 1% of DNA in a plug may be obtained. Assume that the probability of appearance of target DNA as a single molecule in a plug is one in every 10 th plug, then the ratio of target DNA/total DNA is 1:10 in such plugs.
- a platform cartridge incorporating a carrier fluid channel, a sampling channel, and one or two PCR reagent channels may be made. By regulating each fluid, individual plugs containing a single molecule of target DNA or different molecules of DNA from the sample may be generated. Along the channel containing plugs, heating regions are placed in the channel region by repeating heating and cooling process for the denaturation and renaturation of DNA samples.
- Stochastic confinement has applications in the isolation and screening of rare particles or cells from a sample.
- the result is a set of isolated volumes of fluid, most with either no particles or 1 particle.
- rare particles are segregated from ubiquitous particles. The separation of rare particles enables the direct assay of the function and detection of rare particles without interference from other particles in the system.
- rare particle Even if a rare particle has high activity, since it is at low concentration in the bulk sample it may not be detectable due to dilution of the signal and low signal to noise ratio as a result of low background reaction from the ubiquitous particles.
- other plug based microfluidic technologies can be used to screen the rare particle.
- the original sample contains 100 rare particles
- stochastic confinement enables the separation and screening of individual particles, this enables the rare particle to be screened against up to 100 different conditions.
- those droplets may be merged with thousands of different conditions. If the droplets are randomly merged with screening conditions, then up to 100 different conditions will be screened against the rare particles.
- the rare particle is allowed to divide, then the plug containing the rare particle can be split into several smaller plugs and each plug assayed or screened independently, for example, using the hybrid and/or cartridge method. Examples include combining the plug containing many rare particles with plugs of various reagents and conditions in order to determine the function and optimal conditions for the rare particle.
- each daughter array may be interrogated by a different technique or reagent, while preserving the identity of plugs and their relationship in the daughter array (for example, 37 th plug in the first array corresponds to the 37 th plug in the second, third, and forth array).
- the results may be combined to provide information on the response of corresponding daughter plugs to each of the techniques.
- some of the daughter arrays may be retained as a reference culture. When the results from the other three arrays are known, the reference culture arrays may be used for further manipulation, characterization, assaying, and isolation of organisms.
- Isolation of rare particles through stochastic confinement may also be combined with the hybrid and/or cartridge method for screening growth/virulence activation/assay conditions against the rare cells. For example, if a sample contains 10,000 cells, 100 of which belong to a rare cell type, stochastic confinement may be used to isolate the 100 rare cells into plugs containing only a single rare cell and no other types of cells. Then the plugs containing the rare cell types may be used in hybrid and/or cartridge screening by the following methods.
- the plugs generated from the stochastic confinement may be combined with screening conditions using the hybrid and/or cartridge method.
- Plugs containing the rare cells are randomly distributed throughout all of the plugs generated (many of which do not contain a rare cell). If many plugs (100's, 1000's) are merged with a single screening condition, it is likely that at least one of the plugs for that condition will contain a rare cell. In this way, multiple growth/assay/virulence activation conditions may be screened against the rare cell type.
- a separate test may be needed to separate plugs containing rare cells from the other plugs generated by confinement. It may be best to sort the plugs into rare cell/common cell/empty after merging with the hybrid and/or cartridge screen to reduce detection time. Instead of sorting for rare cells first (which may take time) and then merging with screening conditions, the screening and determining the presence of rare cell may be done simultaneously.
- plugs containing rare cells may be desirable to first separate out plugs containing rare cells from plugs containing common cells or no cells. This may be done using antibodies, binding assays, testing for function specific to the rare cell combined with automated sorting mechanisms (optical, magnetic, FACS). Once the rare cell type plugs have been isolated, a hybrid and/or cartridge screen can be used to screen for growth/assay/virulence activating conditions or to run a multitude of functional and genetic tests on the rare cell type.
- confinement may be used to determine the density (number of cells of type X per volume of sample) or the ratio (100 cells of type X for every 1 of type Y) of cells in a sample. This may also be used to find ratios of phenotypes of cell populations that are genetically identical (25% of Staphylococcus cells are resistant to oxacillin or 30% of cells will induce virulence in response to host protein X).
- an organism might be releasing products such as quorum sensing molecules and will not initiate growth until a threshold concentration of released products have accumulated. Confinement will put microbial cells at higher initial cell density and enable cells to grow and optionally activate genes associated with high cell density. Some organisms may be able to grow in culture, which were previously believed to be not culturable by standard techniques due to their slow growth or growth to low densities. These organisms may still undergo a sufficient number of divisions when stochastically confined, and therefore allow further detection by less-sensitive techniques that require multiple copies of the organism to be present.
- plugs When plugs are used to create stochastic confinement, growth of the organism allows further manipulation and analysis that cannot be done on a single plug (for example requiring mutually incompatible methods) by splitting the plugs, injecting reagents into them and monitoring results. These steps may be performed sequentially, where the results of the first experiment guides the design of the second experiment, or in parallel.
- mutually incompatible methods include reagents that produce similar signals (such as fluorescence in the same range of wavelengths), or methods that require different conditions (such as different solvents or pH values), or require different states of the organisms (such as a functional test that requires an alive organism, and a staining protocols that kills the organism).
- a known organism may be screened in the presence of many media and culturing conditions (varying ion concentrations, known autoinducers, amount of confinement, temperature, pH, protein additives, reaction oxygen species, stress inducers; changing carbon source and concentration of carbon source; changing nitrogen source and concentration of nitrogen source; changing availability of various trace metals (Mn, Mo, Cu, Pt, etc.), adding drugs known to interfere with specific cellular activities; adding transport and ion channel inhibitors, small molecules involved in cellular communication, virulence activators, etc.).
- media and culturing conditions varying ion concentrations, known autoinducers, amount of confinement, temperature, pH, protein additives, reaction oxygen species, stress inducers; changing carbon source and concentration of carbon source; changing nitrogen source and concentration of nitrogen source; changing availability of various trace metals (Mn, Mo, Cu, Pt, etc.), adding drugs known to interfere with specific cellular activities; adding transport and ion channel inhibitors, small molecules involved in cellular communication, virulence activators,
- functional tests or other assays may be performed in plugs to determine if compounds have been generated with properties of interest (such as drug targets, antibiotic compounds, ion channel inhibitors, virulence activation, virulence inhibition, degradation of various compounds, binding affinity, etc.).
- properties of interest such as drug targets, antibiotic compounds, ion channel inhibitors, virulence activation, virulence inhibition, degradation of various compounds, binding affinity, etc.
- OSMAC one strain many compounds
- Big Effects from Small Changes Possible Ways to Explore Nature's Chemical Diversity by Helge Bjorn Bode, Barbara Bethe, Regina Höfs, Axel Zeeck, Chem Bio Chem Volume 3 Issue 7, Pages 619-627.
- Small changes in culturing conditions for example, media composition, aeration, culture vessel, addition of enzyme inhibitors
- the molecules released may aid in detection of the organism, or may have functional uses such as antibiotics.
- strain B. subtilis can be cultured and a lot is known about its genome, useful compounds that it is capable of releasing may be missed simply because the organism has never been grown under specific conditions such as, for example, certain concentration of phosphate ions, addition of protease inhibitor, and addition of 10 uM autoinducer 2. Therefore, using hybrid and/or cartridge like approaches, a larger range of metabolites, released compounds, and drug leads may be probed simply by running high throughput screens of various media conditions/additives. Even changes of a single component in the media (for example, phosphate from 20 mM to 1 uM) may activate the production and release of a previously unknown metabolite or compound.
- phosphate for example, phosphate from 20 mM to 1 uM
- Implementation of this type of screening may be done by taking a known organism and screening many media and culturing conditions (ion concentrations, known autoinducers, amount of confinement, temperature, pH, protein additives, reaction oxygen species, stress inducers, carbon sources, concentration of carbon source, nitrogen sources, concentration of nitrogen source, availability of various trace elements and their chemical form (Mn, Mo, Cu, Pt, V, B etc. and corresponding ions), and/or by adding drugs known to interfere with specific cellular activities, adding transport and ion channel inhibitors, and/or small molecules involved in cellular communication, virulence activators, and the like.).
- media and culturing conditions ion concentrations, known autoinducers, amount of confinement, temperature, pH, protein additives, reaction oxygen species, stress inducers, carbon sources, concentration of carbon source, nitrogen sources, concentration of nitrogen source, availability of various trace elements and their chemical form (Mn, Mo, Cu, Pt, V, B etc. and corresponding ions)
- functional tests or other assays may be performed in plugs to determine if compounds have been generated with properties of interest (such as drug targets, antibiotic compounds, ion channel inhibitors, virulence activation, virulence inhibition, degradation of various compounds, binding affinity, etc.).
- this method may also be used with rare cells isolated from natural samples such as soil, aquatic environments including sea water and marine sediments and surfaces, an animal's digestive tract, environmentally contaminated sites including soil, water or air, sludge used in environmental remediation, etc. Cells which are unculturable (no known conditions cause them to divide/reproduce outside of natural environment) may also be used. If small volumes are used, activity may be detected even from a single cell without division.
- Stochastic confinement may be used to isolate rare organisms from various sources, including: soil extract from various types of soil environments and soil layers (including the surface layer, subsoil, substratum), ice shelves, marine and freshwater sediments, naturally occurring biofilms, hot springs, hydrothermal vents, extraterrestrial samples, crevices of rocks, attached to particulates from aqueous environments, growing on or inside of manmade structures, clouds, gastrointestinal tract, and found forming a symbiotic relationship inside of a host organism.
- stochastic confinement may be used to isolate rare cells from soil extract. Once rare cells have been obtained, the plugs containing the cells may be incubated overnight to allow for growth or secretion of molecules.
- the plugs containing the rare cells may then be used as an input into the hybrid and/or cartridge method.
- each plug containing the rare cell may then, for example, be merged with 1000's of plugs containing cells of Streptomyces species. After plugs containing streptomyces have been merged with rare cell supernatant and incubated, screening for antibiotic production is performed. In this way, compounds in the supernatant of the rare cell, or rare cells directly, may induce the production of new antibiotic compounds.
- stochastic confinement may be used to isolate cells from ocean sediments.
- the hybrid and/or cartridge method may be used to screen various media conditions such as phosphate concentration (from 0 to 100 ⁇ M), autoinducer 2 concentration (from 0 to 100 ⁇ M), and glucose concentration (from 0 to 10 mM).
- the cells are then incubated in the new media conditions.
- Various functional/genetic tests are performed in the plugs to determine which media conditions yield growth and or production of compound with desired properties
- cells which are unculturable may be used. If small volumes are used, one may be able to detect activity even from a single cell without division.
- Plug based methods may be used to collect the lysate or cell free supernatant from various types of cells and merge these solutions with other cells to elicit metabolite/compound production. Lysate/supernatant may be diluted during the screen (concentration screen using hybrid method). In this way, uncharacterized/unknown compounds/combinations of compounds may be screened to elicit production of useful compounds.
- Stochastic confinement has applications in isolation of rare particles from samples with many other ubiquitous particles besides a few particles of interest. When samples are stochastically confined, the result is a set of isolated volumes of fluid, most with either no particles or one particle. Rare particles are therefore separated from ubiquitous particles. The separation of rare particles enables the direct assay of the rare particles without interference from other particles in the system. Even if a rare particle has high activity, since it is at low concentration in the bulk sample it may not be detectable due to dilution of the signal and low signal to noise or low signal to background (potentially low background reaction from the ubiquitous particles).
- rare particles are isolated and concentrated through stochastic confinement, other plug based microfluidic technologies may be used to screen the rare particle. If the rare particle is allowed to divide, then the plug containing the rare particle can be split into several smaller plugs and assayed or screened using the hybrid and/or cartridge method (combining the plug containing many rare particles with plugs of various reagents and conditions in order to determine the function and optimal conditions for the rare particle). In addition, if the original sample contains 10 rare particles, since stochastic confinement enables the separation and screening of individual particles, this enables the rare particle to be screened against up to 10 different conditions. When rare particles are bacteria, care must be taken with bacteria to avoid forming biofilms during incubation which might grow and adhere to the wall, interfering with enumerations. Thus it is preferable to use inert surfaces in plugs.
- Occasions when detection is needed include, but are not limited to, when the particles are rare cells such as cancer cells in general, cancer stem cells, or fetal cells in maternal blood, or when the particles are bacteria or viruses causing some diseases, or when the particles are some toxic materials released by some industrial procedure, or particles are results of some military, civil, or natural event that needs detection.
- the particles of interest have some special functions that are useful, isolating and possibly multiplying them is important in efficiently utilizing these special functions.
- stem cells isolated and multiplied from adults may be used for treatment, bypassing the need for embryonic stem cells.
- Natural products used in medicine may be produced by isolating and multiplying natural cells that produce them.
- Bacteria with novel functions such as cleaning up hydrocarbon waste, degrading other environmental pollutants including halogenated compounds, converting biomass into more easily utilizable fuels such as ethanol or butanol or methane, oxidizing methane, or fixing nitrogen may be isolated, multiplied and used for appropriate purposes.
- one or multiple further assays may be done to detect particles of interest and/or one or multiple types of particles detected from the primary assay may be used alone or in combinations for appropriate functions.
- the basis for detection of the particles include but are not limited to: 1) surface properties including functional groups on the surface of particles and signaling molecules on cells (antigens, receptors, sugar groups, lipids, etc); 2) materials inside the particles (chemicals enclosed in materials, DNA, RNA in general, microRNA, signaling molecules in general, proteins, and the like)—these materials may require further processing to the particles to be exposed and used for detection; and 3) chemical exchange with the environment (production and/or consumption of chemicals by material, uptake and/or secretion of molecules such as food, waste, signaling molecules in general, ions, novel molecules, etc. by cells). These chemical exchanges may occur naturally or with human intervention for example by stimulation with reagents.
- Prenatal diagnosis of genetic diseases plays an important role in pregnancy, at least in informing the parents about the possibilities. Women of 35 years of age or more have high risk of abnormalities. However, since there are also many more pregnancies in the “low-risk” 26 year-old group, most (about 70%) abnormalities occur in this group. (Daniilidis, A.; Kouzi-Koliakou, K., Fetal cells in maternal circulation—potentials for prenatal control. Journal of Biological Research-Thessaloniki 2006, 6, 119-130.)
- fetal materials in maternal blood. If the cells and free DNA in the mother's blood may be used effectively to detect genetic disorders, the risk of miscarriage by invasive procedure is diminished and virtually any expecting mother may have a blood draw to check for possible genetic disorders.
- the biggest challenge is the small number of fetal cells (1-6 cells/mL (Daniilidis, A.; Kouzi-Koliakou, K., Fetal cells in maternal circulation—potentials for prenatal control. Journal of Biological Research-Thessaloniki 2006, 6, 119-130.)) and DNA in maternal blood.
- Previously developed methods to isolate such cells involve enrichment methods such as density gradient centrifugation and selective lysis, and sorting methods such as fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting (MACS).
- sorting methods such as fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting (MACS).
- FACS fluorescence-activated cell sorting
- MCS magnetic-activated cell sorting
- Methods to detect genetic disorders include (PCR) and fluorescent in situ hybridization (FISH).
- FACS and MACS depend on tagging the fetal cells with fluorescent or paramagnetic antibodies and using fluorescence intensity as a signal to separate the cells with flow cytometry or using magnets to separate the cells. These techniques rely on specific antibodies.
- MACS density-gradient centrifugation
- Stochastic confinement and autocatalytic kinetics with threshold may allow one to detect reliably plugs containing fetal cells in maternal blood and separate them out to use techniques in further detection or application.
- the two important advantages of this system versus current techniques are:
- Stochastic confinement allows for reliable detection even if the specificity of an antibody label is not ideal.
- the kinetic threshold may be adjusted to lie in between the two concentrations of antibodies in plugs. The adjustment may be carried out by choosing an appropriate amplification method and tuning the concentration of such method (see section about amplification).
- properties of fetal cells such as having a particular disease or not.
- stochastic confinement may be used to detect such properties. Even though the contrast provided by the specificity of the antibodies may not be much, stochastic confinement and/or an amplification method may greatly enhance this contrast.
- the general steps of this method include:
- the volume is chosen because even in such cases when amplification methods may detect single cells, a 1 mL sample of blood still has a significant probability to not contain the cells of interest when the concentration of the fetal cells is 1-6 cells/mL);
- an amplification method is needed to enhance the contrast: merging with plugs containing chemicals or materials needed in the amplification method (if these chemical and materials are added with the antibody this step is not needed);
- plugs containing fetal cells of interest for further assays (such as FISH or PCR to look for genetic disorders, or any other possible methods to detect certain properties of interest of fetal cells) if necessary; and/or
- Fetal materials in maternal blood and markers of disorder after stochastic confinement may also be detected with methods described in the section entitled “amplification.”
- Plugs offer advantages over cuvettes.
- the optical path may be made very thin, so if a bacterium is labeled (for example, with fluorescent antibodies) it is easy to detect.
- a bacterium for example, with fluorescent antibodies
- the same effect may be obtained by squeezing a blood sample between two coverslips separated by a 20 ⁇ m gap, which may be created by placing a thin metal (gold or Pt) wire between the cover slips.
- the cover slips may be covered with something to which bacteria stick, and factors that makes them grow biofilms or multiply aggressively. Probes may be added for detecting these activities or colonies.
- Another advantage is diffusion control in a plug versus a coverslip or cuvette.
- a material produced by bacteria can diffuse away and become diluted.
- the material produced by bacteria builds up to a high enough concentration that it is easy to detect.
- the material produced or the multiplying bacteria may be detected.
- Monitoring the decrease in a nutrient attributable to the presence of the bacteria provides evidence of the bacteria.
- the decrease in O 2 attributable to the presence of the bacteria may be done using agglutination beads.
- Oxygen or other gases or mixtures of gases may need to be provided to encourage growth. Gases may be introduced by various methods including by dissolving them in the fluorocarbon carrier fluid. Care may be taken to avoid evaporation of oil/media particularly for incubation at 37° C.
- the plugs may be sealed in glass or placed in a Teflon capillary that is permeable to gases. The capillary is then placed in a vial of media that is the same (isotonic but not comprising indicators, cells and other components which will not partition across tubing).
- the oxygen concentration of blood in any sepsis assay may need to be controlled in a way other than what is typically done with blood tests.
- Staphylococcus aureus S. aureus
- produces coagulase a protein that binds prothrombin stoichiometrically and leads to cleavage of fibrinogen to fibrin.
- this conversion simply precipitates fibrin and does not result in production of thrombin, feedback, or amplification of the coagulation cascade.
- Escherichia coli E. coli
- Curli are also known to activate coagulation factors, such as factor XII. This process was shown to cause slower initiation of coagulation due to depletion of factor XII. Bacteria do initiate coagulation in some organisms, such as horseshoe crabs, but this mechanism of controlling infection is believed to have been lost during evolution of vertebrates.
- Crab blood is known to clot rapidly on contact with bacteria.
- Plugs with grown bacteria may be merged with plugs that contain crab blood. Clotting occurs rapidly when the crab blood contacts the bacteria, and secondary indicators such as fluorescent indicators or dyes for “crab thrombin” may be used to detect bacteria.
- secondary indicators such as fluorescent indicators or dyes for “crab thrombin” may be used to detect bacteria.
- Other clotting systems are disclosed in Kastrup et al. Acc Chem. Res. “Using chemistry and microfluidics to understand the spatial dynamics of complex biological networks.” 2008 April; 41(4):549-58.
- Another type of molecule exported by bacteria are signaling molecules. If a single bacterium produces activators, these activators can accumulate in the plug, turning a single bacterium ON into the attack mode, and making it easier to detect.
- virulence activation often involves the upregulation of enzymes involved in infection, such as lipases, coagulases, and proteases that may be used as detection targets, specifically as detection targets of virulent species.
- the virulence enzymes and other released molecules may be used to activate detection mechanisms.
- Another possibility is to lyse the cells in the media to detect something that is only produced by bacteria.
- PCR may also be applied to plugs. PCR may be overwhelmed by the background DNA of human cells. In the case of plugs, if plugs are made small enough there would be only one cell per plug (human or bacterial) which eliminate background issues (if bacterial-specific primers are used background from other cells would not interfere). Binding of bacteria to human cells, or bacteria hiding inside of human cells would not be problematic due to the minimal background. Plugs may also be spiked to stimulate bacteria to make them easier to detect.
- bacteria can be detected in people at low concentration (before infection becomes a real threat), these methods may be used for general clinical practice to screen high risk patients including babies and the elderly for bacteria. Viral infections may also be monitored by this method by using vesicles that a virus would try to enter, and detecting the entry by fluorogenic substrates, or by the destruction of vesicles (detected, for example, by a Ca/Fluo4 system).
- Methods of detecting bacteria using microfluidic based techniques comprise: 1) screening a sample against various reagents which results in a detectable signal in the presence of bacteria; and 2) screening these samples in parallel or in series against different drugs to determine which drug is best suited for killing the bacteria in the sample.
- Part 1) of this technique may include screening a sample against preloaded, plug-based cartridges that comprise bacteria-specific reagents. If the sample comprises bacteria that are specific for a reagent in one of the plugs a signal will be detected in that plug. Examples of the detection methods include, but are not limited to: i) magnetic based detection, ii) optical detection, and iii) oxygen detection.
- Part 2) of this technique may include preloading plug-based cartridges with various antibiotics that are known to kill certain types of bacteria.
- WO 05-056826 A1 which discloses methods is incorporated by reference herein in its entirety.
- the method of detecting bacteria comprises confinement of a bacterium into a small volume plug, wherein the confinement induces virulence activation of the bacteria through a quorum sensing type mechanism.
- the activation of virulence in the bacteria may induce the upregulation of various virulence factors such as proteins, enzymes, and small molecules.
- the upregulation and release of these virulence factors may be used as a detection target for the presence of virulent bacteria, may be used to detect a bacterium with the potential to activate virulence mechanisms, or may be used as targets to detect a specific species or type of bacteria.
- the upregulation and release of these virulence factors such as lipases, proteases, and coagulases may be incorporated as the initial step in an enzymatic detection cascade.
- the plug comprises a substance capable of lysing the bacteria.
- Lysis may be accomplished by standard detergent-based bacterial cell lysis. For example, frozen and thawed cell pellets are incubated with lysis buffer that is supplemented with lysozyme, which help disrupt cell walls (Lysozyme hydrolyzes ⁇ (1 ⁇ 4) linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrin).
- Gram-negative bacteria may be hydrolyzed in the presence of EDTA that chelates metal ions in the outer bacterial membrane.
- Cells are incubated with lysis buffer for about 30 min, on ice. If the target is a nucleic acid, proteinase should be supplemented, whereas if the target is a protein, nucleases should be supplemented.
- the sample is centrifuged (14,000 g, 30 min, 4° C.) and the supernatant collected. The supernatant comprises the soluble protein fraction, which can be further purified or directly analyzed, for example by SDS-PAGE.
- the method for detecting bacteria comprises detecting bacteria in various samples using microfluidic based techniques, and screening bacteria using a hybrid and/or cartridge-based method to detect microorganisms by detecting their binding to beads.
- Binding bacteria to magnetic beads may be accomplished by using specific (antibodies, chemical link between bacteria and bead) or non-specific (charge of bacteria, general molecule expressed on outside of bacteria) methods. Bound and unbound magnetic beads may be separated by microfluidic sorting techniques which rely on differences in diffusion based on size or changes of magnetic potential due to bound bacteria. Bound and unbound magnetic beads may also be separated using a magnetic field because migration in the field will be reduced for bound beads with increased drag. This method may be used to isolate specific types of bacteria from a sample or to remove all bacteria from other parts of the sample matrix. Liquid containing bacteria bound to beads may then be used to make plugs.
- Various techniques may be used to detect the presence of a magnetic bead in a plug, including measuring the electric current induced by a moving magnetic particle. Another detection method incorporates a hard-drive head to detect magnetic particles. Another detection method takes a relative measurement of the magnetic beads to measure relative orientation rate in the field. Another detection method relies on bacteria binding to multiple beads and the detection method being able to distinguish between single unbound beads and groups of bound beads (for example by changes in the amplitude of the spike in the detector).
- Magnetic beads may also be used to detect proteins or other molecules by either chemically linking the target to the bead, or by first attaching an antibody to the target. The antibody then recognizes and attaches to the magnetic bead.
- Beads may have an optical signal, and a detection method which differentiates single unbound beads vs. groups of beads may be used to detect the target.
- bead detection schemes may be used to monitor the proliferation of bound objects after exposure to a compound, such as an antibiotic.
- the bead method may be used to isolate the bacteria from the sample and then introduce the antibiotic to the bacteria. Addition of more beads and enumeration of bound beads after incubation with the antibiotic may be used to determine whether or not the antibiotic inhibited proliferation of the bound bacteria.
- Oxygen detection schemes include formation of Prussian blue as a function of oxygen presence, and fluorescence based oxygen sensors.
- the sample may be detected attached to a bead, free in solution, or after deposition on the wall of the channel.
- bacteria may be agglutinated.
- an array of pre-formed nanoliter sized droplets, or plugs is generated.
- Each plug comprises one or more beads.
- all beads are substantially similar.
- Each bead has a specific binding affinity, provided by an antibody for example, for a microorganism or a subset of microorganisms, for example, bacteria, viruses, or fungi.
- the binding affinity can also be for a specific small particle, such as a pollen grain or a spore.
- the beads themselves are detectable, for example a magnetic bead or a fluorescent bead. Ideally, the binding event is also detectable.
- the assay may be performed by the steps of injecting the sample into each of the plugs, incubating to allow the detection, and performing the detection.
- Direct detection may be accomplished by taking advantage of the difference in the magnitude and frequency of the signals produced by many unbound beads inside of a plug vs a microorganism that carries with it the same number of beads bound. Many unbound beads would generate several smaller signals, while an organism with the same number of beads bound would generate a single signal of higher amplitude.
- the detection can be performed by separating bound beads from unbound beads, and detecting bound beads.
- the separation may be performed by a range of methods including a diffusive filter, a Brownian ratchet, or in the case of magnetic beads, a magnetic filter that applies a magnetic field to bias motion of the beads. Separation may require separating the plug fluid from the carrier fluid, flowing through the filter, and re-forming the plugs by adding carrier fluid to the plug fluid that passed the filter and contains predominantly bound beads.
- Detection is performed by a range of methods, including scanning the detector over the array of plugs, or flowing the array of plugs past the detector. Magnetic detection may be performed by detecting currents generated by moving magnetic beads, and may also incorporate technologies used in hard disk drives.
- Spacer and index plugs may be used in the original array of plugs as disclosed in WO 08-079274 A1, the entirety of which is hereby incorporated by reference.
- Index plugs may contain markers detectable by the same method used to detect binding of bacteria to beads.
- This method is discussed in the context of microorganisms and particles, but it is applicable to the detection of molecules and other objects by using a larger bead carrying antibodies against the molecule, and a set of detectable beads carrying another antibody against the same molecule.
- the detectable beads In the absence of the molecule, the detectable beads do not bind larger beads and remain dispersed. In the presence of the molecule, the detectable beads bind to the molecules and therefore to the larger beads, and become detectable by the methods described here.
- plugs may contain antibiotics, and the plugs injected with the sample may be allowed to incubate to permit growth of microorganisms.
- Antibiotics are recognized and are substances which inhibit the growth of or kill microorganisms. Examples of antibiotics include, but are not limited to, chlorotetracycline, bacitracin, nystatin, streptomycin, polymicin, gramicidin, oxytetracyclin, chloramphenicol, rifampicin, cefsulodin, cefotiam, mefoxin, penicillin, tetracycline, chloramphenicol, minocycline, doxycycline, vancomycin, bacitracin, kanamycin, neomycin, gentamycin, erythromycin, cephalosporins, geldanamycin, and analogs thereof.
- cephalosporins examples include cephalothin, cephapirin, cefazolin, cephalexin, cephradine, cefadroxil, cefamandole, cefoxitin, cefaclor, cefuroxime, cefonicid, ceforanide, cefotaxime, moxalactam, ceftizoxime, ceftriaxone, and cefoperazone. Additional examples of antibiotics that may be used are in US 2007/0093894 A1, hereby incorporated by reference in its entirety. Detection of differences in growth and microbial populations in the absence and presence of each antibiotic would provide information on antibiotic susceptibility. First the bacteria in the sample are counted.
- the bacteria sample is merged into the cartridge containing plugs of different growth media and different antibodies along with some as “blank” media and “blank” antibiotics plugs. Recount is preformed by merging with magnetic beads to see which one had bacteria reproducing.
- the detectable signal is produced by the growth of the bacteria.
- Optical detection comprising optical methods for detection may use fluorescent nanoparticles instead of magnetic ones.
- One may also use control of surface chemistry provided by plugs to enhance growth of organisms.
- One method comprises merging the sample with a cartridge, the cartridge may optionally have growth tablets; monitoring bacterial growth by a change in oxygen concentration; and recording the readout.
- the readout may be but is not limited to a change in volume of oxygen bubbles the device, a change in optical signal due to the presence of an oxygen sensitive substrate (the substrate may be incorporated in many ways including in solution, on beads, or immobilized on a film that coats the device), or calorimetric reactions for detecting oxygen.
- Bacteria detection by using agglutination may also be employed.
- This method comprises merging sample with plugs that comprise substance that induces agglutination in the presence of bacteria including for example, antibody labeled beads; forming agglutination screens on a large scale for bacteria detection; filling preformed plugs with beads covered with antibodies specific for different bacteria; and monitoring which plugs result in clumps of beads indicating presence of bacteria. Monitoring may be done by eye or some other detection technique. Secondary agglutination may also be used.
- multiple assays may be performed in one device, for example by splitting a sample into a plurality of samples using techniques described above for splitting plugs.
- Aqueous plugs with fluorinated oil as the carrier fluid will not wet hydrophobic channel walls. Therefore, to have a plug stick to the channel wall it is necessary to create a region of the channel in which the surface chemistry of the channel is hydrophilic.
- a hydrophilic patch may be useful in 2 ways: i) a hydrophilic patch may capture a plug and hold it in place; and ii) a hydrophilic patch may temporarily come into contact with a plug as it is flowing by. This brief contact may result in a small portion of the plug fluid being deposited on the hydrophilic region of the channel wall. Capturing a plug (i) or depositing a portion of a plug onto the channel wall (i) may enable the assays to be run on the plug fluid.
- Another strategy for manipulating plugs is to control pressure drops in the channels by channel constriction. From Hagen-Poiseuille's law, if a channel gets narrower, the pressure drop quickly increases. If the pressure drop in one branch of a microfluidic network becomes narrow, plugs will not be able squeeze through the constriction because the capillary pressure required for the plug to squeeze through will be higher than the pressure drop over the device. In this way, channel constriction may be used to collect plugs and stop them from moving.
- a device with specified pressure drops in each channel in a network of branching channels it may be possible to automatically sort the large number of plugs needed for some stochastic confinement applications. For example, a main channel carrying plugs splits into 10 different smaller channels. If each channel has a different diameter/length (i.e. pressure drops for each channel are different) this would create a bias in the loading of plugs.
- a system may be designed such that the 1st 100 plugs would be loaded into channel 1, then the pressure drop in channel 1 becomes greater than channel 2 due to the presence of many plugs, therefore the next 100 plugs would flow into channel 2, etc.
- This type of bulk sorting of plugs can be achieved simply by designing the channels with specific pressure drops and does not rely on turning on and off pumps, opening and closing valves, or other “active” plug sorting mechanisms.
- Certain embodiments of the invention may be used to detect sepsis in 3 to 4 hours from a blood sample from a patient, and in other embodiments detection times may be reduced to 20 minutes or less.
- detection times may be reduced to 20 minutes or less.
- a 5 to 10 mL blood sample from an infected patient there might be 100 to 1,000 bacteria. Allowing the sample to culture overnight can increase those numbers by 10 to 100-fold. It would also be useful to know patterns of antibiotic resistance, and current methods are very tedious.
- stains and dyes Possible means for detecting bacteria in a sample include stains and dyes, as used in flow cytometry, and which are well known in the art. Alternatively, one may look for a uniform change in color, appearance, scattering or optical density across a plug.
- almarBLUETM resazurin
- almarBLUETM is a fluorescent redox sensitive dye that can be used to detect living cells.
- Certain embodiments of the invention may be used to detect different strains of bacteria, including Pseudomonas, Staphylococcus, E. Coli , etc.
- a severely infected patient can have 10 6 bacteria (CFU)/mL in the blood.
- CFU 10 6 bacteria
- the PCR-based LightCyclerTM can detect 10 3 , but only can only detect bacteria with known, predetermined, target gene sequences, and it does not give any functional information, for example concerning antibiotic resistance, and it is relatively slow, taking 6 to 8 hours.
- Other methods, using 96 well plates have demonstrated the detection of 10 6 bacteria in a 200 ⁇ l sample in 2 to 3 hours, 10 5 bacteria in approximately two hours, and 10 3 bacteria in 8 to 9 hours.
- Another means of detecting and typing cells is PCR amplification of 16S-23S rRNA., as described in Vente, I., et al., “Rapid identification of bacteria by real-time amplification and sequencing of the 16S rRNA gene” Journal of Microbiological Methods 66 (2006) 156-164, and patent application WO 96/119585, hereby incorporated by reference in its entirety.
- This can be accelerated by using a rapid microchip PCR method described recently that uses infrared light to achieve a 12 minute PCR reaction. See “On-chip pressure injection for integration of infrared-mediated DNA amplification with electrophoretic separation” Christopher J. Easley, a James M. Karlinseya and James P. Landers, Lab Chip, 2006, 6, 601-610.
- Fluorogenic media which change color in the presence of specific bacteria, can also be used to detect cells.
- Chromogenic media include, for example, Difco mEl agar, Merck/EMD ChromocultTM Coliform Agars, ChromocultTM Enterococci Agar/Broth, or Fluorocult® LMX Broth, BL ml agar, IDEXX Colilert, CPI ColiTag and Merck/EMD ReadyCult®.
- Typical enzyme substrates linked to chromogens or fluorogens include ONPG, CPRG, and MUG. These are also available in ready-to-use format, e.g. BBL ml agar and ‘convenience’ packs, e.g. IDEXX Colilert, CPI ColiTag and Merck/EMD ReadyCult®.
- Bacteria can also be detected using simple growth and density measurements of plugs. Such measurements may aid detection and characterization of specific antibiotics that block the ability of the bacteria to grow, after combining plugs with specific antibiotics.
- Microchannel PCR is described in U.S. Pat. No. 6,990,290, rapid bacterial PCR is described in U.S. Pat. No. 6,673,578, and a sepsis detection chip is described in US 2005-130185 A1, all incorporated by reference herein in their entirety.
- Confining bacteria in small spaces might influence their phenotype, and gene regulation.
- one bacterium inside of a small volume may respond as if it is in a culture with high cell density because communication molecules that it secretes, such as homoserine lactones, activate quorum sensing. This can be used to an advantage of this to decrease detection times or limits, and/or trigger virulence.
- Typical to monitor bacterial growth blood sample bottles are placed in an incubator and kept at body temperature. They are watched daily for signs of growth, including cloudiness or a color change in the broth, gas bubbles, or clumps of bacteria.
- the laboratory does a gram stain and a subculture.
- a drop of blood is removed from the bottle and placed on a microscope slide. The blood is allowed to dry and then is stained with purple and red stains and examined under the microscope. If bacteria are seen, the color of stain they picked up (purple or red), their shape (such as round or rectangular), and their size provide valuable clues as to what type of microorganism they are and what antibiotics might work best.
- To do the subculture a drop of blood is placed on a culture plate, spread over the surface, and placed in an incubator.
- Aggregation of a signal can be used to detect the presence of a single organism in a plug.
- a single bacterium can simultaneously bind to many antibodies. If each of these antibodies has a signal, then the signal would be localized and therefore become detectable. For instance if each antibody was tagged with a fluorescent marker, then although single fluorescent markers may not be detected, the co-localized signal from many markers would be above the threshold for detection. Similarly, if each antibody was tagged with an enzyme, then many antibodies close together would create a high local concentration of the enzyme. Many enzymatic cascades (such as initiation of blood coagulation) require a threshold local concentration of enzyme.
- a detection method may involve antibodies which bind to the bacteria but also are tagged with the metalloprotease InhA (expressed by Bacillus species which induce blood clotting).
- InhA expressed by Bacillus species which induce blood clotting.
- a bacterium that is recognized by the antibody will bind to many antibodies and create a cluster of antibodies and therefore a localized cluster of InhA.
- the coagulation cascade will respond to the local cluster of InhA and initiate coagulation.
- An additional effect of aggregation of a signal in the decrease in the background signal For instance, if there are 100 molecules of signal in a 1 mL sample, then before clustering the background is 100 molecules/mL. After clustering 80 of the molecules together followed by stochastic confinement (assume in a 1 femtoliter space), the signal is now 80 molecules/fL and the background is now 20 molecules/mL because 80 molecules of signal have been removed from the bulk solution. In this way, aggregation of a signal increases the signal to noise ratio.
- Another advantage of stochastic confinement is to segregate the signal/analyte from background material. For example, in the detection of bacterial strain “A” in a sample that contained numerous contaminant strain “C”, assays in the bulk may experience interference from the presence of strain “C”. This interference may be in the form of “C” influencing the behavior of “A”, or “C” influencing the components of the assay itself. Interference problems may be increased if the sample contains an abundance of “C” and few “A”. By forming plugs which separate species “A” from “C”, the assay may be run successfully for the presence of “A” as some plugs will contain only strain “A” and none of strain “C”. As long as the threshold is tuned properly, the amplification cascade can selectively respond to only the active, target particles even in the presence of a large excess of interfering particles.
- Microwells can be defined as a small compartment with volumes of nanoliters or less.
- the well is open on the top and the walls are impermeable to either the particles to be detected, molecules used in the detection system, or both.
- a top barrier may be placed over the wells in order to completely confine the particle(s) and molecules in the well. Even without complete confinement, a well with a single open wall will still experience some confinement effects due to decreased flux of particles and molecules into and out of the well.
- Another confinement method is to trap the particles in the matrix of a gel or polymer. Confinement effects will be achieved by reducing the diffusion of both the particles and the molecules used in the detection scheme. In this way, high local concentrations of molecules used for detection will accumulate around the particle. Adding an impermeable boundary to the bottom and/or top of the matrix (such as glass, plastic, etc.) will further increase confinement effects due to decreased flux of the accumulating signal away from the particle.
- a microfluidic device was designed to confine single bacterium into plugs of nanoliter volume.
- much of the volume of the initial solution forms plugs that contain no bacteria.
- the concentration of bacteria in the occupied plugs is greater than the concentration of bacteria in the initial solution. For example, if plugs of nanoliter volume were made from a culture with an initial bacterial concentration of 10 5 CFU/mL, one in ten plugs would receive a single bacterium, as illustrated in FIG. 1 a .
- the concentration of cells in these occupied plugs would be one bacterium per nanoliter or 10 6 CFU/mL.
- 10 5 CFU/mL corresponds on average to 0.1 bacterium per 1 mL, and confining this solution into nanoliter plugs creates plugs with 0 bacteria per nanoliter plug and with 1 bacterium per nanoliter plug.
- CFU/mL refers to the colony forming units (CFU), a measure of live bacteria, per milliliter. Confinement effects are increased as the volume of plugs is decreased, therefore when confinement effects could be achieved in nanoliter plugs, picoliter plugs or femtoliter plugs would have increased confinement effects.
- Targeting virulence factor for screening antibacterial drugs is a potential way to develop novel drugs.
- targeting to virulence factors involved in human pathogenesis is considered essential. It has also been suggested that using surrogate infection model systems to screen novel drugs is a key issue for detecting and investigating the virulence factor.
- Bacterial virulence may also be used to identify new therapeutics.
- Targeting virulence helps to preserve the many symbioses between the microorganism and host that contribute to human health.
- Targeting bacterial adhesion and toxin production and function are good approaches to developing the antivirulence drugs which will prevent the assembly of adhesive machinery or toxin expression or secretion.
- Quorum-sensing systems, two-component response systems, and biofilm formation can additional targets for virulence factors control.
- pathogens cause disease in humans adhesion, colonization, invasion, immune response inhibitors, and toxins. Since pathogenic bacteria have different methods of inducing virulence, conditions for inducing/monitoring/evaluating virulence are useful targets for drug discovery.
- ROS reactive oxygen species
- Inflammatory cells have defense mechanisms against invading microorganisms and are known to exert their antimicrobial actions by releasing reactive oxygen species (ROS), proteolytic enzymes and other toxic metabolites. While these ROS and other toxic compounds damage pathogens and host cells together, antioxidant defense system such as superoxide dismutase (SOD), catalase, glutathione, and glutathione peroxidase also affect the host cells specifically.
- SOD superoxide dismutase
- catalase catalase
- glutathione glutathione peroxidase
- the standard procedure for a patient presenting a bacterial infection in the blood is to take a blood sample from the patient, the blood sample having a cell density of 100 CFU/mL. If the patient has an infection of methicillin resistant Staphylococcus aureus , and traditional culture based methods are used, detection of the Staphylococcus aureus takes about 12 hours. At that point the susceptibility of the pathogen to antibiotics would not yet be known; antibiotic testing would require another 6 hours.
- the infection is identified after 12 hours and then it takes 6 additional hours to screen antibiotics. Many patients would not receive appropriate antibiotic treatment for over 18 hours, which means that the infection has worsened and the chance of mortality is greatly increased.
- Stochastic confinement is useful for large scale monitoring of resistant strains in the population and offers many benefits. Bacterial infections in the hospital setting do not routinely undergo in depth characterization of the infecting strain. Stochastic confinement provides a cheap and efficient method of characterizing pathogens so that hospital bacterial infections can be characterized routinely in the hope of better controlling them. In addition, functional tests are a better way to characterize pathogens than genetic tests because the genetic marker for a new resistance mechanism can be found immediately. Therefore there is less of a time delay between identification a new resistance mechanism and the discovery of a genetic marker useful for the diagnosis of the resistant strain. Stochastic confinement also enables increased tracking of resistance patterns leading to early recognition of resistant strains and enables health care agencies to track the spread of resistant strains.
- Target or host cells and potentially infectious organisms are added into plugs and monitored for infection.
- Human/mammalian, bird, live stock, plants/crops can all be used as the target or host cells for these kinds of infectivity assays.
- the same techniques can be used to look for ways of reducing infectivity of microbes in any of these systems.
- virulence is used to mean direct infectivity, or killing remotely, any kind of pathogenicity, or negatively affecting the host cell in other ways or sporulating of bacterial spores, or activation of viral particles, or transition of bacterial cells from dormant to active form (relevant to tuberculosis).
- Particle refers to a cell, a viral particle, a spore, and the like.
- Reducing virulence is a good strategy to fight microbial infections.
- Targeting virulence factors for screening antibacterial drugs is a potential way to develop novel drugs.
- To escape cross-resistance of current drugs, targeting to virulence factors involved in human pathogenesis is considered essential.
- To find compounds that reduce virulence conditions need to be presented that induce virulence so that the virulence and the effects of drugs on virulence can be monitored.
- pathogens cause disease in humans including adhesion, colonization, invasion, immune response inhibition, and toxins. Since pathogenic bacteria have different ways of inducing virulence, conditions of inducing, monitoring, and evaluating virulence should be selected as the target.
- Components may include the presence of host's cellular signals, accumulation of secreted microbial factors, presence of surface-bound cellular components and signals, presence of host cells, presence of molecular species associated the host's environment, presence of molecular species present on surfaces of host cells, reactive oxygen species, or reactive nitrogen species.
- ROS reactive oxygen species
- Inflammatory cells show defense mechanism against invading microorganisms and are known to exert their antimicrobial actions by releasing reactive oxygen species (ROS), proteolytic enzymes and other toxic metabolites. While these ROS and other toxic compounds damage pathogens and host cells together, antioxidant defense system such as superoxide dismutase (SOD), catalase, glutathione, and glutathione peroxidase protect the host cells.
- SOD superoxide dismutase
- catalase catalase
- glutathione glutathione peroxidase
- Bacteria may detect the presence of ROS to control their virulence.
- the bacterial detection method may be used to determine conditions that induce virulence using the hybrid method. Any of the factors that induce virulence may be introduced into plugs containing microbial cells and their concentration varied.
- surface chemistries may be used to incorporate molecules present on host's cell surfaces. These surface chemistries may also be screened in the context of the hybrid and/or cartridge method. A combination of several cartridges, each containing a different set of reagents (e.g. solution-based and surface-based) may be used to screen combinations of reagents at different concentrations. Activation of virulence may be observed as a function of solution and/or surface conditions, leading to determination of optimal conditions and/or conditions that are most physiologically relevant. These methods may be used in combination with confinement.
- An array of host cells may be introduced using the hybrid and/or cartridge method to determine the kinds or types of cells that a microorganism may be virulent against.
- the hybrid and/or cartridge approach may be used to screen a wide range of microorganisms against a particular host to determine which microorganisms may be virulent against the host.
- Confinement alone or in combination with other factors, may be used to induce virulence.
- confinement may lead to accumulation of secreted microbial factors turning on virulence.
- Virulence induced under confinement may be more physiologically relevant.
- microbial cells or particles isolated from a patient may be tested for their ability to induce virulence.
- Hybrid and/or cartridge methods may be especially attractive for such determination because they allow variation in the concentration of the inducing factors.
- Co-confinement of microbial cells and host cells may further improve induction of virulence, as both microbial and host factors may accumulate within the confined volume.
- Such co-confinement may be created, for example, by either forming plugs from at least two streams (one containing a suspension of microbes and the other a suspension of target cells), or by creating plugs containing one type of cells or particles (e.g., microbial cells or viral particles), and injecting them with a suspension containing the other type of particle (e.g., target cells).
- Changes in virulence may be monitored using a variety of methods including assaying for the secretion of surface expression of molecules/proteins/enzymes associated with virulence including lipases, virulence factors, iron siderophores, and the like.
- the assay may be tailored for the specific type of virulence mechanisms. For example, for adhesion, the ability of cells to stick to a host cell and detecting secretion of molecules known to promote adhesion to other cells is important. In colonization and invasion, disruption of cell membranes and promotion of endocytosis is important and thus, injection systems to inject protein/genetic material into another cell (for example via the type III secretion system) may be useful.
- molecules that bind to antibodies, formation of capsules around the cell, induction of fibrin formation to surround the bacterial cell and prevention of recognition by the host are important.
- molecules are released that may be detected using fluorescence assays, agglutination assays, light producing reactions, color change reactions and the like.
- production of certain factors associated with virulence e.g. the lethal factor associated with B. anthracis virulence
- functional tests of the effects on the target cell may be used.
- P. aeruginosa induction of oxidative stress in the host cells may be assessed by measuring changes in lipid peroxidation and glutathione contents in the host cell line or tissues.
- the activity of the antioxidant systems can be evaluated by measuring activities of superoxide dismutase, catalase, and glutathione peroxidase.
- a screen may be conducted for agents that reduce virulence.
- agents may be small molecules, proteins, antibodies, etc.
- the method is especially useful for infections which remain dormant for long periods of time and then cause problems periodically when virulence is induced such as TB, malaria, and herpes.
- Some P. vivax and P. ovale sporozoites do not immediately develop into exoerythrocytic-phase merozoites, but instead produce hypnozoites that remain dormant for periods ranging from several months (6-12 months is typical) to as long as three years. After a period of dormancy, they became reactivate and produce merozoites.
- Hypnozoites are responsible for long incubation and late relapses in these two species of malaria.
- Drugs may be compounds or entities that alter, inhibit, activate, or otherwise affect biological or chemical events.
- drugs may include, but are not limited to, anti-AIDS substances, anti-cancer substances, antibiotics, immunosuppressants, anti-viral substances, enzyme inhibitors, including but not limited to protease and reverse transcriptase inhibitors, fusion inhibitors, neurotoxins, opioids, hypnotics, anti-histamines, lubricants, tranquilizers, anti-convulsants, muscle relaxants and anti-Parkinson substances, anti-spasmodics and muscle contractants including channel blockers, miotics and anti-cholinergics, anti-glaucoma compounds, anti-parasite and/or anti-protozoal compounds, modulators of cell-extracellular matrix interactions including cell growth inhibitors and anti-adhesion molecules, vasodilating agents, inhibitors of DNA, RNA or protein synthesis, anti-hypertensives, analgesics, anti-pyretics, steroidal and non-steroidal
- Possible applications include screening for drugs that reduce virulence/infectivity of a strain of bacteria and testing bacterial isolates from patients for virulence.
- a hybrid screen and/or cartridge system pre-loaded with several drugs may be injected into plugs at the same time as combining infectable host cells with bacteria. Preventing organisms from virulence is less likely to cause evolution of resistance than simply killing them. Importantly, confinement may change virulence. Confinement may induce virulence not observed in well-plates, so the method may have advantages over traditional well-plate methods.
- the sensitivity of a bacterial strain to many antibiotics can be screened in a single experiment by using plug-based microfluidics.
- a single bacterial sample can be combined with many antibiotics to generate an antibiogram, or chart of drug susceptibilty.
- a pre-formed array of plugs of six antibiotics two beta-lactams (ampicillin, AMP, and oxicillin, OXA); a cephalosporin (cefoxitin, CFX); a fluoroquinolone (levofloxicin, LVF); vancomycin, VCM; and a macrolide (erythromycin, ERT)—was generated by aspiration.
- Antibiotics were tested at the breakpoint concentration, (British Society for Antimicrobial Chemotherapy, BSAC Methods for Antimicrobial Susceptiblity Testing, 2007) the accepted concentration of antibiotic at which bacterial susceptibility is determined ( FIG. 2 d ). Since stochastic confinement of the bacterium into nanoliter-sized plugs generates many empty plugs, 50 plugs of each antibiotic were generated such that it was statistically likely that each condition would contain several plugs each occupied by a single bacterium. In total, 400-500 plugs were formed for each screen, which consisted of 6 drug conditions and 2 blank conditions. All 400-500 plugs were collected in the same coil of tubing.
- a blank condition was located at the beginning and end of the array to ensure that the position in the array did not affect assay results.
- the plugs in this antibiotic array were merged with Methicillin Resistant S. aureus (MRSA, ATCC#43300) at an initial cell density of 4 ⁇ 10 5 CFU/mL and the viability indicator on-chip to form plugs approximately 4 mL in volume, as illustrated in FIG. 2 a .
- the merged plugs were collected and incubated for 7 h at 37° C. After incubation, the fluorescence intensity of the plugs was measured.
- FIG. 2 c shows the average intensities of plugs that showed an increase in fluorescence intensity greater than 3 times the baseline (black bars) and plugs that showed an increase in fluorescence intensity less than 3 times the baseline (hatched bars).
- No plugs containing VCM or LVF had a fluorescence increase greater than 3 times the baseline, indicating that MRSA was sensitive to these antibiotics.
- Poisson statistics (Eq. 2) can be used to predict the probability of not loading a bacterium into any of plugs in the conditions LVF or VCM. In other words, Eq. 2 predicts the possibility of the LVF or VCM results being false-negative.
- f is the probability of having k bacteria in a plug given an average bacterial loading of ⁇ bacteria per plugs.
- ⁇ was 0.12, as 12% of control plugs with no antibiotics received bacteria ( FIG. 2 b , +blank plugs).
- the probability of having 49 unoccupied plugs is 0.887 49 , or 0.0028. Given that LVF and VCM had at least 49 plugs, the probability of a false-negative due to loading is less than 0.3%.
- the results from the MRSA antibiotic screen were used to make the antibiogram in FIG. 2 d .
- the antibiotics were tested at the breakpoint concentration, and the fluorescence data was used to determine if the bacterial strain was sensitive (S) or resistant (R) to the antibiotic.
- Sensitive means that no plugs containing a specific antibiotic showed an increase in fluorescence intensity greater than 3 times the VCM baseline.
- Resistant means that at least one plug containing a specific antibiotic showed increased fluorescence intensity greater than 3 times the VCM baseline.
- the susceptibility profile generated for MRSA by using the microfluidic screen was identical to the profile generated by using Mueller-Hinton agar plate tests and similar to previous reports in the literature for MRSA. (B. T. Tsuji, M. J.
- antibiotic sensitivity testing is influenced by many factors, including bacterial load, culturing conditions, temperature, bacterial strain, and type of assay used to detect sensitivity.
- a cell population may contain sub-populations of cells with variable sensitivity to a given antibiotic. All of these factors should be considered and further characterized before formulating guidelines for implementing plug-based antibiotic sensitivity assays.
- Plug-based methods can also be used to determine the minimal inhibitory concentration (MIC) of an antibiotic against a bacterial sample.
- MIC minimal inhibitory concentration
- CFX antibiotic cefoxitin
- MRSA and MSSA MRSA and MSSA
- This assay was similar to the antibiotic screening assay described above, except that the pre-formed array of antibiotic plugs all contained the same antibiotic and the concentration of that antibiotic in each plug of the pre-formed array was different. Again, plugs containing saline solution were included at the beginning and end of the array to serve as negative controls and to ensure that the first and last plugs of the array gave similar assay results.
- the positive control plugs consisted of CFX at a concentration of 24 mg/L, as both strains are known to be inhibited by CFX at this concentration.
- Plugs of the antibiotic array were merged with bacteria and the fluorescent viability indicator as illustrated in FIG. 6 a and incubated at 32° C. Plugs with MRSA were incubated for 6.75 h and plugs with MSSA were incubated for 6.5 h. It should be noted that temperature can affect the results of antibiotic sensitivity assays. Here, the difference in MIC of MRSA and MSSA was discerned by assays conducted at 32° C.
- the issue of screening media conditions along with drugs is of interest.
- the outcome of a drug screen can be heavily influenced by the media and culturing conditions used for the screen.
- To eliminate false negatives in a drug screen it would be useful to screen the same drug condition in a variety of media and culturing conditions.
- an unknown sample of bacteria may be screened against the drug oxicillin at 30 and 37° C., 100 and 150 mM NaCl, and in Luria Bertani media and soy trypticase media.
- the media may: 1) influence the growth rate of bacteria regardless of drug condition (if the media condition is such that bacteria grow very slowly, the assay would falsely determine that the drug is killing the bacteria); or 2) influence the interaction between the bacteria and the drug.
- Stochastic confinement combined with plug-based microfluidic handling methods accelerates bacterial detection and enables rapid functional antibiotic screening.
- assays may be performed on a single bacterium, potentially eliminating the need for pre-incubation.
- detection time is now determined by plug volume. We were able to achieve detailed functional characterization of a bacterial sample in less than 7 hours. We also demonstrated that a bacterium in a 1 mL plug may be detected in as little as 2 hours. The detection time is limited by the formation and measurement of plugs of small volume and is less dependent on the initial concentration and growth rate of bacteria in the sample. This feature may be potentially important for accelerated detection of slowly-growing species such as M.
- tuberculosis a pathogen of significant importance world-wide.
- High-throughput screens with more conditions and increased concentration of the sample would require methods that can handle larger numbers of smaller plugs, including methods for automated sorting and analysis.
- this technique may be used for the detection of bacteria in a sample at a cell density much lower than 10 5 CFU/mL. Since the activity of single cells is being measured, it is conceivable that detecting the presence of even a single bacterium in a sample may be feasible.
- Confinement affects may be of particular use in the detection of slow growing bacterial strains such as Mycobacterium tuberculosis (the strain which causes tuberculosis, TB).
- Mycobacterium tuberculosis the strain which causes tuberculosis, TB.
- To grow a culture of M. tuberculosis using traditional methods takes several weeks.
- Current tests for TB are based on an immune response, but cannot distinguish between someone with an active infection and someone who has previous immunization. Other current tests involve PCR based methods. Stochastic confinement should increase the sensitivity of detection based assays and also remove the need for a lengthy preincubation step before running the detection assay since detection may be done with a single confined cell.
- Confinement effects may be used to screen natural sources for candidate organisms or their genes that perform functions of interest or generate molecules of interest.
- Functions of interest include nitrogen fixation, carbon recycling, hydrocarbon production, pollutant degradation, solar energy conversion, forming a symbiotic relationship with other microbes, producing a toxin that kills other organisms, produces light, produces an odor, generates electricity.
- Molecules of interest include drug candidates, small molecule inhibitors, enzymes which degrade cellulose, enzymes which degrade pollutants, adhesives, electron transport molecules, metal chelators, selective inhibitors of small molecules, catalysts, plasticizing agents, and proteases.
- Some of these functions may not occur in large volume (low density of cell type which performs function) samples or samples with mixtures of microbes.
- One advantage of confinement is that individual microbes will be able to function under high density conditions. This would be useful for rare cell types in a sample, as high density functions would not be occurring in the original sample due to the rare cells being at a low cell density. Such functions would not be occurring in a macroscale sample. Confinement may also enable rare cell types of initiate growth or increase the growth rate due to the high concentration of rare cells in a small volume plug after confinement.
- This type of approach can be extended to rare cell types from mixed species samples by confining rare cell at high densities to enable more rapid growth of the rare cells due to both increased inoculation density and eliminating competition with other strains in the original mixed sample.
- the effect of confinement in small volumes is increased if the molecules accumulating in the plug are immiscible in the carrier fluid (the fluid surrounding the plug). Using immiscible fluids around the plug will prevent released microbial products from diffusing out of the plug and hence the released products will more quickly accumulate and achieve a higher concentration in the plug.
- Other applications include detecting bacteria for applications in homeland security and safety of the food chain and water. It is also possible to apply these methods of detection to the areas of sepsis, bioenergy, proteins, enzyme engineering, blood clotting, biodefense, food safety, safety of water supply, and environmental remediation.
- a process of collecting a useful product from stochastically confined cells may comprise: confining organisms, cells or particles (by themselves, or with their enemies such as other bacterial or other cells), or with addition of stimulating chemicals; accumulating their products (antibiotics or other potentially valuable enzymes); using these products for detection; using these products for further screening (for example, dilute and different concentrations and merging with suspensions of other bacteria to see if those bacteria get killed off, or drip those dilutions into standard growth assay plates); using the accumulated enzyme and assaying for function (as described in this application, including but not limited to cellulose degradation, catalysts for synthesis, disruption of biofilms); and adding other assays.
- plugs When plugs are used for stochastic confinement, allowing an organism to multiply inside a plug and then splitting the plug into daughter plugs (where at least two daughter plugs contain daughter organisms) provides an opportunity to perform multiple assays on clones of the organism (including assays that cannot be performed on a single organism or in a single volume).
- All of the methods and applications described herein may be done under controlled atmosphere using plugs/droplets, where fluorocarbon can enable transport of gases to the plug, and massively parallel small-scale incubations under controlled atmosphere can be performed. This may be useful for control of virulence, for hydrogen generation and for using organisms that require controlled atmosphere (anaerobes, organisms that consume or produce methane or other hydrocarbons or H 2 S, etc).
- the methods described herein may also be used to detect fungi, archaea and other organisms in a sample.
- a test strip comprises an amplification layer and may comprise one or more of the following layers: a filtration wetting layer with selectivity, a detection layer with threshold and a layer of substrate for signal output.
- a signal produced by target bacteria, for example an enzyme, will turn on the amplification reactions in the amplification layer.
- Multiple amplification layers may be applied to achieve a high magnitude of amplification.
- a substrate is used to detect the generation of control molecule or the output of the amplification in the system.
- the amplification region may be regulated by a threshold mechanism.
- the methods for amplification may be chosen from those described in the section entitled “Amplification.” A detailed definition of threshold may be found below.
- each of these techniques consists of multiple modules.
- the two most important modules are the amplification process with positive feedback that produces a large amount of substances in short time and the inhibitory mechanism.
- the interplay between these two processes sets up a threshold or a threshold-like behavior.
- a threshold is the concentration below which an input gives a background output and above which an input gives a the signal output, where the two outputs are easily distinguishable.
- the signal output must be significantly (often by two orders of magnitude or more) different than the background output.
- the transfer function may be a shifted ideal step function.
- a sigmoidal function or a similar function may be used to describe such threshold-like behaviors.
- Another way to look at threshold is the time to reach maximum possible output as a function of input. With an ideal threshold, this function is infinite when the input is below the threshold and reaches a constant small positive value when the input is above the threshold. With a threshold-like behavior, this function is very large when the input is below the threshold.
- this function decreases rapidly and reaches a very small value (such as 10% or less of that at the threshold). In the most ideal case, at threshold, a change in the number of input molecules of 1 unit leads to a drastic change in the output.
- the amplification process may selectively respond to only the active, target particles (molecules) even in the presence of a large excess of interfering particles (molecules).
- One or multiple amplification layers with threshold may be added to increase the degree of amplification.
- Threshold response may be incorporated in the detection layer to limit false positives and false negatives. Diffusion of signal molecules and control molecules may be restricted on each layer by choosing the appropriate material.
- stochastic confinement may be applicable to test strips. For example, a bacterium on the strip is confined by limited diffusion (the reagents and products are not mixed on purpose), or the test strip may be structured to restrict diffusion, for example when based on alumina or track-etched membranes.
- FIG. 8 is a schematic description of a test strip with an amplification system.
- Bacteria are brought into contact with a filtration wetting layer.
- Enzymes (E) produced by target bacteria, for example in the scale of pM or even lower, enter a detection layer with threshold and turn on the reactions to generate control molecules (C).
- C control molecules
- the signal After proceeding to amplification layer, the signal will be amplified and the concentration of control molecule increased to ⁇ M or mM.
- the control molecules will react with chromogenic, fluorogenic or other substrate in the substrate layer to give a strong output signal.
- Output signal can also be generated in any other ways.
- a timer region may be added to the test strip as shown in FIG. 9 .
- This timer region is an analogous reaction which is not detecting the analyte, but instead demonstrating the reaction is running correctly under the current conditions (age of strip, temperature, pressure, humidity, presence of certain impurities, etc.). It also gives the user the assurance that the strip is working and that they have waited long enough for the results.
- the timer region may have the same amplification system with reactions of the same sensitivity as the detection region. It may be used to test for false positive. However, the timer regions may utilize other techniques for specific purposes. Some amplification systems may be previously loaded with a known amount of analyte which may be activated upon the beginning of the test (e.g. by wetting).
- enzyme cascades may be modified to detect the type of molecule not naturally associated with the enzymes.
- the crab blood cascade may be used to detect air pollutants by modifying enzymes at the beginning of the cascade to detect a new type of input.
- Cascade assay formats may be used. These detect an analyte through a process wherein, a first signal generating compound (i.e., SGC #1) produces a product that may be utilized by a second SGC #2 to produce a product which, e.g., may be utilized by a third SGC #3.
- SGC #1 a first signal generating compound
- the subject cascade of products from SGC #1-3 results in amplification which results in a greater overall signal than may be achieved by any single SGC.
- selection may be performed indirectly by coupling a first reaction to subsequent reactions that take place in the same plug.
- first method the product of the first reaction is reacted with, or bound by, a molecule which does not react with the substrate of the first reaction.
- the coupled reaction will only proceed in the presence of the product of the first reaction.
- a genetic element encoding a gene product with a desired activity may then be purified by using the properties of the product of the second reaction to induce a change in the detectable properties of the genetic element.
- the product of the reaction being selected may be the substrate or cofactor for a second enzyme-catalyzed reaction.
- the enzyme to catalyze the second reaction may either be translated in situ in the plug or incorporated in the reaction mixture prior to incorporation into a plug. Only when the first reaction proceeds will the coupled enzyme generate a product which may be used to induce a change in the detectable properties of the genetic element. Stochastic confinement could be used to increase local concentration and signal to noise ratio and to give advantages described elsewhere herein.
- the product of the first reaction could be a substrate, enzyme, or cofactor of the second reaction, or promote the release of inhibition of the second reaction. More reaction steps could be used.
- the concept of coupling may be elaborated to incorporate multiple enzymes, each using as a substrate which is the product of the previous reaction. This allows for selection of enzymes that will not react with an immobilized substrate. It may also be designed to give increased sensitivity by signal amplification if a product of one reaction is a catalyst or a cofactor for a second reaction or series of reactions leading to a selectable product. Furthermore an enzyme cascade system may be based for the production of an activator for an enzyme or the destruction of an enzyme inhibitor. Coupling also has the advantage that a common selection system may be used for a whole group of enzymes which generate the same product and allows for the selection of complicated chemical transformations that cannot be performed in a single step.
- Previously developed methods of detection include those using nucleotide-based amplification (such as immuno-polymerase chain reaction (iPCR), (Adler, M.; Wacker, R.; Niemeyer, C. M., Sensitivity by combination: immuno-PCR and related technologies. Analyst 2008, 133, (6), 702-718.) amplification based on allosteric catalysis, (Zhu, L.; Anslyn, E. V., Signal amplification by allosteric catalysis. Angewandte Chemie-International Edition 2006, 45, (8), 1190-1196.) biobarcode, (Nam, J. M.; Stoeva, S. I.; Mirkin, C.
- iPCR immuno-polymerase chain reaction
- each of these techniques consists of multiple modules.
- the two most important modules are the amplification process with positive feedback that produces a large amount of substances in short time and the inhibitory mechanism.
- the interplay between these two processes sets up a threshold or a threshold-like behavior.
- a threshold is the concentration below which an input gives a background output and above which an input gives a the signal output, where the two outputs are easily distinguishable.
- the signal output must be significantly (often by two orders of magnitude or more) different than the background output.
- the transfer function may be a shifted ideal step function.
- a sigmoidal function or a similar function may be used to describe such threshold-like behaviors.
- Another way to look at threshold is the time to reach maximum possible output as a function of input. With an ideal threshold, this function is infinite when the input is below the threshold and reaches a constant small positive value when the input is above the threshold. With a threshold-like behavior, this function is very large when the input is below the threshold.
- this function decreases rapidly and reaches a very small value (such as 10% or less of that at the threshold). In the most ideal case, at threshold, a change in the number of input molecules of 1 unit leads to a drastic change in the output.
- An elementary amplification method for detecting molecules includes: a) a set of molecules or materials that constitute an amplification process that is capable of amplifying one or multiple components (termed output); b) a set of molecules or materials that provides an inhibitory mechanism to stop or slow down amplification by the amplification process described in a) when the amount of the analyte is insufficient; c) an activating mechanism which, once sufficient analyte (termed input) is present, triggers the amplification process described in a); d) a readout process to provide an apparent signal (with visual signal as one example).
- Inhibition in part (b) and the amplification process in part (a) set up a threshold or threshold-like behavior which gives very little or no output if the input is below the threshold and gives fast and abundant output if the input is above the threshold. This case is termed positive contrast.
- the system may be set up with the input providing a mechanism to inhibit the amplification process.
- a below-threshold amount of input a lot of the output is produced, while an above-threshold amount of input would give little or no output. This phenomenon is called negative contrast.
- the roles of part (b) and part (c) are swapped.
- the general feature is a big contrast (be it positive or negative) between the output of a below- or above-threshold input.
- Elementary amplification methods may be coupled in such a way that outputs of one may be used as inputs for another. This is also called a cascade.
- the number of elementary amplification methods in a cascade may be varied depending on how much more amplification is needed in comparison to what is provided by each elementary amplification method.
- the analyte may be any molecules such as enzymes, DNA, RNA, small molecules, or any other molecules. It may come from any sources including bacterial components, human fluids, water samples, etc.
- the amplification processes may be any reaction that is autocatalytic or a reaction network with one or more positive feedback loops.
- the processes may involve enzymes such as those in the blood clotting cascade, apoptosis, and Limulus amebocyte (horseshoe crab) lysate (LAL), or any other enzymes.
- the processes may involve inorganic chemicals such as the Co(III)-Co(II)-oxone system, (Endo, M.; Abe, S.; Deguchi, Y.; Yotsuyanagi, T., Kinetic determination of trace cobalt(II) by visual autocatalytic indication.
- Phenomena in which nucleation is involved may also be used as an amplification process, in which a crystal of aggregate produced by nucleation may serve as a nucleus to promote more production of such crystal or aggregate.
- An amplification process may also be achieved by using materials that release substances that catalyze the release of more of such substances.
- Each mechanism may occur directly or indirectly through more than one reaction or processes.
- the first mechanism may use chemical inhibitors. These chemical inhibitors may be stoichiometric, such as those that bind to enzymes and block the active sites or ligands that bind to and sequester metal cations.
- the chemical inhibitors may also be catalytic, such an enzyme that cleaves an active enzyme that is important in positive feedback loops.
- the second mechanism may use materials to mechanically separate important components of the amplification process. These materials include, but are not limited to, vesicles containing liquid, particles of solid or gel, and any combination of single-layer or multi-layer particles or vesicles of one type or multiple types.
- the input may be one or multiple types of the substances that are inhibited chemically or mechanically by materials.
- the input may directly or indirectly produce more of the substances that are inhibited chemically or mechanically in the inhibitory mechanism.
- the input may directly or indirectly interfere with the chemical or mechanical inhibition by competition with the substances being inhibited.
- the input may directly or indirectly interfere with the chemical or mechanical inhibition by chemically modifying the chemical inhibitors or the materials used to mechanically separate the components of the amplification process.
- the input generates a high local concentration of substances that may have functions described above.
- Stochastic confinement is an example of this category.
- the methods may be designed to be applicable to many kinds of analytes with different desired degrees of specificity. For example, if an existing method needs modifying to be applicable for detection of a different analyte, the activating mechanism may be changed completely or may be adapted with single of multiple steps to use the analyte of interest to promote the production of the analyte of the existing method.
- One or more substances that are amplified or activated by the amplification process may promote the production of some form of easily detectable readout.
- This readout may be a visual signal based on color.
- the color may come from any reaction that can generate color when the input (over the threshold) is present.
- an enzyme amplified in the amplification process cleaves a fluorogenic substrate or a chromogenic substrate to give a fluorescent signal or color.
- Some other examples are pH indicators, reduction-oxidation potential indicators, and indicators for specific cations.
- the readout may be a visual signal based on production of aggregates (precipitates) or crystals from any method when the input (over the threshold) is present.
- aggregates (precipitates) or crystals may be the result of any process such as chemical reaction or production of paramagnetic substances that come together as solid in a magnetic field.
- Examples of reactions that produce paramagnetic solids that may be used in an amplification process include: 1) Ag + ->Ag:Ag+ has electron configuration of d 10 , so it is diamagnetic. Ag has electron configuration of s 1 d 10 , so it is paramagnetic.
- the autocatalyst is Ag (or its surface to be more detailed);
- Mn(VII) such as, KMnO 4
- Mn(II) some soluble salt such as nitrate or chloride
- the autocatalyst is MnO 2 solid (its surface).
- the readout may be any other detectable signal, such as an electrical signal that gives analog or digital readout or any other kind.
- the amplification process may be an autocatalytic reaction or reaction network that has a positive feedback.
- This positive feedback may be achieved through one step ( FIG. 10 ).
- an autocatalytic enzyme may catalyze the cleavage of its precursor.
- a chemical inhibitor may also used to inhibit this autocatalytic enzyme, and a fluorogenic substrate may be used to detect this autocatalytic enzyme).
- Positive feedback may also be achieved through two steps ( FIG. 11 ).
- enzyme 1 may catalyze the cleavage of enzyme precursor 2 to produce enzyme 2 , which may catalyze the cleavage of enzyme precursor 1 to produce enzyme 1 .
- Common or specific inhibitors and fluorogenic substrates for enzyme 1 and enzyme 2 may be included).
- positive feedback may be achieved through any number of steps, in which one substance, called substance 1 , may catalyze directly the production of itself or indirectly by catalyzing the production of another substance that may directly or indirectly catalyze the production of the substance 1 .
- substance 1 may catalyze directly the production of itself or indirectly by catalyzing the production of another substance that may directly or indirectly catalyze the production of the substance 1 .
- Many positive feedback loops may also be coupled with each other into a cascade, in which the output of one positive feedback loop is used as the input of another ( FIG. 12 ). In such case, the number of positive feedback loops with threshold must be at least 1 and may vary from 1 to all.
- At least one enzyme in the positive feedback loop is inhibited by an inhibitor. Not every enzyme is necessarily inhibited, but many may be.
- the inhibitors may be those found naturally or synthesized. Antibodies may also be used as inhibitors.
- the input may be that enzyme. If there are multiple enzymes involved in the positive feedback loops ( FIG. 11 ), the input may be single ones or combinations of the enzymes.
- the input may produce single or combinations of enzymes from the same or different precursors as in the amplification process, through one or many steps.
- the input may also be much more strongly binding substrate for the inhibitor, or promotes the production of much more strongly binding substrate for the inhibitor.
- the input may chemically alter the inhibitors and disable the inhibitory effect, or promote the production of substances with such function.
- one or multiple fluorogenic substrates may be cleaved by one or multiple enzymes in the amplification process, through one or multiple steps. In certain embodiments, there has to be at least one cleavage reaction but one cleavage reaction may or may not be sufficient. For methods with plasma or whole blood, blood clotting may also be used as a visual readout.
- the unit of the material contains molecules that once released can promote the release of more molecules from other units of the material.
- the units may be vesicles containing liquid (such as liposomes) or particles (of solid or gel).
- Amplification using materials may be coupled with chemical amplification.
- the released molecules may also undergo chemical amplification.
- the molecules enclosed in the materials may be inactive and get activated when released by chemical reactions with substances in the bulk or by any other ways such as change in conformation, release of self-inhibition by an attached inhibitor, etc. They may also be in the same form after release, but the breakage of the material is very slow when they are enclosed, such as when the material is designed to have different reactivity with the molecules in the enclosed environment or in the bulk.
- Inhibitory mechanism These molecules may also be inhibited by some substances in the bulk when they are released.
- the input may also be or produce (through one or multiple steps) a substance that releases the molecules from the materials (this substance may be similar to or different from the enclosed) or releases the molecules from the inhibitor (by competing with the inhibitor or by inactivating the inhibitor).
- Readout process readout processes described elsewhere herein may be used, depending on specific situations.
- the input generates a high local concentration of substances.
- This technique can be used in combination with amplification processes using chemical reactions or materials.
- Stochastic confinement as described above is a powerful tool to generate high local concentrations from a solution of low bulk concentration. This technique may also be used to distinguish interfering particles (molecules) with much weaker activity but much larger number than those of interest. When interfering particles (molecules, etc.) are in a large excess, the total activity of interfering particles may be higher than the total activity of active particles (molecules) of interest. Even with kinetic amplification via a threshold response, it is impossible to detect the signal from the particles of interest in the presence of overwhelming background signal from the interfering particles unless separation is used to isolate the particles of interest. This situation may be commonly encountered in the microbiological analysis of environmental samples.
- human samples including skin, saliva, and stool samples, being analyzed for microorganisms are routinely contaminated with bacteria or other cells (blood).
- Stochastic confinement is a powerful method to compartmentalize the active particles separately from the interfering particles. Therefore, as long as the threshold is tuned properly, the amplification process can selectively respond to only the active, target particles (molecules) even in the presence of a large excess of interfering particles (molecules).
- Surfaces may be the interfaces of a plug, surface of a particle, surface of a microbe, and patterns on a surface which allows it to adsorb specific molecules.
- Many techniques for immobilizing molecules onto a surface may be used. These techniques include but are not limited to using antibodies, biotin/avidin interaction, and His-tag/Ni 2+ /nitrolotriacetic acid (His-tag/Ni/NTA) interaction.
- the molecules are enclosed in the particles.
- the particles release the molecules providing a burst of high concentration of these molecules in solution. This process may or may not be autocatalytic. In other words, the released molecules do not have to promote the release of more molecules, although they may.
- Stochastic confinement immobilizing molecules onto a limited surface and using particles containing molecules, may be used in different combinations to generate even higher local concentrations.
- the analytes are bacteria (with or without background interfering bacteria)
- the specific antibodies for the bacteria of interest can be used to concentrate a reporter enzyme on the surface of the bacteria.
- the bacteria tagged with reporter enzymes are then stochastically confined into plugs. These plugs are then merged with plugs containing vesicles containing secondary reporter enzymes.
- the reporter enzymes tagged on the bacteria promotes the breakage of the vesicles, releasing an amplified number of secondary reporter enzymes.
- the reporter enzymes then act as input for one of the amplification processes.
- a membrane can be used to keep one particular component on one side.
- a membrane that is impermeable to H + but permeable to R ⁇ —H + can be used.
- an amplification process uses R ⁇ —H + (which diffuses in from the other side of the membrane) as input to initiate the production of H + and amplifies the amount of H.
- Other substances and amplification processes may be used with appropriate membranes as well.
- a shuttle substance may transfer between two phases and speeds up the reaction in one or both phases by fast reactions with positive feedback.
- the system contains solid oxidant and iron particles in water. If the analyte is Fe 2+ (or Fe 3+ ) or produces Fe 2+ (or Fe 3+ ), Fe 2+ is oxidized by the solid oxidant to Fe 3+ , which oxidizes Fe(0) (from the iron particles) to Fe 2+ . Eventually, the solution contains a lot of Fe 2+ (if the metal particles are in excess) or Fe 3+ (if the solid oxidant is in excess) which may be detected by strongly colored indicators for Fe 2+ or Fe 3+ .
- Microfluidic devices were fabricated by using soft lithography (Y. N. Xia and G. M. Whitesides, Annu. Rev. Mater. Sci., 1998, 28, 153-184.) as described previously.
- plugs were collected in PFA or PTFE Teflon tubing (Zeus, Orangeburg, S.C.) with 150 ⁇ m or 200 ⁇ m inner diameter (I.D.).
- the tubing was cut at a 45 degree angle, inserted into the outlet of the microfluidic device up to the inlet junction, and sealed into the device by using PDMS prepolymer (10:1 elastomer to curing agent).
- PDMS prepolymer (10:1 elastomer to curing agent).
- the Teflon tubing was wound in a spiral on a glass slide, and PDMS prepolymer was poured over the tubing to fix it in place.
- the device with attached tubing was then autoclaved at 135° C. for 10 min to sterilize. Once sterilized, the glass slide containing the tubing was transferred to a sterile Petri dish.
- Cells were obtained from ATCC ( Staphylococcus aureus ATCC#25923 (MSSA) and Staphylococcus aureus ATCC#43300 (MRSA)).
- Stock solutions of the cells were made by using Luria-Bertani media Miller formulation (LB) (BD, Sparks, Md.) containing 30% (v/v) glycerol and stored at ⁇ 80° C.
- LB Luria-Bertani media Miller formulation
- BD Sparks, Md.
- TSA II Modified Trypticase Soy Agar
- Colonies from the plates were transferred to LB and cultured at 37° C., 140 rpm for 3 h at which point OD 600 was 1.5-2.0. Cell densities were then adjusted by diluting in LB. To maintain sterility, all procedures were performed in a biosafety cabinet and all tubing, devices, syringes, and solutions used were either autoclaved, sterilized by EtOH, packaged sterile, or filtered through a 0.45 ⁇ m PES or PTFE filter.
- Antibiotic stock solutions of ampicillin (AMP), oxacillin (OXA), cefoxitin (CFX), levofloxacin (LVF), vancomycin (VCM), erythromycin (ERT) were made by using 150 mM NaCl aq at a concentration of 4000 times greater than the final concentration in the plugs, filter sterilized, and then frozen at ⁇ 80° C.
- AMP Fisher Bioreagents, Fair Lawn. NJ; OXA, LVF, Fluka, Buchs, Switzerland; CFX, VCM, ERT, Sigma, St. Louis, Mo.
- AMP was tested at the breakpoint concentration of 0.25 mg/L, meaning that the stock solution was prepared at a concentration of 1000 mg/L.
- erythromycin a stock solution was prepared at 1000 times the final concentration in plugs.
- vials of the antibiotics were thawed and diluted 1000 ⁇ (250 ⁇ for ERT) with saline containing 80 ⁇ M fluorescein carboxylate. Fluorescein carboxylate was used to aid in indexing the resultant array of plugs.
- the plugs in FIG. 7 contain no fluorescein carboxylate, since indexing was not required.
- the blank conditions consisted of 150 mM NaCl.
- Antibiotic solutions were further diluted on chip 1:3 (v/v) during plug formation. 20 ⁇ M fluorescein carboxylate did not interfere with the viability assay, the activity of the cells, or effectiveness of antibiotic in tests performed on 96 well plates.
- Plates were made from Mueller Hinton Agar (Fluka, Switzerland). After autoclaving, the agar was cooled and antibiotics were added and 20 mL plates were poured.
- 50 ⁇ L of MRSA and MSSA bacterial culture at 4 ⁇ 10 3 CFU/mL was spread onto separate TSA plates. The plates were incubated at 30° C. After 16.5 h and 40 h the plates were examined for colonies. MRSA colonies appeared on CFX after 16.5 h and on the OXA plates after 40 h. Even after 40 h, MSSA colonies did not appear on the CFX or OXA plates.
- AMP For AMP, ERT, LVF, and VCM, 5 ⁇ L of culture at 2 ⁇ 10 4 CFU/mL were spread onto plates, and the plates were incubated at 37° C. for 12 h. After 12 h, growth of colonies on the plates was considered resistance to the antibiotic and no colonies on the plates were considered sensitivity to the antibiotic. For all tests, control plates with no antibiotic were inoculated to ensure that each plate tested received many CFU during inoculation.
- Plugs were formed by using the general methods described previously. (L. Li, D. Mustafi, Q. Fu, V. Tereshko, D. L. L. Chen, J. D. Tice and R. F. Ismagilov, Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 19243-19248; D. N. Adamson, D. Mustafi, J. X. J. Zhang, B. Zheng and R. F. Ismagilov, Lab Chip, 2006, 6, 1178-1186) Plugs were formed in a 3 inlet PDMS device with 100 ⁇ m wide channels by flowing S.
- Both sets of plugs were immediately imaged by using a epi-fluorescence microscope (IRE2, Leica) with a Cy3 (Chroma 41007, Cy3) filter and a 10 ⁇ 0.3 NA objective for a 5 ms exposure time with binning set to 4 and gain set to 200. Fluorescent images of plugs were processed by subtracting the average background intensity from all images. Line scans ( FIG. 1 b ) with a width of 25 pixels were taken along the long axis of each plug.
- PDMS devices with channel widths ranging from 200 to 800 ⁇ m were prepared. Teflon tubing with diameter similar to that of the channel was cut at a 45° angle, inserted into the device up to the inlet junction, and sealed in place using PDMS.
- plugs were formed as above, with the exception that the ⁇ 1500 mL plugs were made via aspiration by using a manual aspirator.
- 1 mL plugs were formed in PTFE tubing with an outer diameter (OD) of 200 ⁇ m and an inner diameter (ID) of 90 ⁇ m
- 690 mL plugs were formed in PTFE tubing with an OD of 700 ⁇ m and an ID of 600 ⁇ m
- 100 and 120 mL plugs were formed in PTFE tubing with an OD of 800 ⁇ m and an ID of 400 ⁇ m
- 1500 mL plugs were formed in PTFE tubing with an OD of 1100 ⁇ m and an ID of 1000 ⁇ m.
- Plugs were collected in the Teflon tubing, the tubing was sealed with wax, and the tubing was placed in a Petri dish containing LB for incubation and imaging.
- Time zero is defined as the time at which the sample entered the incubator, which was less than 20 min after sample preparation. Fluorescence measurements were taken with 5 ms exposure times with a 5 ⁇ 0.15 NA objective using a 1 ⁇ camera coupler for plug sizes 1, 12.6, 100, and 690 mL plugs and a 0.63 ⁇ camera coupler for 1500 mL plugs. Plugs 125 mL in volume were imaged with 10 ms exposure times with a 5 ⁇ 0.15 NA and a 0.63 ⁇ camera coupler.
- Plugs were analyzed by first separating them from the background by thresholding to exclude intensity below 250. The average intensity of the thresholded plugs was measured. Over time, the intensity of the plugs diverged into 2 groups, occupied plugs and unoccupied plugs. All occupied plugs had a change in intensity more than 2 fold unoccupied plugs. Detection time is defined as the time at which the fold change of the occupied plugs compared to the intensity of unoccupied plugs reaches a maximum. Fold change in intensity is defined as the change in intensity of an occupied plugs divided by the average change in intensity of unoccupied plugs (Eq. 1).
- the intensity of the empty plugs is the average of all empty plugs in each experiment.
- FIG. 1 d 96 well plates results for FIG. 1 d were acquired in a Tecan Safire II plate reader (MTX Lab Systems, Vienna, Va.) with Ex/Em 560/630 nm, gain 25, and 40 ⁇ s integration time. 200 ⁇ L of cell culture suspended in LB with 10% alamarBlue was added to wells of a Costar 96 well assay plate with black sides and a clear, flat bottom (Corning, Corning, N.Y.). Each data point represents triplicate measurements taken at 37° C. Fold change in intensity from 96 well plate results were calculated by using Eq. 1 where the well with LB and alamarBlue only was the unoccupied plug condition.
- an array of ⁇ 50 nL antibiotic plugs was aspirated into Teflon tubing (200 ⁇ m ID) using a manual aspirator. Air spacers were included between each antibiotic plug to prevent merging of adjacent antibiotic plugs and to enable indexing of plugs in the output array. Plugs of saline solution were included as the first and last plugs in the preformed array to serve as positive controls.
- the Teflon tubing containing the array of antibiotic plugs was sealed into a device inlet by using wax (Hampton Research, Aliso Viejo, Calif.). To screen the susceptibility of MRSA and MSSA to each antibiotic, bacterial samples and indicator were merged with the preformed array of antibiotic.
- Bacterial samples were at a density of 4 ⁇ 10 5 CFU/mL in LB, and viability indicator solution was made by mixing 4 parts alamarBlue solution (AbD Serotec, Oxford, UK) with 6 parts 150 mM NaCl.,
- the flow rate of the antibiotic array was 0.25 ⁇ L/min; the flow rate of the bacterial solution was 0.5 ⁇ L/min, and the flow rate of the viability indicator was 0.25 ⁇ L/min.
- the carrier fluid was FC40 (Acros Organics, Morris Plains, N.J.) with a flow rate of 1.6 ⁇ L/min.
- the tubing was disconnected from the PDMS device, and the ends were sealed with wax.
- the Petri dish containing the tubing was filled with 20 mL of LB solution to prevent evaporation of the plugs during incubation.
- the plugs were immediately transferred to a microscope incubator (Pecon GmbH, Erbach, Germany). Time zero is defined as the time which the plugs entered the incubator, which was about 20 minutes after plugs were formed.
- FIG. 3 For MIC determination in plugs ( FIG. 3 ), a procedure similar to screening susceptibility of many antibiotics was used.
- the input array of antibiotics consisted of plugs of CFX at a range of concentrations.
- Bacterial samples were MRSA or MSSA in LB at cell densities near 10 6 CFU/mL.
- fluorescence intensity of plugs was normalized as described for FIG. 2 c.
- Unpaired t-tests were performed to compare antibiotic screening results to positive and negative controls.
- VCM and LVF are statistically different than positive controls and AMP, CFX, OXA, ERT, and blank conditions were all statistically different than the negative control.
- FIG. 3 b 8 and 24 mg/L CFX were statistically different than positive controls and 0, 0.2, 1, 2, and 4 mg/L were statistically different than the negative control.
- FIG. 3 c 4, 8, and 24 mg/L CFX were statistically different than positive controls and 0, 0.2, 1, and 2 mg/L were statistically different than the negative control. P values are two-tailed.
- FIG. 4 cells were suspended in a 1:1 mixture of human blood plasma (Pooled normal plasma George King Bio-Medical, Overland Park, Kans.) and LB containing 40% alamarBlue. Plugs were formed and collected in Teflon tubing (200 ⁇ m ID). Images were taken with a 5 ⁇ 0.15 NA objective with a 0.63 ⁇ camera coupler. Texas red pictures were taking every 10 minutes with exposure times of 25 ms. A bright-field image was taken at beginning and end of experiment. Linescans of original plug images were taken at time 0 and time 7.5 h. Adobe Photoshop was used to enhance contrast of plugs shown in FIG. 4 .
- Microfluidic bacterial detection and drug screening are applicable to complex, natural matrices, including human blood plasma.
- this method was used to detect bacteria in a sample of human blood plasma.
- Bacterial strains MSSA or MRSA were inoculated into pooled human blood plasma at a concentration of 3 ⁇ 10 5 CFU/mL.
- the antibiotic ampicillin (AMP) was added to the culture at the breakpoint concentration.
- the inoculated plasma was then combined on-chip with viability indicator as illustrated FIG. 4 a . After 7.5 h of incubation at 37° C., plasma samples infected with MRSA were distinguishable from samples infected by MSSA by screening the samples against AMP at the breakpoint concentration.
- plugs containing MRSA and AMP showed a similar increase in fluorescence intensity to plugs containing MRSA and no AMP ( FIGS. 4 b and c ), plugs containing MSSA and AMP showed no increase in fluorescence intensity ( FIGS. 7 d and e ).
- Amplification examples 1-6 involve blood coagulation proteins.
- Amplification example 7 involves proteins in apoptosis.
- Amplification example 8 involves Limulus amebocyte lysate from Horseshoe crabs.
- the enzyme precursor is engineered prothrombin that may be cleaved by thrombin to produce more thrombin.
- the potential of this engineering approach is supported by a method to make an engineered factor X that may be cleaved by thrombin.
- the inhibitor is hirudin (or other inhibitors or antibodies of thrombin such as antithrombin III, heparin, or anophelin), which binds to thrombin and prevent the cleavage of prothrombin by thrombin.
- Activating mechanism The analyte, bacterial phosphatase, cleaves a tag attached to an inhibitor of hirudin (anti-hirudin), allowing this activated molecule to inhibit hirudin and release thrombin from hirudin.
- the bacterial phosphatase cleaves a tag attached to thrombin. In both cases, thrombin then cleaves prothrombin and produces more thrombin.
- the specificity of this method may be designed to match expectation by changing the specificity of the cleavage of the tag by bacterial phosphatase. If detection of an enzyme different from phosphatase is needed, a different tag is used.
- Thrombin enzymatically cleaves a fluorogenic substrate (such as Boc-Asp(OBzl)-Pro-Arg-MCA) to give fluorescent signal.
- a fluorogenic substrate such as Boc-Asp(OBzl)-Pro-Arg-MCA
- This method is predicted to be feasible with concentration of prothrombin from 1 nM to 1 ⁇ M, be activated with concentration of thrombin input after concentrating techniques of as low as 10 ⁇ M, give response after 1-10 minutes, and give amplification gain of 3 to 9 orders of magnitude.
- the enzyme precursor is factor XII that may be cleaved by factor XIIa to produce more factor XIIa in the presence of dextran sulfate or negatively charge surface in general.
- factor XIIa may be cleaved by factor XIIa to produce more factor XIIa in the presence of dextran sulfate or negatively charge surface in general.
- the inhibitor is ecotin (or other inhibitors or antibodies of factor XIIa).
- Activating mechanism the analyte, bacterial phosphatase, cleaves a tag attached to an inhibitor of ecotin, allowing this activated molecule to inhibit ecotin and release factor XIIa from ecotin.
- the system may also be designed so that the analyte cleaves a tag attached to factor XIIa or kallikrein. Factor XIIa or kallikrein then cleaves factor XII and produces more factor XIIa.
- the specificity of this method may be designed to match expectation by changing the specificity of the cleavage of the tag by bacterial phosphatase. If detection of an enzyme different from phosphatase is needed, a different tag is used.
- Factor XIIa enzymatically cleaves a fluorogenic substrate (such as Boc-Gln-Gly-Arg-MCA) to give fluorescent signal.
- a fluorogenic substrate such as Boc-Gln-Gly-Arg-MCA
- This method is predicted to be feasible with concentration of factor XII from 0.1 ⁇ M to 10 ⁇ M, be activated with concentration of kallikrein input after concentrating techniques of as low as 1 nM, give response after 1-10 minutes, and give amplification gain of 3 to 5 orders of magnitude.
- the enzyme precursor is factor XI that may be cleaved by factor XIa to produce more factor XIa in the presence of dextran sulfate or negatively charge surface in general.
- Factor-Xi Factor-Xi Activation in a Revised Model of Blood-Coagulation. Science 1991, 253, (5022), 909-912; Naito, K.; Fujikawa, K., Activation of Human Blood-Coagulation Factor-Xi Independent of Factor-Xii-Factor-Xi Is Activated by Thrombin and Factor-Xia in the Presence of Negatively Charged Surfaces. Journal of Biological Chemistry 1991, 266, (12), 7353-7358.)
- the inhibitor is aprotinin (or other inhibitors or antibodies of factor XIa).
- Activating mechanism the analyte, bacterial phosphatase, cleaves a tag attached to an inhibitor of aprotinin, allowing this activated molecule to inhibit aprotinin and release factor XIa from aprotinin.
- the system may also be designed so that the analyte cleaves a tag attached to factor XIa. Factor XIa then cleaves factor XI and produces more factor XIa.
- the specificity of this method may be designed to match expectation by changing the specificity of the cleavage of the tag by bacterial phosphatase. If detection of an enzyme different from phosphatase is needed, a different tag is used.
- Factor XIa enzymatically cleaves a fluorogenic substrate (such as Boc-Glu(OBzl)-Ala-Arg-MCA) to give fluorescent signal.
- a fluorogenic substrate such as Boc-Glu(OBzl)-Ala-Arg-MCA
- This method is predicted to be feasible with concentration of factor XI from 0.1 ⁇ M to 10 ⁇ M, be activated with concentration of factor XIa input after concentrating techniques of as low as 1 nM, give response after 1-10 minutes, and give amplification gain of 3 to 5 orders of magnitude.
- Factor XII and prekallikrein are precursors of factor XIIa and kallikrein, respectively.
- factor XIIa cleaves both factor XII and prekallikrein to produce factor XIIa and kallikrein, respectively, while kallikrein cleaves factor XII to produce factor XIIa.
- Inhibitory mechanism Inhibitors or antibodies that are common to both factor XIIa and kallikrein (such as ecotin) or different inhibitors specific to each may be used.
- Activating mechanism the analyte, bacterial phosphatase, cleaves a tag attached to an inhibitor of ecotin, allowing this activated molecule to inhibit ecotin and release factor XIIa and kallikrein from ecotin.
- the system may also be designed so that the analyte cleaves a tag attached to factor XIIa and/or kallikrein, which then activate the amplification process.
- the specificity of this method may be designed to match expectation by changing the specificity of the cleavage of the tag by bacterial phosphatase. If detection of an enzyme different from phosphatase is needed, a different tag is used.
- Factor XIIa or kallikrein or both enzymatically cleave fluorogenic substrates (such as Boc-Gln-Gly-Arg-MCA for factor XIIa and Pro-Phe-Arg-MCA for kallikrein) to give fluorescent signal.
- fluorogenic substrates such as Boc-Gln-Gly-Arg-MCA for factor XIIa and Pro-Phe-Arg-MCA for kallikrein
- This method is predicted to be feasible with concentration of factor XII from 0.1 ⁇ M to 10 ⁇ M and concentration of kallikrein from 10 ⁇ M to 10 nM, be activated with concentration of kallikrein input after concentrating techniques of as low as 1 nM, give response after 1-10 minutes, and give amplification gain of 3 to 5 orders of magnitude.
- the reaction network with positive feedback is shown in FIG. 13 .
- This is an example of cases in which positive feedback loops may be achieved through multiple steps and many positive feedback loops may be coupled with each other to form a cascade.
- this network there are two positive feedback loops.
- the first one includes the production of factor Xa from factor X catalyzed by the input (InhA1), the production of factor VIIIa from factor VIII, the binding of factor VIIIa to factor IXa to form a complex, and the production of Xa from factor X catalyzed by the VIIIa:IXa complex.
- the output of this first loop is factor Xa.
- the second positive feedback loop includes the production of factor Va from factor V catalyzed by the input (factor Xa), the binding of factor Va to the input (factor Xa), the production of thrombin from prothrombin catalyzed by the Xa:Va complex or the input of the first loop (InhA1), and the production of factor Va from factor V catalyzed by thrombin.
- the output of this loop is thrombin.
- Thrombin is detected by the cleavage of a fluorogenic substrate to release fluorescent molecules catalyzed by thrombin. ATIII/heparin is used to inhibit factor Xa, the VIIIa:IXa complex, and thrombin.
- the chemical inhibitors are ATIII/heparin that may inhibit factor Xa, the VIIIa:IXa complex, and thrombin.
- Other common or specific inhibitors for these enzymes, of for factor VIIIa, Va, and IXa may be used as well.
- the analyte may cleave tagged molecules and release them. These molecules may be the activated factors shown in FIG. 13 or inhibitors of the inhibitors of those activated factors used in the inhibitory mechanism.
- the specificity of this method may be designed to match expectation by changing the specificity of the cleavage of the tag by bacterial phosphatase. If detection of an enzyme different from phosphatase is needed, a different tag is used.
- Thrombin enzymatically cleaves fluorogenic substrates (such as Boc-Asp(OBzl)-Pro-Arg-MCA) to give fluorescent signal as shown in FIG. 13 .
- fluorogenic substrates such as Boc-Asp(OBzl)-Pro-Arg-MCA
- Other single of combinations of activated factors may be used to cleave fluorogenic substrates as well.
- this method is predicted to be feasible with concentration of enzyme precursors from 0.1 ⁇ M to 1 ⁇ M, be activated with concentration of InhA1 input after concentrating techniques of as low as 1 nM, give response after 1-10 minutes, and give amplification gain of 3 to 6 orders of magnitude.
- This example is similar to amplification example 5, but is more complicated.
- the amplification process contains most of the components in the natural blood clotting network, as shown in a review. (Kastrup, C. J.; Runyon, M. K.; Lucchetta, E. M.; Price, J. M.; Ismagilov, R. F., Using chemistry and microfluidics to understand the spatial dynamics of complex biological networks. Accounts of Chemical Research 2008, 41, (4), 549-558.) Positive feedback loops are achieved through multiple steps. Inhibitory mechanism, activating mechanism, and readout process are also similar to amplification example 5, and can be done with single of combinations of enzymes. Additionally, blood clotting may also be visualized by eyes.
- FIGS. 14 and 15 support the ideas in amplification examples 1-6 discussed above. In general, they show a threshold-like behavior in which the time of response (time for amount of some certain substance to reach a detectable value) drastically reduces as the amount of input increases over a certain value.
- amplification examples 1, 2, and 4 were considered in FIG. 14
- amplification example 6 in FIG. 15 the reaction network of amplification example 3 is similar to that of amplification example 1 and the reaction network of amplification example 5 has complexity between those of amplification examples 4 and 6. Therefore, amplification examples 3 and 5 is expected to work as well.
- FIG. 14 is the time to get response versus amount of input obtained by simulation using previously found rate constants (Tankersley, D. L.; Finlayson, J. S., Kinetics of Activation and Autoactivation of Human Factor-Xii. Biochemistry 1984, 23, (2), 273-279; Kuharsky, A. L.; Fogelson, A. L., Surface-mediated control of blood coagulation: The role of binding site densities and platelet deposition. Biophysical Journal 2001, 80, (3), 1050-1074; Ulmer, J. S.; Lindquist, R. N.; Dennis, M. S.; Lazarus, R.
- FIG. 1( a ) is the simulation of the amplification process used in amplification example 1, with set initial concentration of the engineered prothrombin (1.4*10 ⁇ 6 M), thrombin (1.4*10 ⁇ 10 M), and hirudin (1*10 ⁇ 8 M), and varied concentration of input which is thrombin.
- Time of response for each concentration of input was defined as the time when concentration of thrombin reaches 80% of the initial concentration of prothrombin (if this time is larger than 10000 seconds, it was set to 10000 seconds).
- Rate of cleavage of engineered prothrombin by thrombin was taken to be the same as the rate of cleavage of factor V by thrombin.
- FIG. 1( b ) is the simulation of the amplification process used in example 2, with set initial concentration of the factor XII (1 ⁇ 10 ⁇ 6 M), factor XIIa (1 ⁇ 10 ⁇ 10 M), ecotin (1 ⁇ 10 ⁇ 7 M), and Boc-Gln-Gly-Arg-MCA (fluorogenic substrate for factor XIIa), and varied concentration of input which is kallikrein.
- Time of response for each particular concentration of input was defined as the time when concentration of the fluorescent molecules reaches 80% of the initial concentration of the fluorogenic substrate. If this time is larger than 10000 seconds, it was set to 10000 seconds.
- FIG. 1( c ) Simulation of the amplification process used in example 4, with set initial concentration of the factor XII (1 ⁇ 10 ⁇ 6 M), factor XIIa (1 ⁇ 10 ⁇ 10 M), prekallikrein (1 ⁇ 10 ⁇ 10 M), kallikrein (1 ⁇ 10 ⁇ 14 M), ecotin (1 ⁇ 10 ⁇ 7 M), and Boc-Gln-Gly-Arg-MCA (fluorogenic substrate for factor XIIa), and varied concentration of input which is kallikrein.
- Time of response for each particular concentration of input was defined as the time when concentration of the fluorescent molecules reaches 80% of the initial concentration of the fluorogenic substrate. If this time is larger than 10000 seconds, it was set to 10000 seconds.
- FIG. 15 is the experimental results showing how blood clotting time varied with size of patch of tissue factor, an input for the blood clotting network discussed in example 6.
- the patch size in these experiments correlated with local concentration of tissue factor.
- This reaction network with positive feedback involves proteins in apoptosis.
- This network includes the production of caspase-9 from procaspase-9 catalyzed by cytochrome C and Apaf1, the dimerization of caspase-9, the production of caspase-3 from procaspase-3 catalyzed by caspase-9-dimer, the production of caspase-9 from procaspase-9 by catalyzed by either caspase-9 dimer or caspase-3.
- Inhibitory mechanism Inhibitors or antibodies for caspase-3 and/or caspase-9 are used.
- the analyte, bacterial phosphatase may cleave tagged molecules and release them. These molecules may be caspase-3 and/or caspase-9, or inhibitors of the inhibitors used in the inhibitory mechanism.
- the specificity of this method may be designed to match expectation by changing the specificity of the cleavage of the tag by bacterial phosphatase. If detection of an enzyme different from phosphatase is needed, a different tag is used.
- this method is predicted to be feasible with concentrations of enzyme precursors from 0.1 ⁇ M to 10 ⁇ M, be activated with concentration of input after concentrating techniques of as low as 1 nM, give response after 1-10 minutes, and give amplification gain of 3 to 5 orders of magnitude.
- LAL Limulus amebocyte lysate
- LPS bacterial lipopolysaccharide
- LBP LPS-binding protein
- Amplification process The clotting network of LAL.
- the input may be or promote the production of some substance that binds to LBP.
- the input may be bacterial LPS or bacterial phosphatase that may cleave tagged (and inactive) LPS.
- Negative contrast is used instead of positive contrast.
- Amplification processes The processes used in examples 1-8 are used here.
- Inhibitory mechanism There is no inhibitory mechanism.
- Inhibitory mechanism used in examples 1-8 are used as input to see the contrast.
- An enzyme precursor (inactive form) and an enzyme (active form) do not have to be two totally different molecules. They only need to have different reactivity.
- the inactive form may have an inactive conformation while the active form has an active conformation.
- a conformation change may be facilitated by binding of a small molecule to an enzyme, an enzyme to and enzyme, a small molecule to a DNA or RNA molecule, an enzyme to a DNA or RNA molecule, or binding of more than two substances.
- the inactive form may be tagged with an inhibitor, thus being self-inhibitory.
- the linker to the inhibitor is cleaved, the molecule is now active.
- Positive feedback can be incorporated in these variations because the active enzyme can catalyze the change of conformation or the cleavage of the self-inhibiting tag of another enzyme of the same kind or of different kind.
- Detection of molecules other than enzymes may be achieved as well.
- the analyte which may not be an enzyme, promotes the activation of an enzyme that may cleave the tag from the substrate used in activating mechanisms in examples 1-8, through one or multiple reactions.
- activation of enzymes may be done through change of conformation (a result of binding of some molecule to an enzyme), linking two inactive components to make an active substance, or activating another enzyme that may activate the enzyme of interest.
- Amplification process The reaction of the purple complex of Co(III) and 2-(5-bromo-2-pyridylazo)-5[N-n-propyl-N-(3-sulfopropyl)amino]phenol (5-Br-PAPS) and oxone has Co 2+ (aq) as the autocatalyst.
- Endo, M.; Abe, S.; Deguchi, Y.; Yotsuyanagi, T. Kinetic determination of trace cobalt(II) by visual autocatalytic indication.
- Inhibitory mechanism A ligand that can be used to capture Co 2+ .
- the Co(III).(5-Br-PAPS) complex may be separated from oxone by immobilizing them into two different layers or keeping the mixture dry.
- the input which may be an enzyme or a small molecule, may cleave or compete for the ligand that captures Co 2+ discussed in the inhibitory mechanism.
- the input may also be a reducing agent that reduces Co 3+ to Co 2+ rapidly but reduces oxone more slowly.
- Amplification process The reduction of aqueous Ag(I) is catalyzed by its product, Ag(0).
- Other metals such as Pd, Au, and Pt may also be used for the autocatalytic reduction of metal cations to lower oxidation states.
- the reductant may be chemically protected.
- the reductant may be based on hydroquinone, with the hydroxyl groups protected by a group that is removed by the process of interest.
- the metal cation may be captured by a ligand.
- the autocatalyst metal may be coated with small molecules, gel or polymer.
- the input (enzyme or small molecule) may deprotect the reductant by cleaving off the protective rings.
- the input may also destroy or compete for the ligand.
- the input may also remove the coating layer on the metal particle.
- Visual readout may be achieved via aggregates (precipitates) of metal, specific indicator for different oxidation states of the metals, or general reduction-oxidation indicator.
- a compound may be used to consume the autocatalyst, iodine, thus slowing down the reaction effectively to the degree that no significant output is visualized after a long time.
- the input may be iodine, or produce iodine through one or multiple reactions.
- the input may also be a compound that inhibits the consumption of iodine, or may produce such compound after one or many steps.
- Starch may be used to give a strongly colored blue complex with the product iodine.
- Amplification process The reduction-oxidation reaction between thiosulfate and chlorite is autocatalytic in both hydronium ion and chloride ion, (Runyon, M. K.; Johnson-Kerner, B. L.; Ismagilov, R. F., Minimal functional model of hemostasis in a biomimetic microfluidic system. Angewandte Chemie-International Edition 2004, 43, (12), 1531-1536.
- the amount of hydronium ion may be kept in check by using a pH buffer.
- Chloride anion may be sequestered by a cation that is a sufficiently weak oxidizer to not react with thiosulfate.
- Ag + may be sequestered by ligands. Solids that produce an acidic environment or solids that are salts of Cl ⁇ or Ag + may be coated with materials such as gel or polymer.
- the input may be acidic or promote the production of any acid through one or multiple steps.
- the input may also be chloride anion or promote the production of chloride anion, or compete with the cation that captures chloride anion, or react with the cation to disable its ability to capture chloride anion.
- the input may also be Ag + or produce Ag + by compete for or inactivate the ligands for Ag + .
- the input may also break the coating materials of the solid particles if such inhibitory mechanism is used.
- a pH or reduction-oxidation indicator may be used.
- Amplification process The organic reactions developed by Ichimura and coworkers (Ichimura, K., Nonlinear organic reactions to proliferate acidic and basic molecules and their applications. Chemical Record 2002, 2, (1), 46-55.) have acids as autocatalysts.
- the amount of hydronium ion may be kept in check by using a pH buffer or a weak base.
- the input may be acidic or promote the production of any acid through one or multiple steps.
- Negative contrast is used instead of positive contrast.
- Amplification processes The processes used in examples 1-5 described above are used.
- Inhibitory mechanism There is no inhibitory mechanism.
- Activating mechanism Inhibitory mechanism used in examples 1-5 described above are used as input to see the contrast.
- the analytes are particles that can be tagged with some activating molecules through various methods (such as antibodies, His-tag/Ni/NTA, biotin/avidin etc), a method can be used to detect small concentration of the analytes in which the amplification process may be any.
- the activating molecule is first concentrated on particles. Then stochastic confinement is performed to concentrate these particles into plugs. The concentrated activating molecules act as input for the amplification process. Because excess activating molecules are not concentrated on particles, even after stochastic confinement, the concentration is still not high enough to activate the amplification process.
- the amplification process may be chosen as the one described in example 5 of section 1 and in FIG. 13 , the activating molecules may be chosen to be InhA1, as shown in FIG. 16 .
- the particular example is predicted to be able to detect particles of concentration of as low as 1fM, which may hypothetically be amplified to 1 nM after stochastic confinement. To total time of detection is predicted to be 1-10 minutes.
- FIG. 16 illustrates combining amplification cascades with stochastic confinement enables sensitive detection of single particles or more.
- the protease shown here represents an activating molecule in general.
- a and B Particles are added to a container containing the activating molecules.
- C The particles bind to the activating molecules and are stochastically confined in plugs.
- D In plugs loaded with particles, the concentration of activating molecules is above the detection threshold and produces a threshold signal, while plugs without particles do not.
- the analytes are particles which bind to activating molecules.
- the reactions may be chosen from those described in sections 1 and 2. For example, if the system with example 2 in section 1 is chosen, the activating molecule is kallikrein.
- the enzyme precursor is factor XII that may be cleaved by factor XIIa to produce more factor XIIa in the presence of dextran sulfate or negatively charge surface in general.
- type-B particles such as 100 CFU/mL
- type-A particles such as 10 5 CFU/mL
- activating molecules per particle such as 100 fold
- FIGS. 17 A and B the activity due to the excess of type-A particles will dominate the response.
- any kind of particles which can bind to any of activating molecules described in sections 1 and 2 through antibodies or any other method may be detected using this method.
- this technique may be use to detect B. anthracis from a sample containing a lot of interfering bacteria such as B. circulans and other kinds.
- FIG. 17 illustrates selective detection of particles by using stochastic confinement.
- a and B In a bulk solution containing both a high concentration of interfering type-A particles (such as the bacteria B. circulans ) (small gray particles binding few activating molecules (such as kallikrein)) and a low concentration of target type-B particles ( B. anthracis ) (large gray particles binding many activating molecules), the activity of the excess type-A particles dominates. Therefore, solutions with excess type-A particles (A) and excess type-B particle with a low concentration of type-A particles (B) both trigger a detection response (dark gray) (C and D).
- interfering type-A particles such as the bacteria B. circulans
- target type-B particles B. anthracis
- the amount of activating molecule in each plug made from solution A remains below the detectible level, while the amount of activating molecules of plugs containing type-B particles from solution B results in readout of type-B particles (dark gray plug), not from interfering type-A particles (lighter gray plugs).
- This technique is a variation of example 2 in section 2.
- Ag particles are coated with tags to form Ag—(X—Y) n .
- This coated particle cannot bind with bacteria.
- the input cleaves or produces some substance that cleaves X—Y, exposing X on the surface of the particles.
- This technique is a variation of example 4 in section 2.
- This system contains AgCl particles coated with an inert shell (such as Ca 3 (PO 4 ) 2 ) and protected ethylenediaminetetraacetic acid (EDTA) ligands (in the solution or in the particle), and thiosulfate and chlorite in the solution.
- the input deprotects EDTA, allowing it to complex with Ca 2+ , dissolving the inert shell, exposing AgCl to the thiosulfate/chlorite mixture and activates the amplification process.
- the threshold is set up by the thickness of the inert shell.
- the method to protect and deprotect EDTA may be customized. The major reaction in this amplification process was described previously.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Sustainable Development (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Toxicology (AREA)
- Dispersion Chemistry (AREA)
- Clinical Laboratory Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Methods of detecting organisms e.g. bacteria using stochastic confinement effects with microfluidic technologies involving plugs are provided. Signal amplification methods for the detection of molecules are also disclosed.
Description
- The present patent document claims the benefit of the filing date under 35 U.S.C. §119(e) of Provisional U.S. Patent Application Ser. Nos. 60/962,426, filed Jul. 26, 2007, and 61/052,490 filed May 12, 2008, which are hereby incorporated by reference.
- This work was supported in part by Grant No. 0526693 awarded by the National Science Foundation (NSF) CRC and under grant numbers EB01903, GM075827, and GM074961 awarded by the National Institutes of Health (NIH). The government has certain rights in the invention.
- Bacterial infections are a major health problem, leading to more than 130,000 deaths from sepsis annually in the United States alone. (G. S. Martin, D. M. Mannino, S. Eaton and M. Moss, N. Engl. J. Med., 2003, 348, 1546-1554) These deaths are often the result of nosocomial, or hospital acquired, infections and frequently involve drug resistant strains of bacteria. (B. M. Farr, Curr. Opin. Infect. Dis., 2004, 17, 317-322; G. J. Moran, A. Krishnadasan, R. J. Gorwitz, G. E. Fosheim, L. K. McDougal, R. B. Carey and D. A. Talan, N. Engl. J. Med., 2006, 355, 666-674) In addition, bacteremia, the presence of bacteria in the blood, is one of the major causes of sepsis and generally requires a minimum of a day or more to diagnose, increasing the chances of patient mortality. (S. D. Carrigan, G. Scott and M. Tabrizian, Clin. Chem., 2004, 50, 1301-1314) Patient mortality rates further increase when inappropriate antimicrobial treatment is administered, which is estimated to occur in 23-30% of cases. (S. D. Carrigan, G. Scott and M. Tabrizian, Clin. Chem., 2004, 50, 1301-1314)
- Shortening the time necessary to detect and identify an effective antibiotic regimen to treat bacterial infections could significantly decrease the mortality rate and reduce the cost of treating patients with sepsis and other aggressive bacterial infections. (H. B. Nguyen, E. P. Rivers, F. M. Abrahamian, G. J. Moran, E. Abraham, S. Trzeciak, D. T. Huang, T. Osborn, D. Stevens and D. A. Talan, Ann. Emerg. Med., 2006, 48, 28-54) However, attempts to reduce the assay time of traditional diagnosis and characterization techniques are impeded by the necessity to incubate bacterial specimens for hours to days to increase the cell density of the sample to detectible levels. To overcome this challenge, new PCR-based detection methods enable diagnosis in the one to four hour time frame. (S. Poppert, A. Essig, B. Stoehr, A. Steingruber, B. Wirths, S. Juretschko, U. Reischl and N. Wellinghausen, J. Clin. Microbiol., 2005, 43, 3390-3397; K. P. Hunfeld, Int. J. Med. Microbiol., 2007, 297, 32-32.) However, these methods only provide a genetic profile of the infecting bacterial species and lack the ability to directly test the bacteria's function, such as susceptibility to particular antibiotics. Although some types of antibiotic resistance have genetic markers, such as the mecA gene for instance, (K. Murakami, W. Minamide, K. Wada, E. Nakamura, H. Teraoka and S. Watanabe, J. Clin. Microbiol., 1991, 29, 2240-2244) genetic markers have not been identified for all antibiotic resistant strains of bacteria. Therefore, antibiotic susceptibility is more accurately determined by a functional assay, especially for bacterial strains with unknown resistance mechanisms.
- There are many people (105-106) affected every year, and there is no method of detection that works. Early diagnosis of the presence and type of bacteria in a patient's blood stream would help prevent the death of millions of people dying from sepsis. Currently, blood is drawn from a patient and cultures are done to grow the bacteria. However it usually takes days to weeks to grow enough bacteria to detect them, and by the time they grow in the culture, they also grow in the patient, and the patient becomes very sick.
- The broth in the blood culture bottle is the first step in creating an environment in which bacteria will grow. It contains all the nutrients that bacteria need to grow. If the physician expects anaerobic bacteria to grow, oxygen will be kept out of the blood culture bottle; if aerobes are expected, oxygen will be allowed in the bottle.
- The bottles are placed in an incubator and kept at body temperature. They are watched daily for signs of growth, including cloudiness or a color change in the broth, gas bubbles, or clumps of bacteria. When there is evidence of growth, the laboratory does a gram stain and a subculture. To do the gram stain, a drop of blood is removed from the bottle and placed on a microscope slide. The blood is allowed to dry and then is stained with purple and red stains and examined under the microscope. If bacteria are seen, the color of stain they picked up (purple or red), their shape (such as round or rectangular), and their size provide valuable clues as to what type of microorganism they are and what antibiotics might work best. To do the subculture, a drop of blood is placed on a culture plate, spread over the surface, and placed in an incubator.
- If there is no immediate visible evidence of growth in the bottles, the laboratory looks for bacteria by doing gram stains and subcultures. These steps are repeated daily for the first several days and periodically after that.
- When bacteria grow, the laboratory identifies it using biochemical tests and the Gram stain. Sensitivity testing, also called antibiotic susceptibility testing is performed as well. The bacteria are tested against many different antibiotics to see which antibiotics can effectively kill it.
- All information is passed on to the physician as soon as it is known. An early report, known as a preliminary report, is usually available after one day. This report will tell if any bacteria have been found yet, and if so, the results of the gram stain. The next preliminary report may include a description of the bacteria growing on the subculture. The laboratory notifies the physician immediately when an organism is found and as soon as sensitivity tests are complete. Sensitivity tests may be complete before the bacteria are completely identified. The final report may not be available for five to seven days. If bacteria are found, the report will include its complete identification and a list of the antibiotics to which the bacteria is sensitive.
- What is needed is a faster and better method of detecting organisms, including improving the accuracy and decreasing the man-hours associated with standard blood culturing, and shortening the time necessary to detect and identify an effective antibiotic regimen to treat bacterial infections.
- In one embodiment, a method of detecting an organism is provided. The method comprises flowing at least two plugs in a carrier fluid through a microchannel; introducing a sample optionally comprising the organism into the first and second plugs; and analyzing the at least two plugs for the detectable signal. Each plug comprises a plug fluid that is substantially immiscible with the carrier fluid and the organism produces a detectable signal.
- In a second embodiment, a method of detecting bacteria in a patient is provided. The method comprises flowing at least two plugs in a carrier fluid through a microchannel; introducing a patient sample optionally comprising bacteria into the at least two plugs; and analyzing the at least two plugs for the detectable signal. Each plug comprises a plug fluid that is substantially immiscible with the carrier fluid and the bacteria produce a detectable signal.
- In a third embodiment, a method of detecting bacteria is provided. The method comprises flowing at least two plugs in a carrier fluid through a microchannel; introducing a sample optionally comprising bacteria into the first and second plugs, wherein the bacteria produce a detectable signal; and analyzing the plugs for the detectable signal. Each plug comprises a plug fluid substantially immiscible with the carrier fluid. The first plug comprises a means for detecting a first species of bacteria and the second plug comprises a means for detecting a second species of bacteria different from the first species of bacteria.
- In a fourth embodiment, a method of detecting bacteria is provided comprising flowing at least two plugs in a carrier fluid through a microchannel; introducing a sample optionally comprising bacteria into the first and second plugs; and detecting the presence of bacteria bound beads. Each plug comprises a plug fluid substantially immiscible with the carrier fluid. The first plug comprises a first antibody bound bead, the first antibody bound bead comprising a first bead and a first antibody that binds to a first bacteria. The second plug comprises a second antibody bound bead, the second antibody bound bead comprising a second bead and a second antibody that binds to a second bacteria different than the first bacteria. The bacteria bind to the antibody bound beads to form bacteria bound beads.
- In a fifth embodiment, a method of screening for antibiotic activity is provided. The method comprises flowing at least two plugs in a carrier fluid through a microchannel. Each plug comprises a plug fluid substantially immiscible with the carrier fluid and an antibody bound bead, the antibody bound bead comprising a bead and an antibody that binds bacteria; introducing a sample which comprises bacteria into the first and second plugs; and detecting the presence of either antibody bound beads or bacteria bound beads. The first plug comprises a first antibiotic candidate and the second plug comprises a second antibiotic candidate. The bacteria bind to the antibody bound beads to form bacteria bound beads.
- In a sixth embodiment, a method of screening for antibiotic activity is provided comprising flowing at least two plugs in a carrier fluid through a microchannel; introducing a sample which comprises bacteria into the first and second plugs; detecting the presence of either antibody bound beads or bacteria bound beads. Each plug comprises a plug fluid substantially immiscible with the carrier fluid and an antibody bound bead, the antibody bound bead comprising a bead and an antibody that binds bacteria. The first plug comprises a first antibiotic candidate and the second plug comprises a second antibiotic candidate. The bacteria bind to the antibody bound beads to form bacteria bound beads.
- In a seventh embodiment, a method of screening for antibiotic activity is provided comprising flowing at least two plugs in a carrier fluid through a microchannel; introducing a sample which comprises bacteria into the first and second plugs; and detecting the presence of bacterial growth. Each plug comprises a plug fluid immiscible with the carrier fluid and media capable of supporting bacterial growth. The first plug comprises a first antibiotic candidate and the second plug comprises a second antibiotic candidate.
- In an eighth embodiment, a method of detecting molecules is provided comprising providing a first set of molecules that constitute an autocatalytic loop, capable of amplification of one of the components; providing a second set of molecules that modulate the autocatalytic loop when the autocatalytic loop reacts with the target molecules; and analyzing for the presence of the target molecules.
-
FIG. 1 illustrates a method of detecting bacteria using stochastic confinement of bacteria into plugs reduces detection time. (a) A schematic drawing illustrating the increase in cell density resulting from the stochastic confinement of an individual bacterium in a nanoliter-sized plug. (b) A schematic drawing illustrates the experimental procedure to compare the detection of bacteria incubated in nanoliter-sized plugs and bacteria incubated in a milliliter-scale culture. (c) An illustrative graph of decreased detection time vs. the log of the plug volume. (d) An illustrative graph of detection times vs. cell density for bacteria incubated in plugs (circles) and bacteria incubated in 96 well plates (crosses) with similar initial cell densities. -
FIG. 2 . illustrates a method for screening many antibiotics against a bacterial sample using a combination stochastic confinement with microfluidic hybrid and/or cartridge methods. (a) A schematic drawing illustrating the formation of plugs of bacteria, viability indicator, and antibiotic from a preformed array of plugs of different antibiotics. (b) An illustrative graph of fluorescence intensity of the control plugs with no antibiotic (+, blank1, positive control) and vancomycin (A, VCM, negative control). (c) An illustrative bar graph shows the results of the antibiotic screen against the Methicillin Resistant S. aureus (MRSA), indicating that this strain of MRSA was resistant to four antibiotics, but sensitive to two. (d) An illustrative chart shows the agreement between the susceptibility profiles (S, sensitive and R, resistant) of MRSA determined by the plug-based microfluidic screen and the control susceptibility screen using Mueller Hinton plates. -
FIG. 3 illustrates detecting active and inactive particles. (a) a solution of target (large circles) and non-target (small circles) particles; (b) active particle decorated with antibodies or small peptides; (c) decorated target particle separated from non-target particles and concentrated by stochastic confinement; (d) rapid detection and optical readout. -
FIG. 4 illustrates stochastic confinement of particles by (a) encapsulation in droplets, (b) placement in pores of a membrane, and (c) confinement on materials with restricted transport. -
FIG. 5 is an illustrative method for analyte detection. (a) particles stochastically confined into plugs which undergo two-stage amplification on chip to give a macroscale readout; (b) particles confined on membranes which translate their activity to a signal seen by the naked eye on an upper layer; (c) particles trapped in a gel with amplification cascades incorporated localize the output signal over the active particle. -
FIG. 6 is an illustrative method used to identify the minimal inhibitory concentration (MIC) of cefoxitin (CFX) for Methicillin Sensitive S. aureus (MSSA) and Methacillin Resistant S. aureus (MRSA). (a) a schematic drawing illustrates formation of plugs of bacteria, viability indicator, and an antibiotic at varying concentrations; (b and c) Using 24 mg/L CFX as the baseline, graphs show the average change in intensity of plugs greater than (solid) and less than (striped) 3 times the baseline for MRSA (b) and MSSA (c). -
FIG. 7 is an illustrative combination of stochastic confinement with the plug-based microfluidic assay used to determine susceptibility of bacteria to an antibiotic in a natural matrix, blood plasma. (a) a schematic drawing illustrating formation of plugs of bacteria, viability indicator, antibiotic, and plasma/LB mixture; (b and c) Images and linescans of four representative plugs made from a 1:1 blood plasma/LB sample inoculated with MRSA without (left) and with (right) the addition of AMP; (d and e) Images and linescans of four representative plugs made from a 1:1 blood plasma/LB sample inoculated with MSSA without (left) and with (right) the addition of AMP -
FIG. 8 is an illustrative schematic description of a test strip with amplification system. -
FIG. 9 is an illustrative schematic drawing of a test strip with both detection region and control “timer” region. -
FIG. 10 is an illustrative chemical amplification process involving a one-step positive feedback. -
FIG. 11 is an illustrative chemical amplification process involving a two-step positive feedback. -
FIG. 12 is an illustrative chemical amplification process with a cascade of two positive feedback loops. -
FIG. 13 is an illustrative two-step amplification cascade involving blood coagulation enzymes. -
FIG. 14 is a graph of time to get response versus amount of input obtained by simulation. -
FIG. 15 is a graph of blood clotting time varied with size of patch of tissue factor. -
FIG. 16 is an illustrative example of combining amplification cascades with stochastic confinement. -
FIG. 17 is an illustrative example of selective detection of particles by using stochastic confinement. - The term “organism” refers to any organisms or microorganism, including bacteria, yeast, fungi, viruses, protists (protozoan, micro-algae), archaebacteria, and eukaryotes. The term “organism” refers to living matter and viruses comprising nucleic acid that can be detected and identified by the methods of the invention. Organisms include, but are not limited to, bacteria, archaea, prokaryotes, eukaryotes, viruses, protozoa, mycoplasma, fungi, and nematodes. Different organisms can be different strains, different varieties, different species, different genera, different families, different orders, different classes, different phyla, and/or different kingdoms.
- Organisms may be isolated from environmental sources including soil extracts, marine sediments, freshwater sediments, hot springs, ice shelves, extraterrestrial samples, crevices of rocks, clouds, attached to particulates from aqueous environments, involved in symbiotic relationships with multicellular organisms. Examples of such organisms include, but are not limited to Streptomyces species and uncharacterized/unknown species from natural sources.
- Organisms included genetically engineered organisms.
- Further examples of organisms include bacterial pathogens such as: Aeromonas hydrophila and other species (spp.); Bacillus anthracis; Bacillus cereus; Botulinum neurotoxin producing species of Clostridium; Brucella abortus; Brucella melitensis; Brucella suis; Burkholderia mallei (formally Pseudomonas mallei); Burkholderia pseudomallei (formerly Pseudomonas pseudomallei); Campylobacter jejuni; Chlamydia psittaci; Clostridium botulinum; Clostridium botulinum; Clostridium perfringens; Coccidioides immitis; Coccidioides posadasii; Cowdria ruminantium (Heartwater); Coxiella burnetii; Enterovirulent Escherichia coli group (EEC Group) such as Escherichia coli-enterotoxigenic (ETEC), Escherichia coli-enteropathogenic (EPEC), Escherichia coli —O157:H7 enterohemorrhagic (EHEC), and Escherichia coli-enteroinvasive (EIEC); Ehrlichia spp. such as Ehrlichia chaffeensis; Francisella tularensis; Legionella pneumophilia; Liberobacter africanus; Liberobacter asiaticus; Listeria monocytogenes; miscellaneous enterics such as Klebsiella, Enterobacter, Proteus, Citrobacter, Aerobacter, Providencia, and Serratia; Mycobacterium bovis; Mycobacterium tuberculosis; Mycoplasma capricolum; Mycoplasma mycoides ssp mycoides; Peronosclerospora philippinensis; Phakopsora pachyrhizi; Plesiomonas shigelloides;
Ralstonia solanacearum race 3,biovar 2; Rickettsia prowazekii; Rickettsia rickettsii; Salmonella spp.; Schlerophthora rayssiae varzeae; Shigella spp.; Staphylococcus aureus; Streptococcus; Synchytrium endobioticum; Vibrio cholerae non-01; Vibrio cholerae O1; Vibrio parahaemolyticus and other Vibrios; Vibrio vulnificus; Xanthomonas oryzae; Xylella fastidiosa (citrus variegated chlorosis strain); Yersinia enterocolitica and Yersinia pseudotuberculosis; and Yersinia pestis. - Further examples of organisms include viruses such as: African horse sickness virus; African swine fever virus; Akabane virus; Avian influenza virus (highly pathogenic); Bhanja virus; Blue tongue virus (Exotic); Camel pox virus; Cercopithecine herpesvirus 1; Chikungunya virus; Classical swine fever virus; Coronavirus (SARS); Crimean-Congo hemorrhagic fever virus; Dengue viruses; Dugbe virus; Ebola viruses; Encephalitic viruses such as Eastern equine encephalitis virus, Japanese encephalitis virus, Murray Valley encephalitis, and Venezuelan equine encephalitis virus; Equine morbillivirus; Flexal virus; Foot and mouth disease virus; Germiston virus; Goat pox virus; Hantaan or other Hanta viruses; Hendra virus; Issyk-kul virus; Koutango virus; Lassa fever virus; Louping ill virus; Lumpy skin disease virus; Lymphocytic choriomeningitis virus; Malignant catarrhal fever virus (Exotic); Marburg virus; Mayaro virus; Menangle virus; Monkeypox virus; Mucambo virus; Newcastle disease virus (VVND); Nipah Virus; Norwalk virus group; Oropouche virus; Orungo virus; Peste Des Petits Ruminants virus; Piry virus; Plum Pox Potyvirus; Poliovirus; Potato virus; Powassan virus; Rift Valley fever virus; Rinderpest virus; Rotavirus; Semliki Forest virus; Sheep pox virus; South American hemorrhagic fever viruses such as Flexal, Guanarito, Junin, Machupo, and Sabia; Spondweni virus; Swine vesicular disease virus; Tick-borne encephalitis complex (flavi) viruses such as Central European tick-borne encephalitis, Far Eastern tick-borne encephalitis, Russian spring and summer encephalitis, Kyasanur forest disease, and Omsk hemorrhagic fever; Variola major virus (Smallpox virus); Variola minor virus (Alastrim); Vesicular stomatitis virus (Exotic); Wesselbron virus; West Nile virus; Yellow fever virus; and South American hemorrhagic fever viruses such as Junin, Machupo, Sabia, Flexal, and Guanarito.
- Further examples of organisms include parasitic protozoa and worms, such as: Acanthamoeba and other free-living amoebae; Anisakis sp. and other related worms Ascaris lumbricoides and Trichuris trichiura; Cryptosporidium parvum; Cyclospora cayetanensis; Diphyllobothrium spp.; Entamoeba histolytica; Eustrongylides sp.; Giardia lamblia; Nanophyetus spp.; Shistosoma spp.; Toxoplasma gondii; Filarial nematodes and Trichinella. Further examples of analytes include allergens such as plant pollen and wheat gluten.
- Further examples of organisms include fungi such as: Aspergillus spp.; Blastomyces dermatitidis; Candida; Coccidioides immitis; Coccidioides posadasii; Cryptococcus neoformans; Histoplasma capsulatum; Maize rust; Rice blast; Rice brown spot disease; Rye blast; Sporothrix schenckii; and wheat fungus.
- Further examples of organisms include worms such as C. Elegans and pathogenic worms nematodes.
- “Particle” as used herein refers to an organism, molecule, cell, a viral particle, spore, and the like.
- “Patient sample” refers to a sample obtained from a patient or person and includes blood, feces, urine, saliva or other bodily fluid, preferably blood. Food samples may also be analyzed.
- “Sample” refers to any sample potentially comprising an organism. Environments for finding organisms include, but are not limited to geothermal and hydrothermal fields, acidic soils, sulfotara and boiling mud pots, pools, hot-springs and geysers where the enzymes are neutral to alkaline, marine actinomycetes, metazoan, endo and ectosymbionts, tropical soil, temperate soil, arid soil, compost piles, manure piles, marine sediments, freshwater sediments, water concentrates, hypersaline and super-cooled sea ice, arctic tundra, Sargosso sea, open ocean pelagic, marine snow, microbial mats (such as whale falls, springs and hydrothermal vents), insect and nematode gut microbial communities, plant endophytes, epiphytic water samples, industrial sites and ex situ enrichments. Additionally, a sample may be isolated from eukaryotes, prokaryotes, myxobacteria (epothilone), air, water, sediment, soil or rock, a plant sample, a food sample, a gut sample, a salivary sample, a blood sample, a sweat sample, a urine sample, a spinal fluid sample, a tissue sample, a vaginal swab, a stool sample, an amniotic fluid sample and/or a buccal mouthwash sample.
- Microfluidics is an attractive platform for rapid single-cell functional analysis. (M. Y. He, J. S. Edgar, G. D. M. Jeffries, R. M. Lorenz, J. P. Shelby and D. T. Chiu, Anal. Chem., 2005, 77, 1539-1544; A. Grodrian, J. Metze, T. Henkel, K. Martin, M. Roth and J. M. Kohler, Biosens. Bioelectron., 2004, 19, 1421-1428; D. B. Weibel, W. R. DiLuzio and G. M. Whitesides, Nat. Rev. Microbiol., 2007, 5, 209-218; Y. Marcy, T. Ishoey, R. S. Lasken, T. B. Stockwell, B. P. Walenz, A. L. Halpern, K. Y. Beeson, S. M. D. Goldberg and S. R. Quake, PLoS Genet., 2007, 3, 1702-1708; J. El-Ali, S. Gaudet, A. Gunther, P. K. Sorger and K. F. Jensen, Anal. Chem., 2005, 77, 3629-3636; A. Huebner, M. Srisa-Art, D. Holt, C. Abell, F. Hollfelder, A. J. Demello and J. B. Edel, Chem. Commun., 2007, 1218-1220; H. M. Yu, C. M. Alexander and D. J. Beebe, Lab Chip, 2007, 7, 726-730; C. J. Ingham, A. Sprenkels, J. Bomer, D. Molenaar, A. van den Berg, J. Vlieg and W. M. de Vos, Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 18217-18222; R. D. Whitaker and D. R. Walt, Anal. Chem., 2007, 79, 9045-9053.) Plugs, for example, droplets of aqueous solution surrounded by a fluorinated carrier fluid, provide a simple platform for manipulating samples with no dispersion or losses to interfaces. (H. Song, D. L. Chen and R. F. Ismagilov, Angew. Chem.-Int. Edit., 2006, 45, 7336-7356; H. Song, J. D. Tice and R. F. Ismagilov, Angew. Chem.-Int. Edit., 2003, 42, 768-772.) Microfluidic plug-based assays provide the ability to reduce detection time by confining bacterium into nanoliter-sized plugs. This confinement, referred to as “stochastic confinement” decreases detection time by confining the sample into plugs that either have a single bacterium, or are empty. This approach increases the effective concentration of the bacterium, and allows released molecules to accumulate in the plug. Such stochastic trapping is commonly used for single-cell analysis in microfluidic devices, (M. Y. He, J. S. Edgar, G. D. M. Jeffries, R. M. Lorenz, J. P. Shelby and D. T. Chiu, Anal. Chem., 2005, 77, 1539-1544; Y. Marcy, T. Ishoey, R. S. Lasken, T. B. Stockwell, B. P. Walenz, A. L. Halpern, K. Y. Beeson, S. M. D. Goldberg and S. R. Quake, PLoS Genet., 2007, 3, 1702-1708; A. Huebner, M. Srisa-Art, D. Holt, C. Abell, F. Hollfelder, A. J. Demello and J. B. Edel, Chem. Commun., 2007, 1218-1220; S. Takeuchi, W. R. DiLuzio, D. B. Weibel and G. M. Whitesides, Nano Lett., 2005, 5, 1819-1823; P. Boccazzi, A. Zanzotto, N. Szita, S. Bhattacharya, K. F. Jensen and A. J. Sinskey, App. Microbio. Biotech., 2005, 68, 518-532; V. V. Abhyankar and D. J. Beebe, Anal. Chem., 2007, 79, 4066-4073) and similar techniques have been used for single molecule and single enzyme work. (H. H. Gorris, D. M. Rissin and D. R. Walt, Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 17680-17685; A. Aharoni, G. Amitai, K. Bernath, S. Magdassi and D. S. Tawfik, Chem. Biol., 2005, 12, 1281-1289; O. J. Miller, K. Bernath, J. J. Agresti, G. Amitai, B. T. Kelly, E. Mastrobattista, V. Taly, S. Magdassi, D. S. Tawfik and A. D. Griffiths, Nat. Methods, 2006, 3, 561-570; J. Huang and S. L. Schreiber, Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 13396-13401; D. T. Chiu, C. F. Wilson, F. Ryttsen, A. Stromberg, C. Farre, A. Karlsson, S. Nordholm, A. Gaggar, B. P. Modi, A. Moscho, R. A. Garza-Lopez, O. Orwar and R. N. Zare, Science, 1999, 283, 1892-1895; J. Yu, J. Xiao, X. J. Ren, K. Q. Lao and X. S. Xie, Science, 2006, 311, 1600-1603.) Microfluidics also enables simultaneous execution of numerous assays of bacterial function from a single bacterial sample in the same experiment, which is especially useful for rapid antibiotic susceptibility screening. Previously, gel microdroplets had been utilized for susceptibility screening. (Y. Akselband, C. Cabral, D. S. Shapiro and P. McGrath, J. Microbiol. Methods, 2005, 62, 181-197; C. Ryan, B. T. Nguyen and S. J. Sullivan, J. Clin. Microbiol., 1995, 33, 1720-1726) However, this method did not take advantage of the stochastic confinement effects in plugs or high-throughput screening methods of current microfluidic technologies. Confinement effects as described herein are increased if the gel droplets are surrounded by a barrier substantially impermeable to released products (for example, a fluorous liquid or a non-porous solid). An immiscible fluid surrounding the droplet will form a barrier to prevent or reduce loss of released products from a cell, enabling the released products to accumulate more rapidly and reach higher concentrations in the droplet Microfluidic technology offers two advantages over traditional bacterial detection and drug screening methods: 1) stochastic confinement of single cells from dilute samples concentrates the bacteria, eliminates the need for pre-incubation, and reduces detection time; 2) each assay can be performed by using an individual bacterium, enabling hundreds of assays to be performed using a single, low density bacterial sample without pre-incubation. This technology will reduce the time needed to diagnose bacterial infections and enable patient-specific antibiotic regimens. This technology also has the advantage of separating objects into individual and separate volumes of fluid by forming plugs. A further advantage is that by using techniques such as the hybrid method to perform high throughput screening of multiple reagents and conditions using only a small volume sample.
- Examples of microfluidic technology including descriptions of uses, applications and techniques for plug-based methods of analysis, manipulation of plugs, hybrid plug merging, cartridge formation, use and handling, and holding component and loading component handling, use and formation, use of markers and fluid handling include U.S. Pat. No. 7,029,091; U.S. Published Patent Applications 2005/0087122 A1, 2005/0019792 A1, 2007/0172954 A1, 2007/0195127 A1, 2007/0052781 A1, 2006/0003439 A1, 2006/0094119 A1, 2006/0078893 A1; 2006/0078888 A1, 2007/0184489 A1, 2007/0092914 A1, 2005/0221339 A1, 2007/0003442 A1, 2006/0163385 A1, 2005/0172476 A1, 2008/0003142 A1, 2008/0014589 A1; and WIPO published international applications WO 07/081,386 A2, WO 07/081,387 A1, WO 07/133,710 A2, WO 07/081,385 A2, WO 08/063,227 A2, WO 07089541 A2, WO 07/030,501 A2, WO 06/096571 A2. These references are incorporated by reference in their entirety.
- Approaches that may be used for bacterial detection include: 1) the use of cartridges (cartridges pre-loaded with reagents for different detection methods/growth media/antibiotics may be used to detect and identify bacteria); 2) the hybrid method to test many antibiotics/substrates/detection growth conditions or culturing conditions at different concentrations; and 3) screening/sorting.
- In addition to concentrating the sample by stochastic confinement, other microfluidic on-chip approaches may be used to preconcentrate a sample before detection. One method is to flow the initial sample through a device which contains a structure (such as a filter) that would collect all of the objects (cells, particles, molecules or proteins bound to particles) needed to be detected. The structure traps the objects (through size exclusion such as a filter or through specific chemical or physical interactions with the objects) but enables the aqueous fluid in which the objects are suspended to pass through the structure. Once all of the objects have been collected in the structure, the objects may be resuspended by another aqueous flow such that the volume of aqueous fluid used to resuspend the objects is less than the volume in which the objects were originally suspended. The resuspended objects, now at a higher concentration, may then be loaded into plugs or droplets for further concentration due to stochastic confinement.
- Other concentration techniques may be used such as centrifugation, attaching magnetic beads to the particles of interest, or having surfaces which selectively bind to the target and then release the target at a later time. For example, see S. Song and A Singh, Analytical and Bioanalytical Chemistry, Volume 384,
Number 1/January, 2006, 41-43, and P. Gridzinski, J Yang, R H Liu, M D Ward, Biomedical Microdevices,Volume 5,Number 4/December, 2003, pg. 303-310. - The experiments may be done by slowly flowing plugs into a tube, incubating them as they flow (with heating/cooling for PCR if need be along the way), flowing them by the detector, and then dumping them. This may address the “storage of 1,000,000 plugs” problem.
- The 1,000,000 plugs problem with stochastic confinement refers to the fact that to concentrate a sample 1,000,000 fold, 999,999 empty plugs must be formed for every 1,000,000 fold concentrated plug. One approach to this problem is do some initial screening using a less sophisticated method (such as flow cytometry or optical scanning) to sort plugs into occupied/unoccupied groups. These simple tests would not provide a detailed characterization of the object in the plug, but would rapidly determine whether or not the plug is occupied by an object. Then the advantage of stochastic confinement can still be realized by running more tests to rapidly characterize the occupied plugs. It is also possible to run an initial screen that does take advantage of stochastic confinement, by first running a general test for the presence of the object (a simple fluorescent viability assay for bacteria) and then sorting the plugs into occupied/unoccupied before adding additional sets of reagents to test for further characterization of the object. It is also possible to take a blood sample (for example 10 mL), make it into a bulk emulsion, apply the procedure above, and then sort the plugs or analyze the plugs using flow cytometry and the like.
- A possible method for encapsulating large numbers of cells is similar to sequential merging of reagents to plugs flowing in a 1D microfluidic channel (straight channel). However, the cells are introduced into a 2D channel (width of channel much larger than width of cell), and the cells flow through regions in which various reagents are applied to the cells. The 2D channel should be approximately similar in height to the cells such that the cells flowing through the device form a monolayer. For detection, plugs may or may not be encoded. If the plugs are not encoded, plugs may be analyzed for those that respond for more complex tests like susceptibility tests. Plugs may be encoded by position, or by an internal marker (for example a fluorescent marker of different colors) if not encoded. The same tests may be done by performing multiple non-encoded tests in parallel.
- There are many variables involved in performing a blood culture. Before a person's blood is drawn, the physician must make several decisions based on knowledge of infections and the person's clinical condition and medical history.
- Several groups of microorganisms, including bacteria, viruses, mold, and yeast, can cause blood infections. The bacteria group can be further broken down into aerobes and anaerobes. Most aerobes do not need oxygen to live. They can grow with oxygen (aerobic microbes) or without oxygen (anaerobic microbes).
- Based on the clinical condition of the patient, the physician determines what group of microorganisms is likely to be causing the infection and then orders one or more specific types of blood culture, including aerobic, anaerobic, viral, or fungal (for yeasts and molds). Each specific type of culture is handled differently by the laboratory. Most blood cultures test for both aerobic and anaerobic microbes. Fungal, viral, and mycobacterial blood cultures can also be done, but are less common.
- The physician must also decide how many blood cultures should be done. One culture is rarely enough, but two to three are usually adequate. Four cultures are occasionally required. Some factors influencing this decision are the specific microorganisms the physician expects to find based on the person's symptoms or previous culture results, and whether or not the person has had recent antibiotic therapy.
- The time at which the cultures are to be drawn is another decision made by the physician. During most blood infections (called intermittent bacteremia) microorganisms enter the blood at various time intervals. Blood drawn randomly may miss the microorganisms. Since microorganisms enter the blood 30-90 minutes before the person's fever spikes, collecting the culture just after the fever spike offers the best likelihood of finding the microorganism. The second and third cultures may be collected at the same time, but from different places on the person, or spaced at 30-minute or one-hour intervals, as the physician chooses. During continuous bacteremia, such as infective endocarditis, microorganisms are always in the blood and the timing of culture collection is less important. Blood cultures should always be collected before antibiotic treatment has begun.
- Bacteria are the most common microorganisms found in blood infections. Laboratory analysis of a bacterial blood culture differs slightly from that of a fungal culture and significantly from that of a viral culture.
- Blood is drawn from a person and put directly into a blood culture bottle containing a nutritional broth. After the laboratory receives the blood culture bottle, several processes must be completed: providing an environment for the bacteria to grow; detecting the growth when it occurs; identifying the bacteria that grow; testing the bacteria against certain antibiotics to determine which antibiotic will be effective.
- Given that a typical 5 mL blood sample from a patient with bacteremia contains a cell density of 100 CFU/mL, (L. G. Reimer, M. L. Wilson and M. P. Weinstein, Clin. Microbiol. Rev., 1997, 10, 444-7) the methods of the present invention are capable of performing dozens of functional tests on such a sample. Patient-specific characterization of bacterial species not only allows more rapid and effective treatment, but also enables in-depth characterization of bacterial infections at the population level. Such detailed characterization can aid in tracking and identifying new resistance patterns in bacterial pathogens. (S. K. Fridkin, J. R. Edwards, F. C. Tenover, R. P. Gaynes and J. E. McGowan, Clin. Infect. Dis., 2001, 33, 324-329; and R. T. Horvat, N. E. Klutman, M. K. Lacy, D. Grauer and M. Wilson, J. Clin. Microbiol., 2003, 41, 4611-4616) The principles of these methods, stochastic single-cell confinement and multiple functional assays without sample pre-incubation, can also be applied to other areas, including performing functional tests on field samples, detecting contamination of food or water, separating and testing samples with mixtures of species, measuring functional heterogeneity in bacterial populations, and monitoring industrial bioprocesses.
- Other patient samples that may be collected include feces, urine or saliva. The latter would be useful for assessing oral health. Tears may be collected for diagnosing eye infections. Interstitial fluid (also referred to as tissue fluid or intercellular fluid) may be collected and use to diagnose infections in the pleural space around the lungs.
- Examples of bacterial infections, include, but are not limited to those listed in Table 1.
-
TABLE 1 Types of Bacterial Infection Type of Infection Description Examples Inapparent No detectable clinical Asymptomatic (subclinical) symptoms of infection gonorrhea in women and men Dormant (latent) Carrier state Typhoid carrier Accidental Zoonosis or Anthrax, cryptococcal environmanetal or infection, and inadvertent exposures laboratory exposure, respectively Opportunistic Infection caused by Serrati or Candida normal flora or infection of the transient bacteria genitourinary tract when normal host defenses are compromised Primary Clinically apparent Shigella dysentery (e.g. invasion and multiplication of microbes in body tissues, causing local tissue injury) Secondary Microbial invasion Bacterial pneumonia subsequent to primary following viral lung infection infection Mixed Two or more Anaerobic abscess (E. coli microbes infecting the and Bacteroides same tissue fragilis) Acute Rapid onset (hours or Diptheria days); brief duration (days or weeks) Chronic Prolonged duration Mycobacterial (months or years) diseases (tus and leprosy) Localized Confined to a small Staphylococcal boil area or to an organ Generalized Disseminated to many Gram-negative body regions bacteria (gonococcernia) Pyogenic Pus-forming Staphylococcal and streptococcal infection Retrograde Microbes ascending E. coli urinary tract in a duct or tube infection against the flow of secretions or excretions Fulminant Infections that occur Airborne Yersinia suddenly and pestis (pneumonic intensely plague) - Bacterial Detection
- To monitor the presence and metabolically active bacteria in plugs, a fluorescent viability indicator alamarBlue® was added to the cultures. The active ingredient of alamarBlue is the fluorescent redox indicator resazurin. (J. O'Brien and F. Pognan, Toxicology, 2001, 164, 132-132.) Resazurin is reduced by electron receptors used in cellular metabolic activity, such as NADH and FADH, to produce the fluorescent molecule resofurin. Therefore, fluorescence intensity in a plug is correlated with the presence and metabolic activity of a cell, in this case, a bacterium. Because resazurin indicates cell viability, resazurin-based assays have been used previously in antibiotic testing. (S. G. Franzblau, R. S. Witzig, J. C. McLaughlin, P. Torres, G. Madico, A. Hernandez, M. T. Degnan, M. B. Cook, V. K. Quenzer, R. M. Ferguson and R. H. Gilman, J. Clin. Microbiol., 1998, 36, 362-366; A. Martin, M. Camacho, F. Portaels and J. C. Palomino, Antimicrob. Agents Chemother., 2003, 47, 3616-3619; K. T. Mountzouros and A. P. Howell, J. Clin. Microbiol., 2000, 38, 2878-2884; C. N. Baker and F. C. Tenover, J. Clin. Microbiol., 1996, 34, 2654-2659.) Resazurin may be used to detect both the presence of a live bacterium and the response of bacteria to drugs, such as antibiotics. Stochastic confinement decreases detection time because in a plug that has the bacterium, the bacterium is at an effectively higher concentration than in the starting solution, and the signal-to-noise required for detection is reached sooner since the product of reduction of resazurin accumulates in the plug more rapidly.
- To demonstrate the ability of stochastic confinement to reduce detection time, a single sample of Staphylococcus aureus (S. aureus) containing the fluorescent viability indicator was split. Half of the culture was used to generate plugs of nanoliter volume, and the other half remained as a milliliter-scale culture. Both the nanoliter plugs and the milliliter-scale culture were incubated for 2.8 h at 37° C. After incubation, the milliliter-scale culture was used to form plugs. This experimental procedure is illustrated in
FIG. 1 b. Line scans indicate that confining the bacteria at the beginning of incubation (t=0), led to a few occupied plugs with a high fluorescence intensity and many empty plugs with low fluorescence intensity (solid line). All plugs made from the milliliter-scale culture had an intermediate intensity (dotted line). Confining bacteria into plugs of nanoliter volume reduced the time required to detect a change in fluorescence intensity of the viability indicator. Bacteria confined to and incubated in nanoliter-sized plugs showed a greater change in fluorescence intensity after 2.8 h than the bacteria incubated in the “unconfined” milliliter-scale culture (FIG. 1 c). Line scans of the plugs of bacteria that were incubated in plugs showed many empty plugs with low fluorescence intensity and a few occupied plugs with high fluorescence intensity (FIG. 1 b, top). However, lines scans of plugs of bacteria that were incubated in the milliliter-scale culture have a lower, uniform fluorescence intensity (FIG. 1 b, bottom). Therefore, bacteria confined to nanoliter-sizes plugs may be detected earlier than bacteria in a milliliter-scale culture. - In plugs containing single bacterium, the detection time was proportional to plug volume. Detection time was defined as the time at which the increase in fluorescence intensity reached a maximum. When single bacterium were confined in plugs ranging from 1 mL to 1500 mL in volume, detection time increased with the log of plug volume (
FIG. 1 c), implying that bacteria were dividing exponentially inside the plugs. This result is similar to previous estimates that detection time decreases by about 1.5 h for every order of magnitude increase in cell density. (P. Kaltsas, S. Want and J. Cohen, Clin. Microbiol. Infect., 2005, 11, 109-114) The detection times measured for bacteria incubated in plugs were similar to detection times measured for bacteria incubated in a 96 well plate from cultures with similar initial cell densities (FIG. 1 d). This result implies that incubation in plugs had no adverse effects on growth of bacteria. - Detecting low concentrations of species (down to single molecules and single bacteria) is a challenge in food, medical, and security industries. Plugs may allow one to concentrate such samples and perform analysis. For example, a sample containing small amounts of DNA of interest in the presence of an excess of other DNA may be amplified. Amplification may be detected if plugs are made small enough that some plugs contain single DNA molecules of interest, and other plugs contain no DNA molecules of interest. This separation into plugs effectively creates plugs with higher DNA of interest concentration than in the original sample. Amplification of DNA in those plugs, for example by PCR, may lead to higher signal than amplification of the original sample. In addition, localization of bacteria in plugs by a similar method may create a high local concentration of bacteria (1 per very small plug), making them easier to detect. For some bacteria that use quorum sensing, this may be a method to activate and detect them. Such bacteria may be inactive/non-pathogenic and difficult to detect at low concentrations due to lack of activity, but at a high concentration of bacteria, the concentration of a signaling molecule increases, activating the bacteria. If a single bacterium is localized in a plug, the signaling molecule produced by a bacterium cannot diffuse away and its concentration will rapidly increase, triggering activation of the bacterium, making it possible for detection. In addition, plugs may be used to localize cells and bacteria by creating gels or matrixes inside plugs. Bacteria and other species (particles and molecules) may be collected and concentrated into plugs by putting air through a plug fluid such as water, and then using that plug fluid to generate plugs. For example, by making smaller plugs from the initial plug, some of the newly formed smaller plugs will contain sample while other plugs will not contain the sample, but only buffer, for example. This results in concentrated sample containing plugs because some of the plugs do not contain any of the sample.
- This method is not limited to liquid samples. Microorganisms and other particulate matter can be detected in gaseous samples, such as samples of air taken at airports or along train routes. There are numerous methods for collecting airborne particles in water, for example, as described in U.S. Pat. Nos. 7,201,878, 7,243,560, and 5,855,652 all incorporated by reference herein in their entirety. After collecting the airborne particulate matter in water, these samples can then be added directly to the fluorinated oil carrier fluid to form plugs.
- PCR techniques are disclosed in the following published US patent applications and International patent applications: US 2008/0166793 A1, WO 08/069,884 A2, US 2005/0019792 A1, WO 07/081,386 A2, WO 07/081,387 A1, WO 07/133,710 A2, WO 07/081,385 A2, WO 08/063,227 A2, US 2007/0195127 A1, WO 07/089,541 A2, WO 07030501 A2, US 2007/0052781 A1, WO 06096571 A2, US 2006/0078893 A1, US 2006/0078888 A1, US 2007/0184489 A1, US 2007/0092914 A1, US 2005/0221339 A1, US 2007/0003442 A1, US 2006/0163385 A1, US 2005/0172476 A1, US 2008/0003142 A1, and US 2008/0014589 A1, all of which are incorporated by reference herein in their entirety.
- Amplifications of nucleic acids have been performed via polymerase chain reactions (PCR). The key concept of PCR comprises genetic template (primer), thermostable DNA polymerase, and the circuit for regulating temperature. By combining these components in a miniaturized microfluidic device capable of implementing cartridge and/or hybrid methods, a high concentration of interesting DNA fragments from a very small amount of genetic sample via trivial PCR methods may be collected. It has been confirmed that PDMS is a heat-stable material, indicating it is a suitable material for the PCR process.
- With respect to the cartridge, the plug-based microfluidic platform may be used to setup a huge number of reaction centers in nano- or pico-liter volume scale, extending into the femtoliter and microliter scales. With respect to the hybrid method, various conditions of reactions and samples may be incorporated, split, and merged in a microfluidic device.
- For example, a sample comprising 1% of DNA of interest in the presence of 99% of background DNA would need to be amplified enough to harvest and use. However, amplification of 1% of DNA by a factor of 100 only increases the total amount of DNA by a factor of 2, resulting in detection difficulties. By making small enough plugs to comprise a single molecule of DNA of interest, and amplifying each plug by means of conventional PCR techniques in a microfluidic device, highly amplified PCR products of
target 1% of DNA in a plug may be obtained. Assume that the probability of appearance of target DNA as a single molecule in a plug is one in every 10th plug, then the ratio of target DNA/total DNA is 1:10 in such plugs. 1000-Fold amplifications of target DNA molecule in those plugs, affords a 100:10 ratio of target to background DNA, resulting in a 10 fold increase of the total amount of DNA. Conclusively, the target DNA from the very low concentration may easily be detected under the presence of large background signals. In the microfluidic device, a platform cartridge incorporating a carrier fluid channel, a sampling channel, and one or two PCR reagent channels may be made. By regulating each fluid, individual plugs containing a single molecule of target DNA or different molecules of DNA from the sample may be generated. Along the channel containing plugs, heating regions are placed in the channel region by repeating heating and cooling process for the denaturation and renaturation of DNA samples. - Stochastic confinement has applications in the isolation and screening of rare particles or cells from a sample. When samples are stochastically confined, the result is a set of isolated volumes of fluid, most with either no particles or 1 particle. In this way, rare particles are segregated from ubiquitous particles. The separation of rare particles enables the direct assay of the function and detection of rare particles without interference from other particles in the system.
- Even if a rare particle has high activity, since it is at low concentration in the bulk sample it may not be detectable due to dilution of the signal and low signal to noise ratio as a result of low background reaction from the ubiquitous particles. Once rare particles are isolated and concentrated through stochastic confinement, other plug based microfluidic technologies can be used to screen the rare particle.
- For example, if the original sample contains 100 rare particles, since stochastic confinement enables the separation and screening of individual particles, this enables the rare particle to be screened against up to 100 different conditions. After confining all of the particles into droplets, those droplets may be merged with thousands of different conditions. If the droplets are randomly merged with screening conditions, then up to 100 different conditions will be screened against the rare particles. If the rare particle is allowed to divide, then the plug containing the rare particle can be split into several smaller plugs and each plug assayed or screened independently, for example, using the hybrid and/or cartridge method. Examples include combining the plug containing many rare particles with plugs of various reagents and conditions in order to determine the function and optimal conditions for the rare particle. As an additional example, several stochastically confined organisms may be allowed to grow inside an array of plugs. After the array is split into four daughter arrays, each daughter array may be interrogated by a different technique or reagent, while preserving the identity of plugs and their relationship in the daughter array (for example, 37th plug in the first array corresponds to the 37th plug in the second, third, and forth array). The results may be combined to provide information on the response of corresponding daughter plugs to each of the techniques. In addition, some of the daughter arrays may be retained as a reference culture. When the results from the other three arrays are known, the reference culture arrays may be used for further manipulation, characterization, assaying, and isolation of organisms.
- Isolation of rare particles through stochastic confinement may also be combined with the hybrid and/or cartridge method for screening growth/virulence activation/assay conditions against the rare cells. For example, if a sample contains 10,000 cells, 100 of which belong to a rare cell type, stochastic confinement may be used to isolate the 100 rare cells into plugs containing only a single rare cell and no other types of cells. Then the plugs containing the rare cell types may be used in hybrid and/or cartridge screening by the following methods.
- The plugs generated from the stochastic confinement may be combined with screening conditions using the hybrid and/or cartridge method. Plugs containing the rare cells are randomly distributed throughout all of the plugs generated (many of which do not contain a rare cell). If many plugs (100's, 1000's) are merged with a single screening condition, it is likely that at least one of the plugs for that condition will contain a rare cell. In this way, multiple growth/assay/virulence activation conditions may be screened against the rare cell type. A separate test may be needed to separate plugs containing rare cells from the other plugs generated by confinement. It may be best to sort the plugs into rare cell/common cell/empty after merging with the hybrid and/or cartridge screen to reduce detection time. Instead of sorting for rare cells first (which may take time) and then merging with screening conditions, the screening and determining the presence of rare cell may be done simultaneously.
- Alternatively, it may be desirable to first separate out plugs containing rare cells from plugs containing common cells or no cells. This may be done using antibodies, binding assays, testing for function specific to the rare cell combined with automated sorting mechanisms (optical, magnetic, FACS). Once the rare cell type plugs have been isolated, a hybrid and/or cartridge screen can be used to screen for growth/assay/virulence activating conditions or to run a multitude of functional and genetic tests on the rare cell type.
- Another application of stochastic confinement is to accurately count populations of cells. Since confinement isolates 1 cell per plug and may be used to perform tests to identify the type of cell in each plug, confinement may be used to determine the density (number of cells of type X per volume of sample) or the ratio (100 cells of type X for every 1 of type Y) of cells in a sample. This may also be used to find ratios of phenotypes of cell populations that are genetically identical (25% of Staphylococcus cells are resistant to oxacillin or 30% of cells will induce virulence in response to host protein X).
- Screening for growth conditions is an important application because an estimated 99% of all microbes cannot be cultured by standard techniques. Unculturability of these organisms may be due to: 1) nutrient levels of media are too high; 2) requirement of specific ion concentrations; and 3) requirement for additional factors (unusual compounds not found in most media). Confinement has two effects: 1) it reduces competition from other microbes, giving rare and slow growing cell types time to reproduce; and 2) it can be combined with the hybrid and/or cartridge method to screen for media additives and the concentration of the additive to find new growth conditions for a previously uncultured microbe or a microbe which is difficult to grow or slow growing under current conditions. In addition, one may also use control of surface chemistry provided by plugs to enhance growth of organisms. Compounds that modulate surface chemistries may be incorporated into the hybrid screen in addition to or along with compounds modulating growth conditions.
- In addition, an organism might be releasing products such as quorum sensing molecules and will not initiate growth until a threshold concentration of released products have accumulated. Confinement will put microbial cells at higher initial cell density and enable cells to grow and optionally activate genes associated with high cell density. Some organisms may be able to grow in culture, which were previously believed to be not culturable by standard techniques due to their slow growth or growth to low densities. These organisms may still undergo a sufficient number of divisions when stochastically confined, and therefore allow further detection by less-sensitive techniques that require multiple copies of the organism to be present. When plugs are used to create stochastic confinement, growth of the organism allows further manipulation and analysis that cannot be done on a single plug (for example requiring mutually incompatible methods) by splitting the plugs, injecting reagents into them and monitoring results. These steps may be performed sequentially, where the results of the first experiment guides the design of the second experiment, or in parallel. Examples of mutually incompatible methods include reagents that produce similar signals (such as fluorescence in the same range of wavelengths), or methods that require different conditions (such as different solvents or pH values), or require different states of the organisms (such as a functional test that requires an alive organism, and a staining protocols that kills the organism).
- Implementation of this type of screening may be done in many ways. For example, a known organism may be screened in the presence of many media and culturing conditions (varying ion concentrations, known autoinducers, amount of confinement, temperature, pH, protein additives, reaction oxygen species, stress inducers; changing carbon source and concentration of carbon source; changing nitrogen source and concentration of nitrogen source; changing availability of various trace metals (Mn, Mo, Cu, Pt, etc.), adding drugs known to interfere with specific cellular activities; adding transport and ion channel inhibitors, small molecules involved in cellular communication, virulence activators, etc.). After using the hybrid method to screen through many conditions, functional tests or other assays may be performed in plugs to determine if compounds have been generated with properties of interest (such as drug targets, antibiotic compounds, ion channel inhibitors, virulence activation, virulence inhibition, degradation of various compounds, binding affinity, etc.).
- One idea to investigate molecules released by microorganisms is called OSMAC (one strain many compounds)), as described in Big Effects from Small Changes: Possible Ways to Explore Nature's Chemical Diversity by Helge Bjorn Bode, Barbara Bethe, Regina Höfs, Axel Zeeck, Chem
Bio Chem Volume 3Issue 7, Pages 619-627. Small changes in culturing conditions (for example, media composition, aeration, culture vessel, addition of enzyme inhibitors) drastically change the metabolites that are released from a cell. The molecules released may aid in detection of the organism, or may have functional uses such as antibiotics. - Therefore, even though strain B. subtilis can be cultured and a lot is known about its genome, useful compounds that it is capable of releasing may be missed simply because the organism has never been grown under specific conditions such as, for example, certain concentration of phosphate ions, addition of protease inhibitor, and addition of 10
uM autoinducer 2. Therefore, using hybrid and/or cartridge like approaches, a larger range of metabolites, released compounds, and drug leads may be probed simply by running high throughput screens of various media conditions/additives. Even changes of a single component in the media (for example, phosphate from 20 mM to 1 uM) may activate the production and release of a previously unknown metabolite or compound. - Release of compounds is highly dependent on culturing conditions. It is known that phosphate levels, temperature, nutrient availability all influence the production and release of various metabolites (J. E. González-Pastor, E. C. Hobbs, R. Losick, Science, 2003, 301, 510). Hybrid and/or cartridge methods developed previously may enable the screening of media conditions and concentrations of additives both for communities, common species, and rare species of microbes.
- Implementation of this type of screening may be done by taking a known organism and screening many media and culturing conditions (ion concentrations, known autoinducers, amount of confinement, temperature, pH, protein additives, reaction oxygen species, stress inducers, carbon sources, concentration of carbon source, nitrogen sources, concentration of nitrogen source, availability of various trace elements and their chemical form (Mn, Mo, Cu, Pt, V, B etc. and corresponding ions), and/or by adding drugs known to interfere with specific cellular activities, adding transport and ion channel inhibitors, and/or small molecules involved in cellular communication, virulence activators, and the like.). After using hybrid and/or cartridge method to screen through many conditions, functional tests or other assays may be performed in plugs to determine if compounds have been generated with properties of interest (such as drug targets, antibiotic compounds, ion channel inhibitors, virulence activation, virulence inhibition, degradation of various compounds, binding affinity, etc.). Alternatively, this method may also be used with rare cells isolated from natural samples such as soil, aquatic environments including sea water and marine sediments and surfaces, an animal's digestive tract, environmentally contaminated sites including soil, water or air, sludge used in environmental remediation, etc. Cells which are unculturable (no known conditions cause them to divide/reproduce outside of natural environment) may also be used. If small volumes are used, activity may be detected even from a single cell without division.
- It is known that some strains of microbes will not initiate growth or some cellular functions unless cell density is above a minimal threshold. It is also possible that although the process is occurring, the rate at low cell densities may be so slow that it would take weeks or months to observe growth or the function. Therefore, by placing single cells in very confined spaces with small volumes it is likely that they will initiate high density processes and that many processes will have increased rates. This is especially important in the case of rare cells, since the sample may only control 1 or a few copies of the rare cell. Small volume confinement makes it possible to achieve high cell densities of rare cell types.
- Stochastic confinement may be used to isolate rare organisms from various sources, including: soil extract from various types of soil environments and soil layers (including the surface layer, subsoil, substratum), ice shelves, marine and freshwater sediments, naturally occurring biofilms, hot springs, hydrothermal vents, extraterrestrial samples, crevices of rocks, attached to particulates from aqueous environments, growing on or inside of manmade structures, clouds, gastrointestinal tract, and found forming a symbiotic relationship inside of a host organism. Specifically, stochastic confinement may be used to isolate rare cells from soil extract. Once rare cells have been obtained, the plugs containing the cells may be incubated overnight to allow for growth or secretion of molecules. The plugs containing the rare cells may then be used as an input into the hybrid and/or cartridge method. For example, to find rare cells or their secreted molecules that may stimulate production of antibiotics and other compounds by Streptomyces species, each plug containing the rare cell may then, for example, be merged with 1000's of plugs containing cells of Streptomyces species. After plugs containing streptomyces have been merged with rare cell supernatant and incubated, screening for antibiotic production is performed. In this way, compounds in the supernatant of the rare cell, or rare cells directly, may induce the production of new antibiotic compounds.
- In another example, stochastic confinement may be used to isolate cells from ocean sediments. Once plugs containing cells have been collected, the hybrid and/or cartridge method may be used to screen various media conditions such as phosphate concentration (from 0 to 100 μM),
autoinducer 2 concentration (from 0 to 100 μM), and glucose concentration (from 0 to 10 mM). The cells are then incubated in the new media conditions. Various functional/genetic tests are performed in the plugs to determine which media conditions yield growth and or production of compound with desired properties - Alternatively, cells which are unculturable (no known conditions cause them to divide/reproduce outside of natural environment) may be used. If small volumes are used, one may be able to detect activity even from a single cell without division.
- Plug based methods may be used to collect the lysate or cell free supernatant from various types of cells and merge these solutions with other cells to elicit metabolite/compound production. Lysate/supernatant may be diluted during the screen (concentration screen using hybrid method). In this way, uncharacterized/unknown compounds/combinations of compounds may be screened to elicit production of useful compounds.
- It should be noted that using stochastic confinement to enumerate particles including organisms and cells would also be useful for counting the occurrence of rare cell types in a sample. Stochastic confinement has applications in isolation of rare particles from samples with many other ubiquitous particles besides a few particles of interest. When samples are stochastically confined, the result is a set of isolated volumes of fluid, most with either no particles or one particle. Rare particles are therefore separated from ubiquitous particles. The separation of rare particles enables the direct assay of the rare particles without interference from other particles in the system. Even if a rare particle has high activity, since it is at low concentration in the bulk sample it may not be detectable due to dilution of the signal and low signal to noise or low signal to background (potentially low background reaction from the ubiquitous particles). Once rare particles are isolated and concentrated through stochastic confinement, other plug based microfluidic technologies may be used to screen the rare particle. If the rare particle is allowed to divide, then the plug containing the rare particle can be split into several smaller plugs and assayed or screened using the hybrid and/or cartridge method (combining the plug containing many rare particles with plugs of various reagents and conditions in order to determine the function and optimal conditions for the rare particle). In addition, if the original sample contains 10 rare particles, since stochastic confinement enables the separation and screening of individual particles, this enables the rare particle to be screened against up to 10 different conditions. When rare particles are bacteria, care must be taken with bacteria to avoid forming biofilms during incubation which might grow and adhere to the wall, interfering with enumerations. Thus it is preferable to use inert surfaces in plugs.
- Two important purposes when dealing with the particles of interest are detection and harvest, both of which are enabled or greatly enhanced by stochastic confinement when the particles of interest are rare particles mixed with many other ubiquitous particles. Without stochastic confinement, the background is too high compared to the signal for detection, and the probability of isolating the particles of interest is too low for harvest.
- Occasions when detection is needed include, but are not limited to, when the particles are rare cells such as cancer cells in general, cancer stem cells, or fetal cells in maternal blood, or when the particles are bacteria or viruses causing some diseases, or when the particles are some toxic materials released by some industrial procedure, or particles are results of some military, civil, or natural event that needs detection.
- On the other hand, if the particles of interest have some special functions that are useful, isolating and possibly multiplying them is important in efficiently utilizing these special functions. For example, stem cells isolated and multiplied from adults may be used for treatment, bypassing the need for embryonic stem cells. Natural products used in medicine may be produced by isolating and multiplying natural cells that produce them. Bacteria with novel functions such as cleaning up hydrocarbon waste, degrading other environmental pollutants including halogenated compounds, converting biomass into more easily utilizable fuels such as ethanol or butanol or methane, oxidizing methane, or fixing nitrogen may be isolated, multiplied and used for appropriate purposes.
- Therefore, after the particles are separated and the plugs containing the particles of interest are distinguished from others by a primary assay, one or multiple further assays may be done to detect particles of interest and/or one or multiple types of particles detected from the primary assay may be used alone or in combinations for appropriate functions.
- The basis for detection of the particles include but are not limited to: 1) surface properties including functional groups on the surface of particles and signaling molecules on cells (antigens, receptors, sugar groups, lipids, etc); 2) materials inside the particles (chemicals enclosed in materials, DNA, RNA in general, microRNA, signaling molecules in general, proteins, and the like)—these materials may require further processing to the particles to be exposed and used for detection; and 3) chemical exchange with the environment (production and/or consumption of chemicals by material, uptake and/or secretion of molecules such as food, waste, signaling molecules in general, ions, novel molecules, etc. by cells). These chemical exchanges may occur naturally or with human intervention for example by stimulation with reagents.
- Specific applications
- Detection of diseases by examination of fetal materials in maternal blood
- Prenatal diagnosis of genetic diseases plays an important role in pregnancy, at least in informing the parents about the possibilities. Women of 35 years of age or more have high risk of abnormalities. However, since there are also many more pregnancies in the “low-risk” 26 year-old group, most (about 70%) abnormalities occur in this group. (Daniilidis, A.; Kouzi-Koliakou, K., Fetal cells in maternal circulation—potentials for prenatal control. Journal of Biological Research-Thessaloniki 2006, 6, 119-130.)
- Most effective current methods are invasive, where samples are taken directly from the fetus. These procedures have a risk of miscarriage (1-2%). (Daniilidis, A.; Kouzi-Koliakou, K., Fetal cells in maternal circulation—potentials for prenatal control. Journal of Biological Research-Thessaloniki 2006, 6, 119-130.) Thus, these invasion methods are usually applied to those in the high-risk group only. Because of the risk of miscarriage and because of the high collective occurrence of abnormalities in the “low-risk” group that are usually not screened, a non-invasive and reliable method to detect or predict genetic disorders is in high demand.
- One promising possibility is using fetal materials in maternal blood. If the cells and free DNA in the mother's blood may be used effectively to detect genetic disorders, the risk of miscarriage by invasive procedure is diminished and virtually any expecting mother may have a blood draw to check for possible genetic disorders. However, the biggest challenge is the small number of fetal cells (1-6 cells/mL (Daniilidis, A.; Kouzi-Koliakou, K., Fetal cells in maternal circulation—potentials for prenatal control. Journal of Biological Research-Thessaloniki 2006, 6, 119-130.)) and DNA in maternal blood.
- Previously developed methods to isolate such cells involve enrichment methods such as density gradient centrifugation and selective lysis, and sorting methods such as fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting (MACS). Methods to detect genetic disorders include (PCR) and fluorescent in situ hybridization (FISH).
- FACS and MACS depend on tagging the fetal cells with fluorescent or paramagnetic antibodies and using fluorescence intensity as a signal to separate the cells with flow cytometry or using magnets to separate the cells. These techniques rely on specific antibodies. In a recent study in which blood samples spiked with fetal nucleated red blood cells were used to check the sorting procedure which used density-gradient centrifugation, MACS, and selective lysis, only 37% were recovered. (Ponnusamy, S.; Mohammed, N.; Ho, S. S. Y.; Zhang, H. M.; Chan, Y. H.; Ng, Y. W.; Su, L. L.; Mahyuddin, A. P.; Venkat, A.; Chan, J.; Rauff, M.; Biswas, A.; Choolani, M., In vivo model to determine fetal-cell enrichment efficiency of novel noninvasive prenatal diagnosis methods.
Prenatal Diagnosis 2008, 28, (6), 494-502.) - Prenatal diagnosis of fetal physiology, non-genetic diseases, or genetic disorders by fetal cells and possible use of fetal cells.
- Stochastic confinement and autocatalytic kinetics with threshold, as discussed above and in the amplification section, may allow one to detect reliably plugs containing fetal cells in maternal blood and separate them out to use techniques in further detection or application. The two important advantages of this system versus current techniques are:
- 1) Because of the threshold kinetics, the result in each plug is binary or pseudo-binary. In other words, there is a large contrast between plugs containing fetal cells and other plugs (which contain other cells or no cells). Therefore, the signal used to mechanically sort the cells is clear and error in this step is avoided. For example, in conventional FACS background fluorescence and photobleaching may make the results deviate from being ideal.
- 2) Stochastic confinement allows for reliable detection even if the specificity of an antibody label is not ideal. As long as binding to the fetal cells (such as fetal nucleated red blood cell) is at least two orders of magnitude stronger than undesired binding to non-fetal cells, the kinetic threshold may be adjusted to lie in between the two concentrations of antibodies in plugs. The adjustment may be carried out by choosing an appropriate amplification method and tuning the concentration of such method (see section about amplification). There is a need to determine properties of fetal cells (such as having a particular disease or not). Using antibodies that selectively bind to fetal cells of interest, stochastic confinement may be used to detect such properties. Even though the contrast provided by the specificity of the antibodies may not be much, stochastic confinement and/or an amplification method may greatly enhance this contrast.
- The general steps of this method include:
- obtaining about 10-20 mL of blood sample from the expecting mother (the volume is chosen because even in such cases when amplification methods may detect single cells, a 1 mL sample of blood still has a significant probability to not contain the cells of interest when the concentration of the fetal cells is 1-6 cells/mL);
- coarse enrichment by density gradient centrifugation or other methods (optional);
- stochastic confinement into plugs;
- primary detection (such as by using antibodies (such as monoclonal antibody against H315 for trophoblasts, (Daniilidis, A.; Kouzi-Koliakou, K., Fetal cells in maternal circulation—potentials for prenatal control. Journal of Biological Research-Thessaloniki 2006, 6, 119-130) monoclonal antibody against transferring receptor for erythroblass, (Bianchi, D. W.; Flint, A. F.; Pizzimenti, M. F.; Knoll, J. H. M.; Latt, S. A., Isolation of Fetal DNA from Nucleated Erythrocytes in Maternal Blood. Proceedings of the National Academy of Sciences of the United States of America 1990, 87, (9), 3279-3283.) etc.));
- optionally if an amplification method is needed to enhance the contrast: merging with plugs containing chemicals or materials needed in the amplification method (if these chemical and materials are added with the antibody this step is not needed);
- using the plugs containing fetal cells of interest for further assays (such as FISH or PCR to look for genetic disorders, or any other possible methods to detect certain properties of interest of fetal cells) if necessary; and/or
- using the plugs containing fetal cells of interest for applications if there are functions associated with such fetal cells in need, with or without multiplying these cells.
- Fetal materials (including DNA) in maternal blood and markers of disorder after stochastic confinement may also be detected with methods described in the section entitled “amplification.”
- Detection
- The following articles, describing methods for concentrating cells and/or chemicals by making small volume plugs with low numbers of items to no items being incorporated into the plugs, with specific applications involving PCR, are incorporated by reference herein: Anal Chem. 2003 Sep. 1; 75(17):4591-8. Integrating polymerase chain reaction, valving, and electrophoresis in a plastic device for bacterial detection. Koh C G, Tan W, Zhao M Q, Ricco A J, Fan Z H; Lab Chip. 2005 April; 5(4):416-20. Epub 2005 Jan. 28. Parallel nanoliter detection of cancer markers using polymer microchips. Gulliksen A, Solli L A, Drese K S, Sörensen O, Karlsen F, Rogne H, Hovig E, Sirevåg R.; Ann N Y Acad. Sci. 2007 March; 1098:375-88. Development of a microfluidic device for detection of pathogens in oral samples using upconverting phosphor technology (UPT). Abrams W R, Barber C A, McCann K, Tong G, Chen Z, Mauk M G, Wang J, Volkov A, Bourdelle P, Corstjens P L, Zuiderwijk M, Kardos K, Li S, Tanke H J, Sam Niedbala R, Malamud D, Bau H; Sensors, 2004. Proceedings of IEEE 24-27 Oct. 2004 Page(s):1191-1194 vol. 3. A microchip-based DNA purification and real-time PCR biosensor for bacterial detection. Cady, N.C.; Stelick, S.; Kunnavakkam, M. V.; Yuxin Liu; Batt, C. A.; Science. 2006 Dec. 1; 314(5804):1464-7. Microfluidic Digital PCR Enables Multigene Analysis of Individual Environmental Bacteria. Elizabeth A. Ottesen, Jong Wook Hong, Stephen R. Quake, Jared R. Leadbetter; Electrophoresis 2006, 27, 3753-3763. Automated screening using microfluidic chip-based PCR and product detection to assess risk of BK virus-associated nephropathy in renal transplant recipients. Govind V. Kaigala, Ryan J. Huskins, Jutta Preiksaitis, Xiao-Li Pang, Linda M. Pilarski, Christopher J. Backhouse; Journal of Microbiological Methods 62 (2005) 317-326. An insulator-based (electrodeless) dielectrophoretic concentrator for microbes in water. Blanca H. Lapizco-Encinas, Rafael V. Davalos, Blake A. Simmons, Eric B. Cummings, Yolanda Fintschenko; Anal. Chem. 2004, 76, 6908-6914. Electrokinetic Bioprocessor for Concentrating Cells and Molecules. Pak Kin Wong, Che-Yang Chen, Tza-Huei Wang, and Chih-Ming Ho; Lab Chip, 2002, 2, 179-187. High sensitivity PCR assay in plastic micro reactors. Jianing Yang, Yingjie Liu, Cory B. Rauch, Randall L. Stevens, Robin H. Liu, Ralf Lenigk and Piotr Grodzinski; Anal. Chem. 2005, 77, 1330-1337. High-Throughput Nanoliter Sample Introduction Microfluidic Chip-Based Flow Injection Analysis System with Gravity-Driven Flows. Wen-Bin Du, Qun Fang, Qiao-Hong He, and Zhao-Lun Fang; Science Vol 315 5 Jan. 2007, 81-84. Counting Low-Copy Number Proteins in a Single Cell. Bo Huang, Hongkai Wu, Devaki Bhaya, Arthur Grossman, Sebastien Granier, Brian K. Kobilka, Richard N. Zare; Nature Biotechnology Vol 22 (4), April 2004. A nanoliter-scale nucleic acid processor with parallel architecture. Hong J W, Studer V, Hang G, Anderson W F, and Quake S R; Electrophoresis 2002, 23, 1531-1536. A nanoliter rotary device for polymerase chain reaction. Jian Liu, Markus Enzelberger, and Stephen Quake; Biosensors and Bioelectronics 20 (2005) 1482-1490. Microchamber array based DNA quantification and specific sequence detection from a single copy via PCR in nanoliter volumes. Yasutaka Matsubara, Kagan Kerman, Masaaki Kobayashi, Shouhei Yamamura, Yasutaka Morita, Eiichi Tamiya; US Patent Application 2005/0019792 A1, “Microfluidic device and methods of using same”; and
Nature Methods 3, 541-543 (2006) “Overview: methods and applications for droplet compartmentalization of biology” John H Leamon, Darren R Link, Michael Egholm & Jonathan M Rothberg. - Plugs offer advantages over cuvettes. For example, with plugs, the optical path may be made very thin, so if a bacterium is labeled (for example, with fluorescent antibodies) it is easy to detect. Alternatively, the same effect may be obtained by squeezing a blood sample between two coverslips separated by a 20 μm gap, which may be created by placing a thin metal (gold or Pt) wire between the cover slips. Thus, the cover slips may be covered with something to which bacteria stick, and factors that makes them grow biofilms or multiply aggressively. Probes may be added for detecting these activities or colonies.
- Another advantage is diffusion control in a plug versus a coverslip or cuvette. For example, in a cuvette, a material produced by bacteria can diffuse away and become diluted. In a plug, the material produced by bacteria builds up to a high enough concentration that it is easy to detect. The material produced or the multiplying bacteria may be detected. Once the bacteria start growing, they grow until nutrients in the plug are depleted. Monitoring the decrease in a nutrient attributable to the presence of the bacteria provides evidence of the bacteria. For example, the decrease in O2 attributable to the presence of the bacteria may be done using agglutination beads.
- Oxygen or other gases or mixtures of gases may need to be provided to encourage growth. Gases may be introduced by various methods including by dissolving them in the fluorocarbon carrier fluid. Care may be taken to avoid evaporation of oil/media particularly for incubation at 37° C. The plugs may be sealed in glass or placed in a Teflon capillary that is permeable to gases. The capillary is then placed in a vial of media that is the same (isotonic but not comprising indicators, cells and other components which will not partition across tubing). In short, the oxygen concentration of blood in any sepsis assay may need to be controlled in a way other than what is typically done with blood tests.
- Many bacteria and bacterial components can directly activate individual coagulation factors. However, direct initiation of the coagulation cascade and the formation of a propagating clot is not typically observed when humans are infected. These bacterial components usually activate low levels of coagulation factors, but this activation does not result in the amplification and positive feedback necessary to form a clot that can grow and propagate. For example, Staphylococcus aureus (S. aureus) produces coagulase, a protein that binds prothrombin stoichiometrically and leads to cleavage of fibrinogen to fibrin. However, this conversion simply precipitates fibrin and does not result in production of thrombin, feedback, or amplification of the coagulation cascade. Escherichia coli (E. coli) that express the protein Curli are also known to activate coagulation factors, such as factor XII. This process was shown to cause slower initiation of coagulation due to depletion of factor XII. Bacteria do initiate coagulation in some organisms, such as horseshoe crabs, but this mechanism of controlling infection is believed to have been lost during evolution of vertebrates.
- Crab blood is known to clot rapidly on contact with bacteria. Plugs with grown bacteria may be merged with plugs that contain crab blood. Clotting occurs rapidly when the crab blood contacts the bacteria, and secondary indicators such as fluorescent indicators or dyes for “crab thrombin” may be used to detect bacteria. Other clotting systems are disclosed in Kastrup et al. Acc Chem. Res. “Using chemistry and microfluidics to understand the spatial dynamics of complex biological networks.” 2008 April; 41(4):549-58.
- Bacteria export materials out of the cell, for various reasons including to attack the host, to digest food, to fight, to signal, etc. These chemical messengers become more concentrated inside a plug than inside the original sample of blood. If the chemical messenger is an enzyme, a fluorogenic substrate for the enzyme would indicate the presence of the bacteria. Human blood has esterases, etc, that may interfere, but the use of enzymes specific to bacteria would allow detection of the bacteria. In fact, if one had a panel of 30 substrates, one may set up 30 tubes with 1000 plugs each, and looks for specific substrates lighting up (if there is substrate for one bacterium), or one may look for patterns of substrates lighting up if there is a more complicated relationship (each bacterium has a pattern of substrates associated with it).
- Another type of molecule exported by bacteria are signaling molecules. If a single bacterium produces activators, these activators can accumulate in the plug, turning a single bacterium ON into the attack mode, and making it easier to detect.
- Many types of cells react to high cell density by activating behaviors and specific genes through the process of quorum sensing. For instance, the human opportunistic pathogen Pseudomonas aeruginosa releases signaling molecules (homo serine lactones or other signals known as autoinducers) which accumulate in the space surrounding the cells and enable the cells to measure their local cell density. Many pathogens (such as Pseudomonas aeruginosa) activate virulence behaviors in response to the activation of quorum sensing. Because detection of cells in a virulent state is of interest, stochastic confinement would place cells at a high enough density that they should activate virulence mechanisms which may then be detected. In this way, stochastic confinement can detect cells with the potential for virulence, even if they currently have not yet activated virulence in the patient. Additionally, virulence activation often involves the upregulation of enzymes involved in infection, such as lipases, coagulases, and proteases that may be used as detection targets, specifically as detection targets of virulent species. The virulence enzymes and other released molecules may be used to activate detection mechanisms.
- Another possibility is to lyse the cells in the media to detect something that is only produced by bacteria.
- PCR may also be applied to plugs. PCR may be overwhelmed by the background DNA of human cells. In the case of plugs, if plugs are made small enough there would be only one cell per plug (human or bacterial) which eliminate background issues (if bacterial-specific primers are used background from other cells would not interfere). Binding of bacteria to human cells, or bacteria hiding inside of human cells would not be problematic due to the minimal background. Plugs may also be spiked to stimulate bacteria to make them easier to detect.
- If bacteria can be detected in people at low concentration (before infection becomes a real threat), these methods may be used for general clinical practice to screen high risk patients including babies and the elderly for bacteria. Viral infections may also be monitored by this method by using vesicles that a virus would try to enter, and detecting the entry by fluorogenic substrates, or by the destruction of vesicles (detected, for example, by a Ca/Fluo4 system).
- Methods of detecting bacteria using microfluidic based techniques comprise: 1) screening a sample against various reagents which results in a detectable signal in the presence of bacteria; and 2) screening these samples in parallel or in series against different drugs to determine which drug is best suited for killing the bacteria in the sample. Part 1) of this technique may include screening a sample against preloaded, plug-based cartridges that comprise bacteria-specific reagents. If the sample comprises bacteria that are specific for a reagent in one of the plugs a signal will be detected in that plug. Examples of the detection methods include, but are not limited to: i) magnetic based detection, ii) optical detection, and iii) oxygen detection. Part 2) of this technique may include preloading plug-based cartridges with various antibiotics that are known to kill certain types of bacteria. WO 05-056826 A1 which discloses methods is incorporated by reference herein in its entirety.
- In some aspects of the present invention, the method of detecting bacteria comprises confinement of a bacterium into a small volume plug, wherein the confinement induces virulence activation of the bacteria through a quorum sensing type mechanism. The activation of virulence in the bacteria may induce the upregulation of various virulence factors such as proteins, enzymes, and small molecules. The upregulation and release of these virulence factors may be used as a detection target for the presence of virulent bacteria, may be used to detect a bacterium with the potential to activate virulence mechanisms, or may be used as targets to detect a specific species or type of bacteria. The upregulation and release of these virulence factors such as lipases, proteases, and coagulases may be incorporated as the initial step in an enzymatic detection cascade.
- In some aspects of the method of detection of bacteria, the plug comprises a substance capable of lysing the bacteria. Lysis may be accomplished by standard detergent-based bacterial cell lysis. For example, frozen and thawed cell pellets are incubated with lysis buffer that is supplemented with lysozyme, which help disrupt cell walls (Lysozyme hydrolyzes β(1→4) linkages between N-acetylmuramic acid and N-acetyl-D-glucosamine residues in peptidoglycan and between N-acetyl-D-glucosamine residues in chitodextrin). Gram-negative bacteria may be hydrolyzed in the presence of EDTA that chelates metal ions in the outer bacterial membrane. Cells are incubated with lysis buffer for about 30 min, on ice. If the target is a nucleic acid, proteinase should be supplemented, whereas if the target is a protein, nucleases should be supplemented. To separate cell debris and insoluble protein (e.g., inclusion bodies), the sample is centrifuged (14,000 g, 30 min, 4° C.) and the supernatant collected. The supernatant comprises the soluble protein fraction, which can be further purified or directly analyzed, for example by SDS-PAGE.
- Methods for Detecting Bacteria
- In some aspects, the method for detecting bacteria comprises detecting bacteria in various samples using microfluidic based techniques, and screening bacteria using a hybrid and/or cartridge-based method to detect microorganisms by detecting their binding to beads.
- Binding bacteria to magnetic beads may be accomplished by using specific (antibodies, chemical link between bacteria and bead) or non-specific (charge of bacteria, general molecule expressed on outside of bacteria) methods. Bound and unbound magnetic beads may be separated by microfluidic sorting techniques which rely on differences in diffusion based on size or changes of magnetic potential due to bound bacteria. Bound and unbound magnetic beads may also be separated using a magnetic field because migration in the field will be reduced for bound beads with increased drag. This method may be used to isolate specific types of bacteria from a sample or to remove all bacteria from other parts of the sample matrix. Liquid containing bacteria bound to beads may then be used to make plugs. Various techniques may be used to detect the presence of a magnetic bead in a plug, including measuring the electric current induced by a moving magnetic particle. Another detection method incorporates a hard-drive head to detect magnetic particles. Another detection method takes a relative measurement of the magnetic beads to measure relative orientation rate in the field. Another detection method relies on bacteria binding to multiple beads and the detection method being able to distinguish between single unbound beads and groups of bound beads (for example by changes in the amplitude of the spike in the detector).
- Magnetic beads may also be used to detect proteins or other molecules by either chemically linking the target to the bead, or by first attaching an antibody to the target. The antibody then recognizes and attaches to the magnetic bead.
- Optical detection schemes may also be used. Beads may have an optical signal, and a detection method which differentiates single unbound beads vs. groups of beads may be used to detect the target.
- If the beads-based method provides means to count the number of detected objects, then bead detection schemes may be used to monitor the proliferation of bound objects after exposure to a compound, such as an antibiotic. The bead method may be used to isolate the bacteria from the sample and then introduce the antibiotic to the bacteria. Addition of more beads and enumeration of bound beads after incubation with the antibiotic may be used to determine whether or not the antibiotic inhibited proliferation of the bound bacteria.
- Other detection schemes may be used to detect the bacteria themselves, such as oxygen or carbon dioxide detectors. Oxygen detection schemes include formation of Prussian blue as a function of oxygen presence, and fluorescence based oxygen sensors.
- The sample may be detected attached to a bead, free in solution, or after deposition on the wall of the channel. Instead of a bead, bacteria may be agglutinated.
- In some aspects, an array of pre-formed nanoliter sized droplets, or plugs is generated. Each plug comprises one or more beads. In each plug, all beads are substantially similar. Each bead has a specific binding affinity, provided by an antibody for example, for a microorganism or a subset of microorganisms, for example, bacteria, viruses, or fungi. The binding affinity can also be for a specific small particle, such as a pollen grain or a spore. The beads themselves are detectable, for example a magnetic bead or a fluorescent bead. Ideally, the binding event is also detectable.
- If the binding event of one or more beads with a bacterium is directly detectable, the assay may be performed by the steps of injecting the sample into each of the plugs, incubating to allow the detection, and performing the detection. Direct detection may be accomplished by taking advantage of the difference in the magnitude and frequency of the signals produced by many unbound beads inside of a plug vs a microorganism that carries with it the same number of beads bound. Many unbound beads would generate several smaller signals, while an organism with the same number of beads bound would generate a single signal of higher amplitude.
- If the binding event is not detectable, then the detection can be performed by separating bound beads from unbound beads, and detecting bound beads. The separation may be performed by a range of methods including a diffusive filter, a Brownian ratchet, or in the case of magnetic beads, a magnetic filter that applies a magnetic field to bias motion of the beads. Separation may require separating the plug fluid from the carrier fluid, flowing through the filter, and re-forming the plugs by adding carrier fluid to the plug fluid that passed the filter and contains predominantly bound beads. Detection is performed by a range of methods, including scanning the detector over the array of plugs, or flowing the array of plugs past the detector. Magnetic detection may be performed by detecting currents generated by moving magnetic beads, and may also incorporate technologies used in hard disk drives.
- Spacer and index plugs may be used in the original array of plugs as disclosed in WO 08-079274 A1, the entirety of which is hereby incorporated by reference. Index plugs may contain markers detectable by the same method used to detect binding of bacteria to beads.
- This method is discussed in the context of microorganisms and particles, but it is applicable to the detection of molecules and other objects by using a larger bead carrying antibodies against the molecule, and a set of detectable beads carrying another antibody against the same molecule. In the absence of the molecule, the detectable beads do not bind larger beads and remain dispersed. In the presence of the molecule, the detectable beads bind to the molecules and therefore to the larger beads, and become detectable by the methods described here.
- To perform an antibiotic screen, plugs may contain antibiotics, and the plugs injected with the sample may be allowed to incubate to permit growth of microorganisms. Antibiotics are recognized and are substances which inhibit the growth of or kill microorganisms. Examples of antibiotics include, but are not limited to, chlorotetracycline, bacitracin, nystatin, streptomycin, polymicin, gramicidin, oxytetracyclin, chloramphenicol, rifampicin, cefsulodin, cefotiam, mefoxin, penicillin, tetracycline, chloramphenicol, minocycline, doxycycline, vancomycin, bacitracin, kanamycin, neomycin, gentamycin, erythromycin, cephalosporins, geldanamycin, and analogs thereof. Examples of cephalosporins include cephalothin, cephapirin, cefazolin, cephalexin, cephradine, cefadroxil, cefamandole, cefoxitin, cefaclor, cefuroxime, cefonicid, ceforanide, cefotaxime, moxalactam, ceftizoxime, ceftriaxone, and cefoperazone. Additional examples of antibiotics that may be used are in US 2007/0093894 A1, hereby incorporated by reference in its entirety. Detection of differences in growth and microbial populations in the absence and presence of each antibiotic would provide information on antibiotic susceptibility. First the bacteria in the sample are counted. Then, the bacteria sample is merged into the cartridge containing plugs of different growth media and different antibodies along with some as “blank” media and “blank” antibiotics plugs. Recount is preformed by merging with magnetic beads to see which one had bacteria reproducing.
- In some aspects, the detectable signal is produced by the growth of the bacteria. Optical detection comprising optical methods for detection may use fluorescent nanoparticles instead of magnetic ones. One may also use control of surface chemistry provided by plugs to enhance growth of organisms. One method comprises merging the sample with a cartridge, the cartridge may optionally have growth tablets; monitoring bacterial growth by a change in oxygen concentration; and recording the readout. The readout may be but is not limited to a change in volume of oxygen bubbles the device, a change in optical signal due to the presence of an oxygen sensitive substrate (the substrate may be incorporated in many ways including in solution, on beads, or immobilized on a film that coats the device), or calorimetric reactions for detecting oxygen.
- Bacteria detection by using agglutination may also be employed. This method comprises merging sample with plugs that comprise substance that induces agglutination in the presence of bacteria including for example, antibody labeled beads; forming agglutination screens on a large scale for bacteria detection; filling preformed plugs with beads covered with antibodies specific for different bacteria; and monitoring which plugs result in clumps of beads indicating presence of bacteria. Monitoring may be done by eye or some other detection technique. Secondary agglutination may also be used.
- In addition, multiple assays may be performed in one device, for example by splitting a sample into a plurality of samples using techniques described above for splitting plugs.
- One strategy is to change the hydrophobicity of the channel. Aqueous plugs with fluorinated oil as the carrier fluid will not wet hydrophobic channel walls. Therefore, to have a plug stick to the channel wall it is necessary to create a region of the channel in which the surface chemistry of the channel is hydrophilic.
- A hydrophilic patch may be useful in 2 ways: i) a hydrophilic patch may capture a plug and hold it in place; and ii) a hydrophilic patch may temporarily come into contact with a plug as it is flowing by. This brief contact may result in a small portion of the plug fluid being deposited on the hydrophilic region of the channel wall. Capturing a plug (i) or depositing a portion of a plug onto the channel wall (i) may enable the assays to be run on the plug fluid.
- Methods which require a surface such as ELISA, or an oxygen sensor incorporated into the surface, etc. may then be performed at the hydrophilic patch of channel wall. There are some papers which suggest that measurements performed on surfaces are more sensitive than measurements in bulk fluid. More generally, the concept of controlling channel wall surface chemistry can be implemented in the trafficking and measurement of plug fluids.
- Another strategy for manipulating plugs is to control pressure drops in the channels by channel constriction. From Hagen-Poiseuille's law, if a channel gets narrower, the pressure drop quickly increases. If the pressure drop in one branch of a microfluidic network becomes narrow, plugs will not be able squeeze through the constriction because the capillary pressure required for the plug to squeeze through will be higher than the pressure drop over the device. In this way, channel constriction may be used to collect plugs and stop them from moving.
- By designing a device with specified pressure drops in each channel in a network of branching channels, it may be possible to automatically sort the large number of plugs needed for some stochastic confinement applications. For example, a main channel carrying plugs splits into 10 different smaller channels. If each channel has a different diameter/length (i.e. pressure drops for each channel are different) this would create a bias in the loading of plugs. A system may be designed such that the 1st 100 plugs would be loaded into
channel 1, then the pressure drop inchannel 1 becomes greater thanchannel 2 due to the presence of many plugs, therefore the next 100 plugs would flow intochannel 2, etc. This type of bulk sorting of plugs can be achieved simply by designing the channels with specific pressure drops and does not rely on turning on and off pumps, opening and closing valves, or other “active” plug sorting mechanisms. - Certain embodiments of the invention may be used to detect sepsis in 3 to 4 hours from a blood sample from a patient, and in other embodiments detection times may be reduced to 20 minutes or less. In a 5 to 10 mL blood sample from an infected patient, there might be 100 to 1,000 bacteria. Allowing the sample to culture overnight can increase those numbers by 10 to 100-fold. It would also be useful to know patterns of antibiotic resistance, and current methods are very tedious.
- Possible means for detecting bacteria in a sample include stains and dyes, as used in flow cytometry, and which are well known in the art. Alternatively, one may look for a uniform change in color, appearance, scattering or optical density across a plug. almarBLUE™ (resazurin) is a fluorescent redox sensitive dye that can be used to detect living cells.
- Certain embodiments of the invention may be used to detect different strains of bacteria, including Pseudomonas, Staphylococcus, E. Coli, etc.
- When testing whole blood for bacteria one can use known methods to get rid of white blood cells, which would also be metabolically active, before testing for the presence of bacteria. For example, there are lysing agents well known in the art that selectively lyse eukaryotic cells.
- A severely infected patient can have 106 bacteria (CFU)/mL in the blood. There are known methods for detecting 102 to 103 bacteria/mL, but only with culturing overnight. For example, the PCR-based LightCycler™ can detect 103, but only can only detect bacteria with known, predetermined, target gene sequences, and it does not give any functional information, for example concerning antibiotic resistance, and it is relatively slow, taking 6 to 8 hours. Other methods, using 96 well plates have demonstrated the detection of 106 bacteria in a 200 μl sample in 2 to 3 hours, 105 bacteria in approximately two hours, and 103 bacteria in 8 to 9 hours. However, it is desirable to be able to detect low concentrations of clinically relevant bacteria in 3 to 4 hours or less.
- Another means of detecting and typing cells is PCR amplification of 16S-23S rRNA., as described in Vliegen, I., et al., “Rapid identification of bacteria by real-time amplification and sequencing of the 16S rRNA gene” Journal of Microbiological Methods 66 (2006) 156-164, and patent application WO 96/119585, hereby incorporated by reference in its entirety. This can be accelerated by using a rapid microchip PCR method described recently that uses infrared light to achieve a 12 minute PCR reaction. See “On-chip pressure injection for integration of infrared-mediated DNA amplification with electrophoretic separation” Christopher J. Easley, a James M. Karlinseya and James P. Landers, Lab Chip, 2006, 6, 601-610.
- Fluorogenic media, which change color in the presence of specific bacteria, can also be used to detect cells. Chromogenic media include, for example, Difco mEl agar, Merck/EMD Chromocult™ Coliform Agars, Chromocult™ Enterococci Agar/Broth, or Fluorocult® LMX Broth, BL ml agar, IDEXX Colilert, CPI ColiTag and Merck/EMD ReadyCult®. Typical enzyme substrates linked to chromogens or fluorogens include ONPG, CPRG, and MUG. These are also available in ready-to-use format, e.g. BBL ml agar and ‘convenience’ packs, e.g. IDEXX Colilert, CPI ColiTag and Merck/EMD ReadyCult®.
- Bacteria can also be detected using simple growth and density measurements of plugs. Such measurements may aid detection and characterization of specific antibiotics that block the ability of the bacteria to grow, after combining plugs with specific antibiotics.
- Microchannel PCR is described in U.S. Pat. No. 6,990,290, rapid bacterial PCR is described in U.S. Pat. No. 6,673,578, and a sepsis detection chip is described in US 2005-130185 A1, all incorporated by reference herein in their entirety.
- Confining bacteria in small spaces might influence their phenotype, and gene regulation. For example, one bacterium inside of a small volume may respond as if it is in a culture with high cell density because communication molecules that it secretes, such as homoserine lactones, activate quorum sensing. This can be used to an advantage of this to decrease detection times or limits, and/or trigger virulence.
- Staining
- Typically to monitor bacterial growth, blood sample bottles are placed in an incubator and kept at body temperature. They are watched daily for signs of growth, including cloudiness or a color change in the broth, gas bubbles, or clumps of bacteria. When there is evidence of growth, the laboratory does a gram stain and a subculture. To do the gram stain, a drop of blood is removed from the bottle and placed on a microscope slide. The blood is allowed to dry and then is stained with purple and red stains and examined under the microscope. If bacteria are seen, the color of stain they picked up (purple or red), their shape (such as round or rectangular), and their size provide valuable clues as to what type of microorganism they are and what antibiotics might work best. To do the subculture, a drop of blood is placed on a culture plate, spread over the surface, and placed in an incubator.
- Aggregation of a signal can be used to detect the presence of a single organism in a plug. With reference to
FIG. 3 , a single bacterium can simultaneously bind to many antibodies. If each of these antibodies has a signal, then the signal would be localized and therefore become detectable. For instance if each antibody was tagged with a fluorescent marker, then although single fluorescent markers may not be detected, the co-localized signal from many markers would be above the threshold for detection. Similarly, if each antibody was tagged with an enzyme, then many antibodies close together would create a high local concentration of the enzyme. Many enzymatic cascades (such as initiation of blood coagulation) require a threshold local concentration of enzyme. In this way, single antibodies would not be detected, but a local cluster of antibodies all bound to the same bacteria would create a detectable local concentration of enzymes. In a more specific example, if the bacteria sample was in blood or in a solution that contained the coagulation cascade, a detection method may involve antibodies which bind to the bacteria but also are tagged with the metalloprotease InhA (expressed by Bacillus species which induce blood clotting). A bacterium that is recognized by the antibody will bind to many antibodies and create a cluster of antibodies and therefore a localized cluster of InhA. The coagulation cascade will respond to the local cluster of InhA and initiate coagulation. - An additional effect of aggregation of a signal in the decrease in the background signal. For instance, if there are 100 molecules of signal in a 1 mL sample, then before clustering the background is 100 molecules/mL. After
clustering 80 of the molecules together followed by stochastic confinement (assume in a 1 femtoliter space), the signal is now 80 molecules/fL and the background is now 20 molecules/mL because 80 molecules of signal have been removed from the bulk solution. In this way, aggregation of a signal increases the signal to noise ratio. - Another advantage of stochastic confinement is to segregate the signal/analyte from background material. For example, in the detection of bacterial strain “A” in a sample that contained numerous contaminant strain “C”, assays in the bulk may experience interference from the presence of strain “C”. This interference may be in the form of “C” influencing the behavior of “A”, or “C” influencing the components of the assay itself. Interference problems may be increased if the sample contains an abundance of “C” and few “A”. By forming plugs which separate species “A” from “C”, the assay may be run successfully for the presence of “A” as some plugs will contain only strain “A” and none of strain “C”. As long as the threshold is tuned properly, the amplification cascade can selectively respond to only the active, target particles even in the presence of a large excess of interfering particles.
- In addition to stochastic confinement using plug-based microfluidics, there are other methods that may be used to achieve confinement of individual organisms or molecules as shown in
FIG. 4 . One such method is to generate an array of microwells. Microwells can be defined as a small compartment with volumes of nanoliters or less. The well is open on the top and the walls are impermeable to either the particles to be detected, molecules used in the detection system, or both. Once the wells are loaded, a top barrier may be placed over the wells in order to completely confine the particle(s) and molecules in the well. Even without complete confinement, a well with a single open wall will still experience some confinement effects due to decreased flux of particles and molecules into and out of the well. Another confinement method is to trap the particles in the matrix of a gel or polymer. Confinement effects will be achieved by reducing the diffusion of both the particles and the molecules used in the detection scheme. In this way, high local concentrations of molecules used for detection will accumulate around the particle. Adding an impermeable boundary to the bottom and/or top of the matrix (such as glass, plastic, etc.) will further increase confinement effects due to decreased flux of the accumulating signal away from the particle. - Stochastic confinement of individual bacteria into plugs of nanoliter volume or smaller volumes reduces detection time.
- To reduce the time required to detect bacteria in a sample, a microfluidic device was designed to confine single bacterium into plugs of nanoliter volume. In principle, when generating plugs with a small volume from a solution with a low concentration of bacteria, much of the volume of the initial solution forms plugs that contain no bacteria. There are a few occupied plugs, each occupied by single bacterium. As a result, the concentration of bacteria in the occupied plugs is greater than the concentration of bacteria in the initial solution. For example, if plugs of nanoliter volume were made from a culture with an initial bacterial concentration of 105 CFU/mL, one in ten plugs would receive a single bacterium, as illustrated in
FIG. 1 a. The concentration of cells in these occupied plugs would be one bacterium per nanoliter or 106 CFU/mL. In other words, 105 CFU/mL corresponds on average to 0.1 bacterium per 1 mL, and confining this solution into nanoliter plugs creates plugs with 0 bacteria per nanoliter plug and with 1 bacterium per nanoliter plug. CFU/mL refers to the colony forming units (CFU), a measure of live bacteria, per milliliter. Confinement effects are increased as the volume of plugs is decreased, therefore when confinement effects could be achieved in nanoliter plugs, picoliter plugs or femtoliter plugs would have increased confinement effects. - Targeting virulence factor for screening antibacterial drugs is a potential way to develop novel drugs. To escape cross-resistance of current drugs, targeting to virulence factors involved in human pathogenesis is considered essential. It has also been suggested that using surrogate infection model systems to screen novel drugs is a key issue for detecting and investigating the virulence factor.
- Bacterial virulence may also be used to identify new therapeutics. Targeting virulence helps to preserve the many symbioses between the microorganism and host that contribute to human health. Targeting bacterial adhesion and toxin production and function are good approaches to developing the antivirulence drugs which will prevent the assembly of adhesive machinery or toxin expression or secretion. Quorum-sensing systems, two-component response systems, and biofilm formation can additional targets for virulence factors control.
- The following methods are the ways in which pathogens cause disease in humans: adhesion, colonization, invasion, immune response inhibitors, and toxins. Since pathogenic bacteria have different methods of inducing virulence, conditions for inducing/monitoring/evaluating virulence are useful targets for drug discovery.
- A representative example of inducing virulence is the generation of reactive oxygen species (ROS). Inflammatory cells have defense mechanisms against invading microorganisms and are known to exert their antimicrobial actions by releasing reactive oxygen species (ROS), proteolytic enzymes and other toxic metabolites. While these ROS and other toxic compounds damage pathogens and host cells together, antioxidant defense system such as superoxide dismutase (SOD), catalase, glutathione, and glutathione peroxidase also affect the host cells specifically.
- Standard Method Vs Stochastic Confinement
- The standard procedure for a patient presenting a bacterial infection in the blood, is to take a blood sample from the patient, the blood sample having a cell density of 100 CFU/mL. If the patient has an infection of methicillin resistant Staphylococcus aureus, and traditional culture based methods are used, detection of the Staphylococcus aureus takes about 12 hours. At that point the susceptibility of the pathogen to antibiotics would not yet be known; antibiotic testing would require another 6 hours.
- If the blood sample is stochastically confined into 0.1 mL plugs, detection takes less than 4 hours. Because stochastic confinement has the ability to screen individual bacterium, up to 100 different antibiotic conditions may be screened from a 1 mL blood sample without a preincubation step. Detection time for bacteria with S. aureus decreases by 1.5 hours for every order of magnitude increase in cell density at time zero (i.e. 100 CFU/mL takes 12 hours, 1000 CFU/mL take 9.5 hours). Therefore with confinement in nL plugs, concentration can be increased from 100 CFU/mL to 107 CFU/mL which decreases detection time by 7.5 hours. (P. Kaltsas, S. Want and J. Cohen, Clin. Microbiol. Infect., 2005, 11, 109-114.) In 23-30% of all cases, an inappropriate antibiotic is initially administered (S. D. Carrigan, G. Scott and M. Tabrizian, Clin. Chem., 2004, 50, 1301-1314.)
- In the standard method, the infection is identified after 12 hours and then it takes 6 additional hours to screen antibiotics. Many patients would not receive appropriate antibiotic treatment for over 18 hours, which means that the infection has worsened and the chance of mortality is greatly increased.
- In the stochastic confinement method, infection and antibiotic sensitivity of infection is known after 4 hours or less. Antibiotic treatment can begin much sooner. Other advantages of stochastic confinement are the ability to run multiple tests on the sample without preincubation, therefore the clinician can have an in depth characterization of the pathogen (antibiotic sensitivity, serotype, strain, genetic information, other functional tests like propensity for virulence) within a few hours. Since confinement involves testing individual cells, heterogeneity in the activity/phenotype within the population of cells may be tested. For instance, it may be detected that 1% of bacteria in the sample are resistant to oxacillin even though 99% of the cells are sensitive. A traditional method might not detect this difference. Consider starting with a sample at 100 CFU/mL in which only 1% of cells are resistant. Detection time of resistant cells would be for a density of 1 CFU/mL. In the standard method, protocols for running the test might not be long enough (an additional 3 hours or more) to even detect this type of resistance in the standard method. In addition, subpopulations of resistant cells typically grow more slowly, increasing the chances of not detecting the cells in traditional tests.
- Stochastic confinement is useful for large scale monitoring of resistant strains in the population and offers many benefits. Bacterial infections in the hospital setting do not routinely undergo in depth characterization of the infecting strain. Stochastic confinement provides a cheap and efficient method of characterizing pathogens so that hospital bacterial infections can be characterized routinely in the hope of better controlling them. In addition, functional tests are a better way to characterize pathogens than genetic tests because the genetic marker for a new resistance mechanism can be found immediately. Therefore there is less of a time delay between identification a new resistance mechanism and the discovery of a genetic marker useful for the diagnosis of the resistant strain. Stochastic confinement also enables increased tracking of resistance patterns leading to early recognition of resistant strains and enables health care agencies to track the spread of resistant strains.
- Functional detection is possible as well wherein target or host cells and potentially infectious organisms are added into plugs and monitored for infection. Human/mammalian, bird, live stock, plants/crops can all be used as the target or host cells for these kinds of infectivity assays. The same techniques can be used to look for ways of reducing infectivity of microbes in any of these systems. The term virulence is used to mean direct infectivity, or killing remotely, any kind of pathogenicity, or negatively affecting the host cell in other ways or sporulating of bacterial spores, or activation of viral particles, or transition of bacterial cells from dormant to active form (relevant to tuberculosis). “Particle” refers to a cell, a viral particle, a spore, and the like.
- The same ideas can be applied to general screening of cells and their activity such as switching from one state to another which may depend on the concentration of soluble or surface-bound factors, or presence of other cells. Examples include stem-cell differentiation and cancer cell activation.
- The hybrid approach is described in Liang Li, Debarshi Mustafi, Qiang Fu, Valentina Tereshko, Delai L. Chen, Joshua D. Tice, and Rustem F. Ismagilov, “Nanoliter microfluidic hybrid method for simultaneous screening and optimization validated with crystallization of membrane proteins”, PNAS 2006 103: 19243-19248 as well as in publications incorporated by reference above.
- An example of chemical systems capable of amplification is described in Kastrup et al. PNAS 2006 Oct. 24; 103(43):15747-52 as well as in publications incorporated by reference above. This simple chemical model system, built by using a modular approach, can be used to predict the spatiotemporal dynamics of complex chemical networks. Microfluidics is used to create in vitro environments that expose both the complex network and the model system to surfaces patterned with patches presenting stimuli. Such chemical model systems, implemented with microfluidics, may be used to predict spatiotemporal dynamics of complex biochemical networks.
- Reducing virulence is a good strategy to fight microbial infections. Targeting virulence factors for screening antibacterial drugs is a potential way to develop novel drugs. To escape cross-resistance of current drugs, targeting to virulence factors involved in human pathogenesis is considered essential. To find compounds that reduce virulence, conditions need to be presented that induce virulence so that the virulence and the effects of drugs on virulence can be monitored. There are a number of ways that pathogens cause disease in humans including adhesion, colonization, invasion, immune response inhibition, and toxins. Since pathogenic bacteria have different ways of inducing virulence, conditions of inducing, monitoring, and evaluating virulence should be selected as the target.
- Conditions that lead to virulence are often not known. Components may include the presence of host's cellular signals, accumulation of secreted microbial factors, presence of surface-bound cellular components and signals, presence of host cells, presence of molecular species associated the host's environment, presence of molecular species present on surfaces of host cells, reactive oxygen species, or reactive nitrogen species.
- One representative example of inducing virulence is the generation of reactive oxygen species (ROS). Inflammatory cells show defense mechanism against invading microorganisms and are known to exert their antimicrobial actions by releasing reactive oxygen species (ROS), proteolytic enzymes and other toxic metabolites. While these ROS and other toxic compounds damage pathogens and host cells together, antioxidant defense system such as superoxide dismutase (SOD), catalase, glutathione, and glutathione peroxidase protect the host cells. Bacteria may detect the presence of ROS to control their virulence.
- The bacterial detection method may be used to determine conditions that induce virulence using the hybrid method. Any of the factors that induce virulence may be introduced into plugs containing microbial cells and their concentration varied. In addition, surface chemistries may be used to incorporate molecules present on host's cell surfaces. These surface chemistries may also be screened in the context of the hybrid and/or cartridge method. A combination of several cartridges, each containing a different set of reagents (e.g. solution-based and surface-based) may be used to screen combinations of reagents at different concentrations. Activation of virulence may be observed as a function of solution and/or surface conditions, leading to determination of optimal conditions and/or conditions that are most physiologically relevant. These methods may be used in combination with confinement.
- An array of host cells may be introduced using the hybrid and/or cartridge method to determine the kinds or types of cells that a microorganism may be virulent against. The hybrid and/or cartridge approach may be used to screen a wide range of microorganisms against a particular host to determine which microorganisms may be virulent against the host.
- Confinement, alone or in combination with other factors, may be used to induce virulence. For example, confinement may lead to accumulation of secreted microbial factors turning on virulence. Virulence induced under confinement may be more physiologically relevant.
- Using the methods described herein, microbial cells or particles isolated from a patient may be tested for their ability to induce virulence. Hybrid and/or cartridge methods may be especially attractive for such determination because they allow variation in the concentration of the inducing factors.
- Co-confinement of microbial cells and host cells (human/mammalian or bird/live stock/plants/crops hosts) may further improve induction of virulence, as both microbial and host factors may accumulate within the confined volume. Such co-confinement may be created, for example, by either forming plugs from at least two streams (one containing a suspension of microbes and the other a suspension of target cells), or by creating plugs containing one type of cells or particles (e.g., microbial cells or viral particles), and injecting them with a suspension containing the other type of particle (e.g., target cells).
- Changes in virulence may be monitored using a variety of methods including assaying for the secretion of surface expression of molecules/proteins/enzymes associated with virulence including lipases, virulence factors, iron siderophores, and the like. The assay may be tailored for the specific type of virulence mechanisms. For example, for adhesion, the ability of cells to stick to a host cell and detecting secretion of molecules known to promote adhesion to other cells is important. In colonization and invasion, disruption of cell membranes and promotion of endocytosis is important and thus, injection systems to inject protein/genetic material into another cell (for example via the type III secretion system) may be useful. For immune response inhibitors, molecules that bind to antibodies, formation of capsules around the cell, induction of fibrin formation to surround the bacterial cell and prevention of recognition by the host are important. For toxins, molecules are released that may be detected using fluorescence assays, agglutination assays, light producing reactions, color change reactions and the like. Also, production of certain factors associated with virulence (e.g. the lethal factor associated with B. anthracis virulence) may be detected, or functional tests of the effects on the target cell may be used.
- In terms of ROS, P. aeruginosa induction of oxidative stress in the host cells may be assessed by measuring changes in lipid peroxidation and glutathione contents in the host cell line or tissues. In addition, the activity of the antioxidant systems can be evaluated by measuring activities of superoxide dismutase, catalase, and glutathione peroxidase. (Microbial Pathogenesis, Volume 32,
Issue 1, January 2002, pages 27-34). - If conditions leading to activation of virulence are known, or for example once they are identified using methods described in this application, a screen may be conducted for agents that reduce virulence. These agents may be small molecules, proteins, antibodies, etc. There are numerous applications to humans, livestock, plants, and the like. The method is especially useful for infections which remain dormant for long periods of time and then cause problems periodically when virulence is induced such as TB, malaria, and herpes. Some P. vivax and P. ovale sporozoites do not immediately develop into exoerythrocytic-phase merozoites, but instead produce hypnozoites that remain dormant for periods ranging from several months (6-12 months is typical) to as long as three years. After a period of dormancy, they became reactivate and produce merozoites. Hypnozoites are responsible for long incubation and late relapses in these two species of malaria.
- Drugs may be compounds or entities that alter, inhibit, activate, or otherwise affect biological or chemical events. For example, drugs may include, but are not limited to, anti-AIDS substances, anti-cancer substances, antibiotics, immunosuppressants, anti-viral substances, enzyme inhibitors, including but not limited to protease and reverse transcriptase inhibitors, fusion inhibitors, neurotoxins, opioids, hypnotics, anti-histamines, lubricants, tranquilizers, anti-convulsants, muscle relaxants and anti-Parkinson substances, anti-spasmodics and muscle contractants including channel blockers, miotics and anti-cholinergics, anti-glaucoma compounds, anti-parasite and/or anti-protozoal compounds, modulators of cell-extracellular matrix interactions including cell growth inhibitors and anti-adhesion molecules, vasodilating agents, inhibitors of DNA, RNA or protein synthesis, anti-hypertensives, analgesics, anti-pyretics, steroidal and non-steroidal anti-inflammatory agents, anti-angiogenic factors, anti-secretory factors, anticoagulants and/or antithrombotic agents, local anesthetics, ophthalmics, prostaglandins, anti-depressants, anti-psychotic substances, anti-emetics, and imaging agents.
- Possible applications include screening for drugs that reduce virulence/infectivity of a strain of bacteria and testing bacterial isolates from patients for virulence. For example, a hybrid screen and/or cartridge system pre-loaded with several drugs may be injected into plugs at the same time as combining infectable host cells with bacteria. Preventing organisms from virulence is less likely to cause evolution of resistance than simply killing them. Importantly, confinement may change virulence. Confinement may induce virulence not observed in well-plates, so the method may have advantages over traditional well-plate methods.
- The sensitivity of a bacterial strain to many antibiotics can be screened in a single experiment by using plug-based microfluidics. A single bacterial sample can be combined with many antibiotics to generate an antibiogram, or chart of drug susceptibilty. A pre-formed array of plugs of six antibiotics—two beta-lactams (ampicillin, AMP, and oxicillin, OXA); a cephalosporin (cefoxitin, CFX); a fluoroquinolone (levofloxicin, LVF); vancomycin, VCM; and a macrolide (erythromycin, ERT)—was generated by aspiration. Antibiotics were tested at the breakpoint concentration, (British Society for Antimicrobial Chemotherapy, BSAC Methods for Antimicrobial Susceptiblity Testing, 2007) the accepted concentration of antibiotic at which bacterial susceptibility is determined (
FIG. 2 d). Since stochastic confinement of the bacterium into nanoliter-sized plugs generates many empty plugs, 50 plugs of each antibiotic were generated such that it was statistically likely that each condition would contain several plugs each occupied by a single bacterium. In total, 400-500 plugs were formed for each screen, which consisted of 6 drug conditions and 2 blank conditions. All 400-500 plugs were collected in the same coil of tubing. A blank condition was located at the beginning and end of the array to ensure that the position in the array did not affect assay results. The plugs in this antibiotic array were merged with Methicillin Resistant S. aureus (MRSA, ATCC#43300) at an initial cell density of 4×105 CFU/mL and the viability indicator on-chip to form plugs approximately 4 mL in volume, as illustrated inFIG. 2 a. The merged plugs were collected and incubated for 7 h at 37° C. After incubation, the fluorescence intensity of the plugs was measured. - Occupied plugs containing an antibiotic to which the bacterial strain was resistant showed increased fluorescence intensity, whereas plugs containing an antibiotic to which the bacterial strain was sensitive showed no significant increase in fluorescence intensity (
FIG. 2 c). Plugs containing VCM were used as a negative control, because VCM inhibited this S. aureus strain in macro-scale experiments, in agreement with expectations (B. T. Tsuji, M. J. Rybak, C. M. Cheung, M. Amjad and G. W. Kaatz, Diagn. Microbiol. Infect. Dis., 2007, 58, 41-47). The average increase in fluorescence from all plugs containing VCM was used a baseline to which the increase in fluorescence intensity of all other plugs was compared (FIG. 2 b, Δ VCM). Four out of 49 (12%) control plugs with no antibiotic (FIG. 2 b, +blank 1) showed an increase in fluorescence intensity more than three times greater than the VCM baseline, indicating that they were occupied by bacteria. However, the other plugs with no antibiotic showed an increase in fluorescence intensity similar to the baseline, indicating that they were unoccupied (FIG. 2 b, +blank 1). - By comparing the fluorescence increase in each plug to the VCM baseline, it can determine which antibiotics were toxic to the bacteria. Plugs occupied with a viable bacterium showed an increase in fluorescence intensity greater than three times the VCM baseline.
FIG. 2 c shows the average intensities of plugs that showed an increase in fluorescence intensity greater than 3 times the baseline (black bars) and plugs that showed an increase in fluorescence intensity less than 3 times the baseline (hatched bars). No plugs containing VCM or LVF had a fluorescence increase greater than 3 times the baseline, indicating that MRSA was sensitive to these antibiotics. Poisson statistics (Eq. 2) can be used to predict the probability of not loading a bacterium into any of plugs in the conditions LVF or VCM. In other words, Eq. 2 predicts the possibility of the LVF or VCM results being false-negative. -
- In Eq. 2, f is the probability of having k bacteria in a plug given an average bacterial loading of λ bacteria per plugs. The experimentally determined λ was 0.12, as 12% of control plugs with no antibiotics received bacteria (
FIG. 2 b, +blank plugs). For k=0 and λ=0.12, we calculated the probability of having an unoccupied plug to be 0.887. The probability of having 49 unoccupied plugs is 0.88749, or 0.0028. Given that LVF and VCM had at least 49 plugs, the probability of a false-negative due to loading is less than 0.3%. - The results from the MRSA antibiotic screen were used to make the antibiogram in
FIG. 2 d. The antibiotics were tested at the breakpoint concentration, and the fluorescence data was used to determine if the bacterial strain was sensitive (S) or resistant (R) to the antibiotic. Sensitive means that no plugs containing a specific antibiotic showed an increase in fluorescence intensity greater than 3 times the VCM baseline. Resistant means that at least one plug containing a specific antibiotic showed increased fluorescence intensity greater than 3 times the VCM baseline. The susceptibility profile generated for MRSA by using the microfluidic screen was identical to the profile generated by using Mueller-Hinton agar plate tests and similar to previous reports in the literature for MRSA. (B. T. Tsuji, M. J. Rybak, C. M. Cheung, M. Amjad and G. W. Kaatz, Diagn. Microbiol. Infect. Dis., 2007, 58, 41-47) However, antibiotic sensitivity testing is influenced by many factors, including bacterial load, culturing conditions, temperature, bacterial strain, and type of assay used to detect sensitivity. In addition, a cell population may contain sub-populations of cells with variable sensitivity to a given antibiotic. All of these factors should be considered and further characterized before formulating guidelines for implementing plug-based antibiotic sensitivity assays. - Plug-based methods can also be used to determine the minimal inhibitory concentration (MIC) of an antibiotic against a bacterial sample.
- Next, this microfluidic approach was used to determine the MIC of the antibiotic cefoxitin (CFX) for MRSA and MSSA (
FIG. 6 ). This assay was similar to the antibiotic screening assay described above, except that the pre-formed array of antibiotic plugs all contained the same antibiotic and the concentration of that antibiotic in each plug of the pre-formed array was different. Again, plugs containing saline solution were included at the beginning and end of the array to serve as negative controls and to ensure that the first and last plugs of the array gave similar assay results. The positive control plugs consisted of CFX at a concentration of 24 mg/L, as both strains are known to be inhibited by CFX at this concentration. Plugs of the antibiotic array were merged with bacteria and the fluorescent viability indicator as illustrated inFIG. 6 a and incubated at 32° C. Plugs with MRSA were incubated for 6.75 h and plugs with MSSA were incubated for 6.5 h. It should be noted that temperature can affect the results of antibiotic sensitivity assays. Here, the difference in MIC of MRSA and MSSA was discerned by assays conducted at 32° C. - After incubation, the fluorescence intensity of the plugs was measured. Here, the average increase in fluorescence intensity of plugs containing 24 mg/L CFX was used as the baseline to which the increase in fluorescence intensity of other plugs was compared. Because MRSA is resistant to many beta-lactam antibiotics, CFX should be less effective against the strain MRSA. As expected, the MIC of CFX was higher for MRSA (<8 mg/L) than the MIC of CFX for MSSA (<4.0 mg/L) (
FIG. 6 b). These results validate the use of this plug-based technology for screening both the susceptibility and the minimal inhibitory concentration of many antibiotics against a single bacterial sample. - The issue of screening media conditions along with drugs is of interest. The outcome of a drug screen can be heavily influenced by the media and culturing conditions used for the screen. To eliminate false negatives in a drug screen, it would be useful to screen the same drug condition in a variety of media and culturing conditions. For instance, an unknown sample of bacteria may be screened against the drug oxicillin at 30 and 37° C., 100 and 150 mM NaCl, and in Luria Bertani media and soy trypticase media. The media may: 1) influence the growth rate of bacteria regardless of drug condition (if the media condition is such that bacteria grow very slowly, the assay would falsely determine that the drug is killing the bacteria); or 2) influence the interaction between the bacteria and the drug.
- Stochastic confinement combined with plug-based microfluidic handling methods accelerates bacterial detection and enables rapid functional antibiotic screening. By using this method, assays may be performed on a single bacterium, potentially eliminating the need for pre-incubation. By confining and analyzing single bacterium in plugs, detection time is now determined by plug volume. We were able to achieve detailed functional characterization of a bacterial sample in less than 7 hours. We also demonstrated that a bacterium in a 1 mL plug may be detected in as little as 2 hours. The detection time is limited by the formation and measurement of plugs of small volume and is less dependent on the initial concentration and growth rate of bacteria in the sample. This feature may be potentially important for accelerated detection of slowly-growing species such as M. tuberculosis, a pathogen of significant importance world-wide. (E. Keeler, M. D. Perkins, P. Small, C. Hanson, S. Reed, J. Cunningham, J. E. Aledort, L. Hillborne, M. E. Rafael, F. Girosi and C. Dye, Nature, 2006, 444
Suppl 1, 49-57) Here, we have demonstrated a screen with 400-500 mL plugs. High-throughput screens with more conditions and increased concentration of the sample would require methods that can handle larger numbers of smaller plugs, including methods for automated sorting and analysis. (Y. C. Tan, Y. L. Ho and A. P. Lee, Microfluid. Nanofluid., 2008, 4, 343-348; D. Huh, J. H. Bahng, Y. B. Ling, H. H. Wei, O. D. Kripfgans, J. B. Fowlkes, J. B. Grotberg and S. Takayama, Anal. Chem., 2007, 79, 1369-1376; K. Ahn, C. Kerbage, T. P. Hunt, R. M. Westervelt, D. R. Link and D. A. Weitz, Appl. Phys. Lett., 2006, 88, 024104; M. Chabert and J.-L. Viovy, Proceedings of the National Academy of Sciences, 2008, 105, 3191-3196) Upon incorporating such methods for handling and sorting large numbers of plugs of small volume, this technique may be used for the detection of bacteria in a sample at a cell density much lower than 105 CFU/mL. Since the activity of single cells is being measured, it is conceivable that detecting the presence of even a single bacterium in a sample may be feasible. - Given that a typical 5 mL blood sample from a patient with bacteremia contains a cell density of 100 CFU/mL, (L. G. Reimer, M. L. Wilson and M. P. Weinstein, Clin. Microbiol. Rev., 1997, 10, 444-7) this method is capable of performing dozens of functional tests on such a sample. Patient-specific characterization of bacterial species would not only lead to more rapid and effective treatment, but such an advance would also enable in-depth characterization of bacterial infections at the population level. Such detailed characterization may aid in tracking and identifying new resistance patterns in bacterial pathogens. (S. K. Fridkin, J. R. Edwards, F. C. Tenover, R. P. Gaynes and J. E. McGowan, Clin. Infect. Dis., 2001, 33, 324-329; R. T. Horvat, N. E. Klutman, M. K. Lacy, D. Grauer and M. Wilson, J. Clin. Microbiol., 2003, 41, 4611-4616) The principles of these methods, stochastic single-cell confinement and multiple functional assays without sample pre-incubation, may also be applied to other areas, including performing functional tests on field samples, detecting contamination of food or water, separating and testing samples with mixtures of species, measuring functional heterogeneity in bacterial populations, and monitoring industrial bioprocesses.
- Other Applications
- Confinement affects may be of particular use in the detection of slow growing bacterial strains such as Mycobacterium tuberculosis (the strain which causes tuberculosis, TB). To grow a culture of M. tuberculosis using traditional methods takes several weeks. Current tests for TB are based on an immune response, but cannot distinguish between someone with an active infection and someone who has previous immunization. Other current tests involve PCR based methods. Stochastic confinement should increase the sensitivity of detection based assays and also remove the need for a lengthy preincubation step before running the detection assay since detection may be done with a single confined cell.
- Confinement effects may be used to screen natural sources for candidate organisms or their genes that perform functions of interest or generate molecules of interest. Functions of interest include nitrogen fixation, carbon recycling, hydrocarbon production, pollutant degradation, solar energy conversion, forming a symbiotic relationship with other microbes, producing a toxin that kills other organisms, produces light, produces an odor, generates electricity. Molecules of interest include drug candidates, small molecule inhibitors, enzymes which degrade cellulose, enzymes which degrade pollutants, adhesives, electron transport molecules, metal chelators, selective inhibitors of small molecules, catalysts, plasticizing agents, and proteases.
- Some of these functions may not occur in large volume (low density of cell type which performs function) samples or samples with mixtures of microbes. One advantage of confinement is that individual microbes will be able to function under high density conditions. This would be useful for rare cell types in a sample, as high density functions would not be occurring in the original sample due to the rare cells being at a low cell density. Such functions would not be occurring in a macroscale sample. Confinement may also enable rare cell types of initiate growth or increase the growth rate due to the high concentration of rare cells in a small volume plug after confinement. This type of approach can be extended to rare cell types from mixed species samples by confining rare cell at high densities to enable more rapid growth of the rare cells due to both increased inoculation density and eliminating competition with other strains in the original mixed sample. The effect of confinement in small volumes is increased if the molecules accumulating in the plug are immiscible in the carrier fluid (the fluid surrounding the plug). Using immiscible fluids around the plug will prevent released microbial products from diffusing out of the plug and hence the released products will more quickly accumulate and achieve a higher concentration in the plug.
- Other applications include detecting bacteria for applications in homeland security and safety of the food chain and water. It is also possible to apply these methods of detection to the areas of sepsis, bioenergy, proteins, enzyme engineering, blood clotting, biodefense, food safety, safety of water supply, and environmental remediation.
- The following patents and patent applications are hereby entirely incorporated by reference in their entirety: WO 05-010169A2, U.S. Pat. No. 6,500,617, WO 2007-009082 A1.
- A process of collecting a useful product from stochastically confined cells may comprise: confining organisms, cells or particles (by themselves, or with their enemies such as other bacterial or other cells), or with addition of stimulating chemicals; accumulating their products (antibiotics or other potentially valuable enzymes); using these products for detection; using these products for further screening (for example, dilute and different concentrations and merging with suspensions of other bacteria to see if those bacteria get killed off, or drip those dilutions into standard growth assay plates); using the accumulated enzyme and assaying for function (as described in this application, including but not limited to cellulose degradation, catalysts for synthesis, disruption of biofilms); and adding other assays. When plugs are used for stochastic confinement, allowing an organism to multiply inside a plug and then splitting the plug into daughter plugs (where at least two daughter plugs contain daughter organisms) provides an opportunity to perform multiple assays on clones of the organism (including assays that cannot be performed on a single organism or in a single volume).
- All of the methods and applications described herein may be done under controlled atmosphere using plugs/droplets, where fluorocarbon can enable transport of gases to the plug, and massively parallel small-scale incubations under controlled atmosphere can be performed. This may be useful for control of virulence, for hydrogen generation and for using organisms that require controlled atmosphere (anaerobes, organisms that consume or produce methane or other hydrocarbons or H2S, etc).
- The methods described herein may also be used to detect fungi, archaea and other organisms in a sample.
- Test Strips
- General Components of Test-Strips
- A test strip comprises an amplification layer and may comprise one or more of the following layers: a filtration wetting layer with selectivity, a detection layer with threshold and a layer of substrate for signal output. A signal produced by target bacteria, for example an enzyme, will turn on the amplification reactions in the amplification layer. Multiple amplification layers may be applied to achieve a high magnitude of amplification. A substrate is used to detect the generation of control molecule or the output of the amplification in the system.
- The amplification region may be regulated by a threshold mechanism. The methods for amplification may be chosen from those described in the section entitled “Amplification.” A detailed definition of threshold may be found below.
- The techniques described in this section aim to detect a small number of molecules or particles in a short time with a high resistance to noise and background signals. To achieve such goals, each of these techniques consists of multiple modules. The two most important modules are the amplification process with positive feedback that produces a large amount of substances in short time and the inhibitory mechanism. The interplay between these two processes sets up a threshold or a threshold-like behavior. In an ideal system, a threshold is the concentration below which an input gives a background output and above which an input gives a the signal output, where the two outputs are easily distinguishable. To achieve most useful amplification, the signal output must be significantly (often by two orders of magnitude or more) different than the background output. The transfer function, the function of output versus input, may be a shifted ideal step function. However, in many cases, it is impossible to achieve an ideal threshold, but possible to achieve a threshold-like behavior, with which the transfer function is similar to a step function but has a finite slope at the transition region. A sigmoidal function or a similar function may be used to describe such threshold-like behaviors. Another way to look at threshold is the time to reach maximum possible output as a function of input. With an ideal threshold, this function is infinite when the input is below the threshold and reaches a constant small positive value when the input is above the threshold. With a threshold-like behavior, this function is very large when the input is below the threshold. As the amount of input increases from the threshold, this function decreases rapidly and reaches a very small value (such as 10% or less of that at the threshold). In the most ideal case, at threshold, a change in the number of input molecules of 1 unit leads to a drastic change in the output.
- As long as the threshold is tuned properly, the amplification process may selectively respond to only the active, target particles (molecules) even in the presence of a large excess of interfering particles (molecules). One or multiple amplification layers with threshold may be added to increase the degree of amplification. Threshold response may be incorporated in the detection layer to limit false positives and false negatives. Diffusion of signal molecules and control molecules may be restricted on each layer by choosing the appropriate material. Thus, stochastic confinement may be applicable to test strips. For example, a bacterium on the strip is confined by limited diffusion (the reagents and products are not mixed on purpose), or the test strip may be structured to restrict diffusion, for example when based on alumina or track-etched membranes.
-
FIG. 8 is a schematic description of a test strip with an amplification system. Bacteria are brought into contact with a filtration wetting layer. Enzymes (E) produced by target bacteria, for example in the scale of pM or even lower, enter a detection layer with threshold and turn on the reactions to generate control molecules (C). After proceeding to amplification layer, the signal will be amplified and the concentration of control molecule increased to μM or mM. The control molecules will react with chromogenic, fluorogenic or other substrate in the substrate layer to give a strong output signal. Output signal can also be generated in any other ways. - A timer region may be added to the test strip as shown in
FIG. 9 . This timer region is an analogous reaction which is not detecting the analyte, but instead demonstrating the reaction is running correctly under the current conditions (age of strip, temperature, pressure, humidity, presence of certain impurities, etc.). It also gives the user the assurance that the strip is working and that they have waited long enough for the results. There may be one or multiple timer regions to indicate different parameters (age of strip, temperature, pressure, humidity, presence of certain impurities, etc.) - The timer region may have the same amplification system with reactions of the same sensitivity as the detection region. It may be used to test for false positive. However, the timer regions may utilize other techniques for specific purposes. Some amplification systems may be previously loaded with a known amount of analyte which may be activated upon the beginning of the test (e.g. by wetting).
- Amplification
- Amplification schemes using enzyme cascades are known. In particular, enzyme cascades may be modified to detect the type of molecule not naturally associated with the enzymes. For example, the crab blood cascade may be used to detect air pollutants by modifying enzymes at the beginning of the cascade to detect a new type of input.
- Cascade assay formats may be used. These detect an analyte through a process wherein, a first signal generating compound (i.e., SGC #1) produces a product that may be utilized by a
second SGC # 2 to produce a product which, e.g., may be utilized by athird SGC # 3. The subject cascade of products from SGC #1-3 results in amplification which results in a greater overall signal than may be achieved by any single SGC. - Many substances could be detected by a scheme which uses the same (generic) amplification mechanism. For different analyte, a different starter reaction is designed, but all starter reactions produce the same output. For example, a detection scheme with the first step which is designed to detect a specific activity and the second steps which is able to amplify the product of the first step. An example is using the coagulation cascade as the generic amplification mechanism, and a set of started reactions that all produce an activator of thrombin. One would only have to redesign the starter reaction to detect a new analyte
- Alternatively, selection may be performed indirectly by coupling a first reaction to subsequent reactions that take place in the same plug. There are two general ways in which this may be performed. In the first method, the product of the first reaction is reacted with, or bound by, a molecule which does not react with the substrate of the first reaction. In a second, the coupled reaction will only proceed in the presence of the product of the first reaction. For example, a genetic element encoding a gene product with a desired activity may then be purified by using the properties of the product of the second reaction to induce a change in the detectable properties of the genetic element.
- Alternatively, the product of the reaction being selected may be the substrate or cofactor for a second enzyme-catalyzed reaction. The enzyme to catalyze the second reaction may either be translated in situ in the plug or incorporated in the reaction mixture prior to incorporation into a plug. Only when the first reaction proceeds will the coupled enzyme generate a product which may be used to induce a change in the detectable properties of the genetic element. Stochastic confinement could be used to increase local concentration and signal to noise ratio and to give advantages described elsewhere herein. The product of the first reaction could be a substrate, enzyme, or cofactor of the second reaction, or promote the release of inhibition of the second reaction. More reaction steps could be used.
- The concept of coupling may be elaborated to incorporate multiple enzymes, each using as a substrate which is the product of the previous reaction. This allows for selection of enzymes that will not react with an immobilized substrate. It may also be designed to give increased sensitivity by signal amplification if a product of one reaction is a catalyst or a cofactor for a second reaction or series of reactions leading to a selectable product. Furthermore an enzyme cascade system may be based for the production of an activator for an enzyme or the destruction of an enzyme inhibitor. Coupling also has the advantage that a common selection system may be used for a whole group of enzymes which generate the same product and allows for the selection of complicated chemical transformations that cannot be performed in a single step.
- Previously developed methods of detection include those using nucleotide-based amplification (such as immuno-polymerase chain reaction (iPCR), (Adler, M.; Wacker, R.; Niemeyer, C. M., Sensitivity by combination: immuno-PCR and related technologies. Analyst 2008, 133, (6), 702-718.) amplification based on allosteric catalysis, (Zhu, L.; Anslyn, E. V., Signal amplification by allosteric catalysis. Angewandte Chemie-
International Edition 2006, 45, (8), 1190-1196.) biobarcode, (Nam, J. M.; Stoeva, S. I.; Mirkin, C. A., Bio-bar-code-based DNA detection with PCR-like sensitivity. Journal of the American Chemical Society 2004, 126, (19), 5932-5933; Nam, J. M.; Thaxton, C. S.; Mirkin, C. A., Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 2003, 301, (5641), 1884-1886.) molecular beacon, (Li, J. W. J.; Chu, Y. Z.; Lee, B. Y. H.; Xie, X. L. S., Enzymatic signal amplification of molecular beacons for sensitive DNA detection.Nucleic Acids Research 2008, 36, (6).) liposome-based amplification, (Edwards, K. A.; Baeumner, A. J., Liposomes in analyses. Talanta 2006, 68, (5), 1421-1431.) and nanowire sensor. (Zheng, G. F.; Patolsky, F.; Cui, Y.; Wang, W. U.; Lieber, C. M., Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nature Biotechnology 2005, 23, (10), 1294-1301; Cui, Y.; Wei, Q. Q.; Park, H. K.; Lieber, C. M., Nanowire nanosensors for highly sensitive and selective detection of biological and chemical species. Science 2001, 293, (5533), 1289-1292.) Each of these techniques has one or multiple disadvantages: slow response, vulnerability to noise and environmental degradation, low detection limit, and requirement for highly sophisticated and expensive fabrication. - The techniques described in this section aim to detect a small number of molecules or particles in a short time with a high resistance to noise and background signals. To achieve such goals, each of these techniques consists of multiple modules. The two most important modules are the amplification process with positive feedback that produces a large amount of substances in short time and the inhibitory mechanism. The interplay between these two processes sets up a threshold or a threshold-like behavior. In an ideal system, a threshold is the concentration below which an input gives a background output and above which an input gives a the signal output, where the two outputs are easily distinguishable. To achieve most useful amplification, the signal output must be significantly (often by two orders of magnitude or more) different than the background output. The transfer function, the function of output versus input, may be a shifted ideal step function. However, in many cases, it is impossible to achieve an ideal threshold, but possible to achieve a threshold-like behavior, with which the transfer function is similar to a step function but has a finite slope at the transition region. A sigmoidal function or a similar function may be used to describe such threshold-like behaviors. Another way to look at threshold is the time to reach maximum possible output as a function of input. With an ideal threshold, this function is infinite when the input is below the threshold and reaches a constant small positive value when the input is above the threshold. With a threshold-like behavior, this function is very large when the input is below the threshold. As the amount of input increases from the threshold, this function decreases rapidly and reaches a very small value (such as 10% or less of that at the threshold). In the most ideal case, at threshold, a change in the number of input molecules of 1 unit leads to a drastic change in the output.
- An elementary amplification method for detecting molecules includes: a) a set of molecules or materials that constitute an amplification process that is capable of amplifying one or multiple components (termed output); b) a set of molecules or materials that provides an inhibitory mechanism to stop or slow down amplification by the amplification process described in a) when the amount of the analyte is insufficient; c) an activating mechanism which, once sufficient analyte (termed input) is present, triggers the amplification process described in a); d) a readout process to provide an apparent signal (with visual signal as one example).
- Inhibition in part (b) and the amplification process in part (a) set up a threshold or threshold-like behavior which gives very little or no output if the input is below the threshold and gives fast and abundant output if the input is above the threshold. This case is termed positive contrast.
- Alternatively, the system may be set up with the input providing a mechanism to inhibit the amplification process. In such cases, with a below-threshold amount of input, a lot of the output is produced, while an above-threshold amount of input would give little or no output. This phenomenon is called negative contrast. The roles of part (b) and part (c) are swapped. The general feature is a big contrast (be it positive or negative) between the output of a below- or above-threshold input.
- Elementary amplification methods may be coupled in such a way that outputs of one may be used as inputs for another. This is also called a cascade. The number of elementary amplification methods in a cascade may be varied depending on how much more amplification is needed in comparison to what is provided by each elementary amplification method.
- The analyte may be any molecules such as enzymes, DNA, RNA, small molecules, or any other molecules. It may come from any sources including bacterial components, human fluids, water samples, etc.
- The amplification processes may be any reaction that is autocatalytic or a reaction network with one or more positive feedback loops. The processes may involve enzymes such as those in the blood clotting cascade, apoptosis, and Limulus amebocyte (horseshoe crab) lysate (LAL), or any other enzymes. The processes may involve inorganic chemicals such as the Co(III)-Co(II)-oxone system, (Endo, M.; Abe, S.; Deguchi, Y.; Yotsuyanagi, T., Kinetic determination of trace cobalt(II) by visual autocatalytic indication. Talanta 1998, 47, (2), 349-353; Endo, M.; Ishihara, M.; Yotsuyanagi, T., Autocatalytic decomposition of cobalt complexes as an indicator system for the determination of trace amounts of cobalt and effectors. Analyst 1996, 121, (4), 391-394; Tsukada, S.; Miki, H.; Lin, J. M.; Suzuki, T.; Yamada, M., Chemiluminescence from fluorescent organic compounds induced by cobalt(II) catalyzed decomposition of peroxomonosulfate. Analytica Chimica Acta 1998, 371, (2-3), 163-170.) Ag+-Ag(0) system, systems in which a metal surface catalyzes reduction of Ag+ or other ions, producing more metal surface available for catalysis the chlorite-iodide system, (Dateo, C. E.; Orban, M.; Dekepper, P.; Epstein, I. R., J. Am. Chem. Soc. 1982, 104, 2, 504-509) or thiosulfate-chlorite-hydronium system. (Runyon, M. K.; Johnson-Kerner, B. L.; Ismagilov, R. F., Minimal functional model of hemostasis in a biomimetic microfluidic system. Angewandte Chemie-
International Edition 2004, 43, (12), 1531-1536; Horvath, A. K.; Nagypal, I.; Epstein, I. R., Kinetics and mechanism of the chlorine dioxide-tetrathionate reaction. Journal of Physical Chemistry A 2003, 107, (47), 10063-10068; Horvath, A. K.; Nagypal, I.; Epstein, I. R., Oscillatory photochemical decomposition of tetrathionate ion. Journal of the American Chemical Society 2002, 124, (37), 10956-10957; Nagypal, I.; Epstein, I. R., Systematic Design of Chemical Oscillators 0.37. Fluctuations and Stirring Rate Effects in the Chlorite Thiosulfate Reaction. Journal of Physical Chemistry 1986, 90, (23), 6285-6292.). They may also involve organic reactions, such as those with acid as autocatalysts. (Ichimura, K., Nonlinear organic reactions to proliferate acidic and basic molecules and their applications.Chemical Record 2002, 2, (1), 46-55.) They may also be combinations of different types of chemicals. - Phenomena in which nucleation is involved may also be used as an amplification process, in which a crystal of aggregate produced by nucleation may serve as a nucleus to promote more production of such crystal or aggregate.
- An amplification process may also be achieved by using materials that release substances that catalyze the release of more of such substances.
- There are many inhibitory mechanisms. Each mechanism may occur directly or indirectly through more than one reaction or processes.
- The first mechanism may use chemical inhibitors. These chemical inhibitors may be stoichiometric, such as those that bind to enzymes and block the active sites or ligands that bind to and sequester metal cations. The chemical inhibitors may also be catalytic, such an enzyme that cleaves an active enzyme that is important in positive feedback loops.
- The second mechanism may use materials to mechanically separate important components of the amplification process. These materials include, but are not limited to, vesicles containing liquid, particles of solid or gel, and any combination of single-layer or multi-layer particles or vesicles of one type or multiple types.
- There are many activating mechanisms. For example, the input may be one or multiple types of the substances that are inhibited chemically or mechanically by materials. The input may directly or indirectly produce more of the substances that are inhibited chemically or mechanically in the inhibitory mechanism. The input may directly or indirectly interfere with the chemical or mechanical inhibition by competition with the substances being inhibited. The input may directly or indirectly interfere with the chemical or mechanical inhibition by chemically modifying the chemical inhibitors or the materials used to mechanically separate the components of the amplification process.
- The input generates a high local concentration of substances that may have functions described above. Stochastic confinement is an example of this category.
- With such flexibility of activating mechanism, the methods may be designed to be applicable to many kinds of analytes with different desired degrees of specificity. For example, if an existing method needs modifying to be applicable for detection of a different analyte, the activating mechanism may be changed completely or may be adapted with single of multiple steps to use the analyte of interest to promote the production of the analyte of the existing method.
- One or more substances that are amplified or activated by the amplification process may promote the production of some form of easily detectable readout. This readout may be a visual signal based on color. The color may come from any reaction that can generate color when the input (over the threshold) is present. For example, an enzyme amplified in the amplification process cleaves a fluorogenic substrate or a chromogenic substrate to give a fluorescent signal or color. Some other examples are pH indicators, reduction-oxidation potential indicators, and indicators for specific cations.
- Alternatively, the readout may be a visual signal based on production of aggregates (precipitates) or crystals from any method when the input (over the threshold) is present. These aggregates (precipitates) or crystals may be the result of any process such as chemical reaction or production of paramagnetic substances that come together as solid in a magnetic field.
- Examples of reactions that produce paramagnetic solids that may be used in an amplification process include: 1) Ag+->Ag:Ag+ has electron configuration of d10, so it is diamagnetic. Ag has electron configuration of s1d10, so it is paramagnetic. The autocatalyst is Ag (or its surface to be more detailed);
- 2) Guyard reaction: Mn(VII) (such as, KMnO4) reacts with Mn(II) (some soluble salt such as nitrate or chloride) and makes MnO2 which is a black paramagnetic powder. The autocatalyst is MnO2 solid (its surface). (Polissar, M. J. Journal of
Physical Chemistry 1935, 39, 1057.) - Further still, the readout may be any other detectable signal, such as an electrical signal that gives analog or digital readout or any other kind.
- Amplification Process Involving Enzymes with Chemical Amplification Processes
- The amplification process may be an autocatalytic reaction or reaction network that has a positive feedback. This positive feedback may be achieved through one step (
FIG. 10 ). In such case, an autocatalytic enzyme may catalyze the cleavage of its precursor. (A chemical inhibitor may also used to inhibit this autocatalytic enzyme, and a fluorogenic substrate may be used to detect this autocatalytic enzyme). Positive feedback may also be achieved through two steps (FIG. 11 ). In such case,enzyme 1 may catalyze the cleavage ofenzyme precursor 2 to produceenzyme 2, which may catalyze the cleavage ofenzyme precursor 1 to produceenzyme 1. (Common or specific inhibitors and fluorogenic substrates forenzyme 1 andenzyme 2 may be included). Generally, positive feedback may be achieved through any number of steps, in which one substance, calledsubstance 1, may catalyze directly the production of itself or indirectly by catalyzing the production of another substance that may directly or indirectly catalyze the production of thesubstance 1. Many positive feedback loops may also be coupled with each other into a cascade, in which the output of one positive feedback loop is used as the input of another (FIG. 12 ). In such case, the number of positive feedback loops with threshold must be at least 1 and may vary from 1 to all. - In certain embodiments at least one enzyme in the positive feedback loop is inhibited by an inhibitor. Not every enzyme is necessarily inhibited, but many may be. The inhibitors may be those found naturally or synthesized. Antibodies may also be used as inhibitors.
- If there is only one enzyme involved in the positive feedback loops (
FIG. 10 ), the input may be that enzyme. If there are multiple enzymes involved in the positive feedback loops (FIG. 11 ), the input may be single ones or combinations of the enzymes. The input may produce single or combinations of enzymes from the same or different precursors as in the amplification process, through one or many steps. The input may also be much more strongly binding substrate for the inhibitor, or promotes the production of much more strongly binding substrate for the inhibitor. The input may chemically alter the inhibitors and disable the inhibitory effect, or promote the production of substances with such function. - If fluorogenic substrates are used, one or multiple fluorogenic substrates may be cleaved by one or multiple enzymes in the amplification process, through one or multiple steps. In certain embodiments, there has to be at least one cleavage reaction but one cleavage reaction may or may not be sufficient. For methods with plasma or whole blood, blood clotting may also be used as a visual readout.
- Amplification Using Materials
- Amplification process: The unit of the material contains molecules that once released can promote the release of more molecules from other units of the material. The units may be vesicles containing liquid (such as liposomes) or particles (of solid or gel).
- Amplification using materials may be coupled with chemical amplification. In other words, besides effects on the material, the released molecules may also undergo chemical amplification.
- The molecules enclosed in the materials may be inactive and get activated when released by chemical reactions with substances in the bulk or by any other ways such as change in conformation, release of self-inhibition by an attached inhibitor, etc. They may also be in the same form after release, but the breakage of the material is very slow when they are enclosed, such as when the material is designed to have different reactivity with the molecules in the enclosed environment or in the bulk.
- Inhibitory mechanism: These molecules may also be inhibited by some substances in the bulk when they are released.
- Activating mechanism: The input may also be or produce (through one or multiple steps) a substance that releases the molecules from the materials (this substance may be similar to or different from the enclosed) or releases the molecules from the inhibitor (by competing with the inhibitor or by inactivating the inhibitor).
- Readout process: readout processes described elsewhere herein may be used, depending on specific situations.
- Activating mechanism via generating a high concentration of substances.
- In certain embodiments, the input generates a high local concentration of substances.
- This technique can be used in combination with amplification processes using chemical reactions or materials.
- Stochastic Confinement
- Stochastic confinement as described above is a powerful tool to generate high local concentrations from a solution of low bulk concentration. This technique may also be used to distinguish interfering particles (molecules) with much weaker activity but much larger number than those of interest. When interfering particles (molecules, etc.) are in a large excess, the total activity of interfering particles may be higher than the total activity of active particles (molecules) of interest. Even with kinetic amplification via a threshold response, it is impossible to detect the signal from the particles of interest in the presence of overwhelming background signal from the interfering particles unless separation is used to isolate the particles of interest. This situation may be commonly encountered in the microbiological analysis of environmental samples. For example, human samples, including skin, saliva, and stool samples, being analyzed for microorganisms are routinely contaminated with bacteria or other cells (blood). Stochastic confinement is a powerful method to compartmentalize the active particles separately from the interfering particles. Therefore, as long as the threshold is tuned properly, the amplification process can selectively respond to only the active, target particles (molecules) even in the presence of a large excess of interfering particles (molecules).
- Immobilizing Molecules onto a Limited Surface
- Surfaces may be the interfaces of a plug, surface of a particle, surface of a microbe, and patterns on a surface which allows it to adsorb specific molecules. Many techniques for immobilizing molecules onto a surface may be used. These techniques include but are not limited to using antibodies, biotin/avidin interaction, and His-tag/Ni2+/nitrolotriacetic acid (His-tag/Ni/NTA) interaction.
- Using Particles Containing Molecules
- In some embodiments, the molecules are enclosed in the particles. When needed the particles release the molecules providing a burst of high concentration of these molecules in solution. This process may or may not be autocatalytic. In other words, the released molecules do not have to promote the release of more molecules, although they may.
- Stochastic confinement, immobilizing molecules onto a limited surface and using particles containing molecules, may be used in different combinations to generate even higher local concentrations. For example, if the analytes are bacteria (with or without background interfering bacteria), the specific antibodies for the bacteria of interest can be used to concentrate a reporter enzyme on the surface of the bacteria. The bacteria tagged with reporter enzymes are then stochastically confined into plugs. These plugs are then merged with plugs containing vesicles containing secondary reporter enzymes. The reporter enzymes tagged on the bacteria promotes the breakage of the vesicles, releasing an amplified number of secondary reporter enzymes. The reporter enzymes then act as input for one of the amplification processes.
- Using Membranes
- To generate a high local concentration, a membrane can be used to keep one particular component on one side. For example, a membrane that is impermeable to H+ but permeable to R−—H+ can be used. On one side of the membrane, an amplification process uses R−—H+ (which diffuses in from the other side of the membrane) as input to initiate the production of H+ and amplifies the amount of H. Other substances and amplification processes may be used with appropriate membranes as well.
- Using Phase for Separation
- Two sets of substances are separated into insoluble or immiscible phases (solid/solid, solid/liquid, or liquid/liquid). A shuttle substance may transfer between two phases and speeds up the reaction in one or both phases by fast reactions with positive feedback. For example, the system contains solid oxidant and iron particles in water. If the analyte is Fe2+ (or Fe3+) or produces Fe2+ (or Fe3+), Fe2+ is oxidized by the solid oxidant to Fe3+, which oxidizes Fe(0) (from the iron particles) to Fe2+. Eventually, the solution contains a lot of Fe2+ (if the metal particles are in excess) or Fe3+ (if the solid oxidant is in excess) which may be detected by strongly colored indicators for Fe2+ or Fe3+.
- Microfluidic devices were fabricated by using soft lithography (Y. N. Xia and G. M. Whitesides, Annu. Rev. Mater. Sci., 1998, 28, 153-184.) as described previously. (L. S. Roach, H. Song and R. F. Ismagilov, Anal. Chem., 2005, 77, 785-796; H. Song and R. F. Ismagilov, J. Am. Chem. Soc., 2003, 125, 14613-14619; L. Li, D. Mustafi, Q. Fu, V. Tereshko, D. L. L. Chen, J. D. Tice and R. F. Ismagilov, Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 19243-19248.) Except where noted below, plugs were collected in PFA or PTFE Teflon tubing (Zeus, Orangeburg, S.C.) with 150 μm or 200 μm inner diameter (I.D.). The tubing was cut at a 45 degree angle, inserted into the outlet of the microfluidic device up to the inlet junction, and sealed into the device by using PDMS prepolymer (10:1 elastomer to curing agent). To aid in imaging of the plugs, the Teflon tubing was wound in a spiral on a glass slide, and PDMS prepolymer was poured over the tubing to fix it in place. The device with attached tubing was then autoclaved at 135° C. for 10 min to sterilize. Once sterilized, the glass slide containing the tubing was transferred to a sterile Petri dish.
- Flowing Solutions into the Microfluidic Devices
- All solutions were loaded into 1700 series Gastight syringes (Hamilton, Reno, Nev.) with removable 27 gauge needles and 30 gauge Teflon tubing (Weico, Wire & Cable, Edgewood, N.Y.). To maintain sterility, the syringes were filled and attached to the device within a biosafety cabinet. Syringes were connected to the microfluidic devices by using 30 gauge Teflon tubing. Solutions where flowed into the microfluidic devices by using previously described methods. (L. Li, D. Mustafi, Q. Fu, V. Tereshko, D. L. L. Chen, J. D. Tice and R. F. Ismagilov, Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 19243-19248) Flow rates were controlled by using
PHD 2000 infusion syringe pumps (Harvard Apparatus, Holliston, Mass.). - Bacterial Cell Culture
- Cells were obtained from ATCC (Staphylococcus aureus ATCC#25923 (MSSA) and Staphylococcus aureus ATCC#43300 (MRSA)). Stock solutions of the cells were made by using Luria-Bertani media Miller formulation (LB) (BD, Sparks, Md.) containing 30% (v/v) glycerol and stored at −80° C. For each experiment, a vial of frozen stock was brought to room temperature and streaked onto a Modified Trypticase Soy Agar (TSA II, BD, Sparks, Md.) plate and incubated overnight at 30° C. Colonies from the plates were transferred to LB and cultured at 37° C., 140 rpm for 3 h at which point OD600 was 1.5-2.0. Cell densities were then adjusted by diluting in LB. To maintain sterility, all procedures were performed in a biosafety cabinet and all tubing, devices, syringes, and solutions used were either autoclaved, sterilized by EtOH, packaged sterile, or filtered through a 0.45 μm PES or PTFE filter.
- Antibiotic Preparation
- Antibiotic stock solutions of ampicillin (AMP), oxacillin (OXA), cefoxitin (CFX), levofloxacin (LVF), vancomycin (VCM), erythromycin (ERT) were made by using 150 mM NaClaq at a concentration of 4000 times greater than the final concentration in the plugs, filter sterilized, and then frozen at −80° C. (AMP, Fisher Bioreagents, Fair Lawn. NJ; OXA, LVF, Fluka, Buchs, Switzerland; CFX, VCM, ERT, Sigma, St. Louis, Mo.). For example, AMP was tested at the breakpoint concentration of 0.25 mg/L, meaning that the stock solution was prepared at a concentration of 1000 mg/L. In the case of erythromycin (ERT), a stock solution was prepared at 1000 times the final concentration in plugs. Before each experiment, vials of the antibiotics were thawed and diluted 1000×(250× for ERT) with saline containing 80 μM fluorescein carboxylate. Fluorescein carboxylate was used to aid in indexing the resultant array of plugs. The plugs in
FIG. 7 contain no fluorescein carboxylate, since indexing was not required. The blank conditions consisted of 150 mM NaCl. Antibiotic solutions were further diluted on chip 1:3 (v/v) during plug formation. 20 μM fluorescein carboxylate did not interfere with the viability assay, the activity of the cells, or effectiveness of antibiotic in tests performed on 96 well plates. - Antibiotic Testing on Plates
- Plates were made from Mueller Hinton Agar (Fluka, Switzerland). After autoclaving, the agar was cooled and antibiotics were added and 20 mL plates were poured. For CFX and OXA testing, 50 μL of MRSA and MSSA bacterial culture at 4×103 CFU/mL was spread onto separate TSA plates. The plates were incubated at 30° C. After 16.5 h and 40 h the plates were examined for colonies. MRSA colonies appeared on CFX after 16.5 h and on the OXA plates after 40 h. Even after 40 h, MSSA colonies did not appear on the CFX or OXA plates. For AMP, ERT, LVF, and VCM, 5 μL of culture at 2×104 CFU/mL were spread onto plates, and the plates were incubated at 37° C. for 12 h. After 12 h, growth of colonies on the plates was considered resistance to the antibiotic and no colonies on the plates were considered sensitivity to the antibiotic. For all tests, control plates with no antibiotic were inoculated to ensure that each plate tested received many CFU during inoculation.
- Comparing Detection Times of Bacteria in Nanoliter Plugs and Milliliter-Scale Culture
- Plugs were formed by using the general methods described previously. (L. Li, D. Mustafi, Q. Fu, V. Tereshko, D. L. L. Chen, J. D. Tice and R. F. Ismagilov, Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 19243-19248; D. N. Adamson, D. Mustafi, J. X. J. Zhang, B. Zheng and R. F. Ismagilov, Lab Chip, 2006, 6, 1178-1186) Plugs were formed in a 3 inlet PDMS device with 100 μm wide channels by flowing S. aureus culture in LB at 2×105 CFU/mL at 1 μL/min, a 20% alamarBlue solution in saline at 1 μL/min, and fluorinated carrier fluid at 5 μL/min. 25 plugs were collected in the channel. Inlets and the outlet were sealed with silicon grease and the device was placed in a Petri dish containing LB for incubation. The same aqueous solutions were mixed 1:1 (total volume 0.6 mL) in a 14 mL polypropylene round-bottom tube (BD Falcon, Franklin Lakes, N.J.). After 2.8 h, plugs were made from the milliliter-scale culture by using the same method, with the cell culture containing alamarBlue for both aqueous inlets. Both sets of plugs were immediately imaged by using a epi-fluorescence microscope (IRE2, Leica) with a Cy3 (Chroma 41007, Cy3) filter and a 10×0.3 NA objective for a 5 ms exposure time with binning set to 4 and gain set to 200. Fluorescent images of plugs were processed by subtracting the average background intensity from all images. Line scans (
FIG. 1 b) with a width of 25 pixels were taken along the long axis of each plug. - Experiment to Compare Plug Size to Detection Time
- PDMS devices with channel widths ranging from 200 to 800 μm were prepared. Teflon tubing with diameter similar to that of the channel was cut at a 45° angle, inserted into the device up to the inlet junction, and sealed in place using PDMS. For
FIGS. 1 c and d, plugs were formed as above, with the exception that the ˜1500 mL plugs were made via aspiration by using a manual aspirator. In addition, 1 mL plugs were formed in PTFE tubing with an outer diameter (OD) of 200 μm and an inner diameter (ID) of 90 μm, 690 mL plugs were formed in PTFE tubing with an OD of 700 μm and an ID of 600 μm, 100 and 120 mL plugs were formed in PTFE tubing with an OD of 800 μm and an ID of 400 μm, and 1500 mL plugs were formed in PTFE tubing with an OD of 1100 μm and an ID of 1000 μm. Plugs were collected in the Teflon tubing, the tubing was sealed with wax, and the tubing was placed in a Petri dish containing LB for incubation and imaging. Incubation and imaging was performed in a microscope incubator (Pecon GmbH, Erbach, Germany). Time zero is defined as the time at which the sample entered the incubator, which was less than 20 min after sample preparation. Fluorescence measurements were taken with 5 ms exposure times with a 5×0.15 NA objective using a 1× camera coupler forplug sizes 1, 12.6, 100, and 690 mL plugs and a 0.63× camera coupler for 1500 mL plugs. Plugs 125 mL in volume were imaged with 10 ms exposure times with a 5×0.15 NA and a 0.63× camera coupler. - Plugs were analyzed by first separating them from the background by thresholding to exclude intensity below 250. The average intensity of the thresholded plugs was measured. Over time, the intensity of the plugs diverged into 2 groups, occupied plugs and unoccupied plugs. All occupied plugs had a change in intensity more than 2 fold unoccupied plugs. Detection time is defined as the time at which the fold change of the occupied plugs compared to the intensity of unoccupied plugs reaches a maximum. Fold change in intensity is defined as the change in intensity of an occupied plugs divided by the average change in intensity of unoccupied plugs (Eq. 1).
-
Fold change(t=ti)=Occupied plug(I t=ti −I t=1)/Unoccupied plugs(I t=1 −I t=1) (1) - In Eq. 1, It=ti is intensity at time point i. The intensity of the empty plugs is the average of all empty plugs in each experiment.
- Comparing Detection Times of Bacteria in Nanoliter Plugs and 96 Well Plates
- For
FIG. 1 d, 96 well plates results forFIG. 1 d were acquired in a Tecan Safire II plate reader (MTX Lab Systems, Vienna, Va.) with Ex/Em 560/630 nm, gain 25, and 40 μs integration time. 200 μL of cell culture suspended in LB with 10% alamarBlue was added to wells of a Costar 96 well assay plate with black sides and a clear, flat bottom (Corning, Corning, N.Y.). Each data point represents triplicate measurements taken at 37° C. Fold change in intensity from 96 well plate results were calculated by using Eq. 1 where the well with LB and alamarBlue only was the unoccupied plug condition. - Screening Susceptibility of Bacteria to Many Antibiotics
- For antibiotic screening experiments (
FIG. 2 ), an array of ˜50 nL antibiotic plugs was aspirated into Teflon tubing (200 μm ID) using a manual aspirator. Air spacers were included between each antibiotic plug to prevent merging of adjacent antibiotic plugs and to enable indexing of plugs in the output array. Plugs of saline solution were included as the first and last plugs in the preformed array to serve as positive controls. The Teflon tubing containing the array of antibiotic plugs was sealed into a device inlet by using wax (Hampton Research, Aliso Viejo, Calif.). To screen the susceptibility of MRSA and MSSA to each antibiotic, bacterial samples and indicator were merged with the preformed array of antibiotic. Bacterial samples were at a density of 4×105 CFU/mL in LB, and viability indicator solution was made by mixing 4 parts alamarBlue solution (AbD Serotec, Oxford, UK) with 6 parts 150 mM NaCl., The flow rate of the antibiotic array was 0.25 μL/min; the flow rate of the bacterial solution was 0.5 μL/min, and the flow rate of the viability indicator was 0.25 μL/min. The carrier fluid was FC40 (Acros Organics, Morris Plains, N.J.) with a flow rate of 1.6 μL/min. For each antibiotic plug in the preformed array, approximately 50 smaller plugs (4 mL in volume) were formed, each potentially containing a single bacterium. The resulting plugs were collected in the coil PTFE Teflon tubing (I.D.=150 μm). - After plug formation, the tubing was disconnected from the PDMS device, and the ends were sealed with wax. The Petri dish containing the tubing was filled with 20 mL of LB solution to prevent evaporation of the plugs during incubation. The plugs were immediately transferred to a microscope incubator (Pecon GmbH, Erbach, Germany). Time zero is defined as the time which the plugs entered the incubator, which was about 20 minutes after plugs were formed. Fluorescence measurements for plugs were recorded by using an inverted epi-fluorescence microscope (DMI6000, Leica, Bannockburn, Ill.) with a 10×0.3 NA objective (HCX PL Fluotar) coupled to a CCD camera ORCA ERG 1394 (12-bit, 1344×1024 resolution) (Hamamatsu Photonics) by using a 0.63× camera coupler. Images were taken of each plug using Metamorph Imaging Software (Molecular Devices, Sunnyvale, Calif.) every 30 min with exposure times of 5 ms. Plugs were analyzed by first separating them from the background by thresholding to exclude intensity below 250. The average intensity of the thresholded plugs was measured. The change in intensity at time point ti is It=ti−It=1. In the experiment described in
FIG. 2 c, fluorescence intensity of plugs was normalized by setting the intensity of the brightest plug to 100. - Determining the Minimal Inhibitory Concentration of a Drug Against a Bacterial Sample
- For MIC determination in plugs (
FIG. 3 ), a procedure similar to screening susceptibility of many antibiotics was used. The input array of antibiotics consisted of plugs of CFX at a range of concentrations. Bacterial samples were MRSA or MSSA in LB at cell densities near 106 CFU/mL. InFIGS. 3 b and c, fluorescence intensity of plugs was normalized as described forFIG. 2 c. - Statistical Analysis of Antibiotic Screening Results
- Unpaired t-tests were performed to compare antibiotic screening results to positive and negative controls. For
FIG. 2 c: VCM and LVF are statistically different than positive controls and AMP, CFX, OXA, ERT, and blank conditions were all statistically different than the negative control. ForFIG. 3 b: 8 and 24 mg/L CFX were statistically different than positive controls and 0, 0.2, 1, 2, and 4 mg/L were statistically different than the negative control. ForFIG. 3 c: 4, 8, and 24 mg/L CFX were statistically different than positive controls and 0, 0.2, 1, and 2 mg/L were statistically different than the negative control. P values are two-tailed. - Detection and Drug Screening of MRSA and MSSA in Human Blood Plasma
- For
FIG. 4 , cells were suspended in a 1:1 mixture of human blood plasma (Pooled normal plasma George King Bio-Medical, Overland Park, Kans.) and LB containing 40% alamarBlue. Plugs were formed and collected in Teflon tubing (200 μm ID). Images were taken with a 5×0.15 NA objective with a 0.63× camera coupler. Texas red pictures were taking every 10 minutes with exposure times of 25 ms. A bright-field image was taken at beginning and end of experiment. Linescans of original plug images were taken attime 0 and time 7.5 h. Adobe Photoshop was used to enhance contrast of plugs shown inFIG. 4 . - Microfluidic bacterial detection and drug screening are applicable to complex, natural matrices, including human blood plasma.
- To validate the applicability of this method to detecting bacteria in natural matrices, this method was used to detect bacteria in a sample of human blood plasma. Bacterial strains MSSA or MRSA were inoculated into pooled human blood plasma at a concentration of 3×105 CFU/mL. To test the sensitivity of the bacteria to beta-lactams, the antibiotic ampicillin (AMP) was added to the culture at the breakpoint concentration. The inoculated plasma was then combined on-chip with viability indicator as illustrated
FIG. 4 a. After 7.5 h of incubation at 37° C., plasma samples infected with MRSA were distinguishable from samples infected by MSSA by screening the samples against AMP at the breakpoint concentration. While plugs containing MRSA and AMP showed a similar increase in fluorescence intensity to plugs containing MRSA and no AMP (FIGS. 4 b and c), plugs containing MSSA and AMP showed no increase in fluorescence intensity (FIGS. 7 d and e). - Amplification examples 1-6 involve blood coagulation proteins. Amplification example 7 involves proteins in apoptosis. Amplification example 8 involves Limulus amebocyte lysate from Horseshoe crabs.
- Amplification process: The enzyme precursor is engineered prothrombin that may be cleaved by thrombin to produce more thrombin. The potential of this engineering approach is supported by a method to make an engineered factor X that may be cleaved by thrombin. (Louvain-Quintard, V. B.; Bianchini, E. P.; Calmel-Tareau, C.; Tagzirt, M.; Le Bonniec, B. F., Thrombin-activable factor X re-establishes an intrinsic amplification in tenase-deficient plasmas. Journal of Biological Chemistry 2005, 280, (50), 41352-41359.)
- Inhibitory mechanism: The inhibitor is hirudin (or other inhibitors or antibodies of thrombin such as antithrombin III, heparin, or anophelin), which binds to thrombin and prevent the cleavage of prothrombin by thrombin.
- Activating mechanism: The analyte, bacterial phosphatase, cleaves a tag attached to an inhibitor of hirudin (anti-hirudin), allowing this activated molecule to inhibit hirudin and release thrombin from hirudin. Alternatively, the bacterial phosphatase cleaves a tag attached to thrombin. In both cases, thrombin then cleaves prothrombin and produces more thrombin. The specificity of this method may be designed to match expectation by changing the specificity of the cleavage of the tag by bacterial phosphatase. If detection of an enzyme different from phosphatase is needed, a different tag is used.
- Readout process: Thrombin enzymatically cleaves a fluorogenic substrate (such as Boc-Asp(OBzl)-Pro-Arg-MCA) to give fluorescent signal.
- This method is predicted to be feasible with concentration of prothrombin from 1 nM to 1 μM, be activated with concentration of thrombin input after concentrating techniques of as low as 10 μM, give response after 1-10 minutes, and give amplification gain of 3 to 9 orders of magnitude.
- Amplification process: The enzyme precursor is factor XII that may be cleaved by factor XIIa to produce more factor XIIa in the presence of dextran sulfate or negatively charge surface in general. (Tankersley, D. L.; Finlayson, J. S., Kinetics of Activation and Autoactivation of Human Factor-Xii. Biochemistry 1984, 23, (2), 273-279.)
- Inhibitory mechanism: The inhibitor is ecotin (or other inhibitors or antibodies of factor XIIa).
- Activating mechanism: the analyte, bacterial phosphatase, cleaves a tag attached to an inhibitor of ecotin, allowing this activated molecule to inhibit ecotin and release factor XIIa from ecotin. The system may also be designed so that the analyte cleaves a tag attached to factor XIIa or kallikrein. Factor XIIa or kallikrein then cleaves factor XII and produces more factor XIIa. The specificity of this method may be designed to match expectation by changing the specificity of the cleavage of the tag by bacterial phosphatase. If detection of an enzyme different from phosphatase is needed, a different tag is used.
- Readout process: Factor XIIa enzymatically cleaves a fluorogenic substrate (such as Boc-Gln-Gly-Arg-MCA) to give fluorescent signal.
- This method is predicted to be feasible with concentration of factor XII from 0.1 μM to 10 μM, be activated with concentration of kallikrein input after concentrating techniques of as low as 1 nM, give response after 1-10 minutes, and give amplification gain of 3 to 5 orders of magnitude.
- Amplification process: The enzyme precursor is factor XI that may be cleaved by factor XIa to produce more factor XIa in the presence of dextran sulfate or negatively charge surface in general. (Gailani, D.; Broze, G. J., Factor-Xi Activation in a Revised Model of Blood-Coagulation. Science 1991, 253, (5022), 909-912; Naito, K.; Fujikawa, K., Activation of Human Blood-Coagulation Factor-Xi Independent of Factor-Xii-Factor-Xi Is Activated by Thrombin and Factor-Xia in the Presence of Negatively Charged Surfaces. Journal of Biological Chemistry 1991, 266, (12), 7353-7358.)
- Inhibitory mechanism: The inhibitor is aprotinin (or other inhibitors or antibodies of factor XIa).
- Activating mechanism: the analyte, bacterial phosphatase, cleaves a tag attached to an inhibitor of aprotinin, allowing this activated molecule to inhibit aprotinin and release factor XIa from aprotinin. The system may also be designed so that the analyte cleaves a tag attached to factor XIa. Factor XIa then cleaves factor XI and produces more factor XIa. The specificity of this method may be designed to match expectation by changing the specificity of the cleavage of the tag by bacterial phosphatase. If detection of an enzyme different from phosphatase is needed, a different tag is used.
- Readout process: Factor XIa enzymatically cleaves a fluorogenic substrate (such as Boc-Glu(OBzl)-Ala-Arg-MCA) to give fluorescent signal.
- This method is predicted to be feasible with concentration of factor XI from 0.1 μM to 10 μM, be activated with concentration of factor XIa input after concentrating techniques of as low as 1 nM, give response after 1-10 minutes, and give amplification gain of 3 to 5 orders of magnitude.
- Amplification process: Factor XII and prekallikrein are precursors of factor XIIa and kallikrein, respectively. In the presence of dextran sulfate or a negatively charged surface in general, factor XIIa cleaves both factor XII and prekallikrein to produce factor XIIa and kallikrein, respectively, while kallikrein cleaves factor XII to produce factor XIIa. (Tankersley, D. L.; Finlayson, J. S., Kinetics of Activation and Autoactivation of Human Factor-Xii. Biochemistry 1984, 23, (2), 273-279.)
- Inhibitory mechanism: Inhibitors or antibodies that are common to both factor XIIa and kallikrein (such as ecotin) or different inhibitors specific to each may be used.
- Activating mechanism: the analyte, bacterial phosphatase, cleaves a tag attached to an inhibitor of ecotin, allowing this activated molecule to inhibit ecotin and release factor XIIa and kallikrein from ecotin. The system may also be designed so that the analyte cleaves a tag attached to factor XIIa and/or kallikrein, which then activate the amplification process. The specificity of this method may be designed to match expectation by changing the specificity of the cleavage of the tag by bacterial phosphatase. If detection of an enzyme different from phosphatase is needed, a different tag is used.
- Readout process: Factor XIIa or kallikrein or both enzymatically cleave fluorogenic substrates (such as Boc-Gln-Gly-Arg-MCA for factor XIIa and Pro-Phe-Arg-MCA for kallikrein) to give fluorescent signal.
- This method is predicted to be feasible with concentration of factor XII from 0.1 μM to 10 μM and concentration of kallikrein from 10 μM to 10 nM, be activated with concentration of kallikrein input after concentrating techniques of as low as 1 nM, give response after 1-10 minutes, and give amplification gain of 3 to 5 orders of magnitude.
- Amplification process: The reaction network with positive feedback is shown in
FIG. 13 . This is an example of cases in which positive feedback loops may be achieved through multiple steps and many positive feedback loops may be coupled with each other to form a cascade. In this network, there are two positive feedback loops. The first one includes the production of factor Xa from factor X catalyzed by the input (InhA1), the production of factor VIIIa from factor VIII, the binding of factor VIIIa to factor IXa to form a complex, and the production of Xa from factor X catalyzed by the VIIIa:IXa complex. The output of this first loop is factor Xa. The second positive feedback loop includes the production of factor Va from factor V catalyzed by the input (factor Xa), the binding of factor Va to the input (factor Xa), the production of thrombin from prothrombin catalyzed by the Xa:Va complex or the input of the first loop (InhA1), and the production of factor Va from factor V catalyzed by thrombin. The output of this loop is thrombin. Thrombin is detected by the cleavage of a fluorogenic substrate to release fluorescent molecules catalyzed by thrombin. ATIII/heparin is used to inhibit factor Xa, the VIIIa:IXa complex, and thrombin. - Inhibitory mechanism: The chemical inhibitors are ATIII/heparin that may inhibit factor Xa, the VIIIa:IXa complex, and thrombin. Other common or specific inhibitors for these enzymes, of for factor VIIIa, Va, and IXa may be used as well.
- Activation mechanism: Similar to examples 1-4, the analyte, bacterial phosphatase, may cleave tagged molecules and release them. These molecules may be the activated factors shown in
FIG. 13 or inhibitors of the inhibitors of those activated factors used in the inhibitory mechanism. The specificity of this method may be designed to match expectation by changing the specificity of the cleavage of the tag by bacterial phosphatase. If detection of an enzyme different from phosphatase is needed, a different tag is used. - Readout process: Thrombin enzymatically cleaves fluorogenic substrates (such as Boc-Asp(OBzl)-Pro-Arg-MCA) to give fluorescent signal as shown in
FIG. 13 . Other single of combinations of activated factors may be used to cleave fluorogenic substrates as well. - Using the techniques described in this application, this method is predicted to be feasible with concentration of enzyme precursors from 0.1 μM to 1 μM, be activated with concentration of InhA1 input after concentrating techniques of as low as 1 nM, give response after 1-10 minutes, and give amplification gain of 3 to 6 orders of magnitude.
- This example is similar to amplification example 5, but is more complicated. Here the amplification process contains most of the components in the natural blood clotting network, as shown in a review. (Kastrup, C. J.; Runyon, M. K.; Lucchetta, E. M.; Price, J. M.; Ismagilov, R. F., Using chemistry and microfluidics to understand the spatial dynamics of complex biological networks. Accounts of Chemical Research 2008, 41, (4), 549-558.) Positive feedback loops are achieved through multiple steps. Inhibitory mechanism, activating mechanism, and readout process are also similar to amplification example 5, and can be done with single of combinations of enzymes. Additionally, blood clotting may also be visualized by eyes. (Song, H.; Li, H. W.; Munson, M. S.; Van Ha, T. G.; Ismagilov, R. F., On-chip titration of an anticoagulant argatroban and determination of the clotting time within whole blood or plasma using a plug-based microfluidic system. Analytical Chemistry 2006, 78, (14), 4839-4849.)
- Using the techniques described in this application and the reaction conditions previously described, (Kastrup, C. J.; Runyon, M. K.; Shen, F.; Ismagilov, R. F., Modular chemical mechanism predicts spatiotemporal dynamics of initiation in the complex network of hemostasis. Proceedings of the National Academy of Sciences of the United States of
America 2006, 103, (43), 15747-15752.) the predicted response is in 1-5 minutes. - Results from simulations and experiments (Kastrup, C. J.; Runyon, M. K.; Shen, F.; Ismagilov, R. F., Modular chemical mechanism predicts spatiotemporal dynamics of initiation in the complex network of hemostasis. Proceedings of the National Academy of Sciences of the United States of
America 2006, 103, (43), 15747-15752.) shown inFIGS. 14 and 15 support the ideas in amplification examples 1-6 discussed above. In general, they show a threshold-like behavior in which the time of response (time for amount of some certain substance to reach a detectable value) drastically reduces as the amount of input increases over a certain value. Although only amplification examples 1, 2, and 4 were considered inFIG. 14 , and amplification example 6 inFIG. 15 , the reaction network of amplification example 3 is similar to that of amplification example 1 and the reaction network of amplification example 5 has complexity between those of amplification examples 4 and 6. Therefore, amplification examples 3 and 5 is expected to work as well. -
FIG. 14 is the time to get response versus amount of input obtained by simulation using previously found rate constants (Tankersley, D. L.; Finlayson, J. S., Kinetics of Activation and Autoactivation of Human Factor-Xii. Biochemistry 1984, 23, (2), 273-279; Kuharsky, A. L.; Fogelson, A. L., Surface-mediated control of blood coagulation: The role of binding site densities and platelet deposition.Biophysical Journal 2001, 80, (3), 1050-1074; Ulmer, J. S.; Lindquist, R. N.; Dennis, M. S.; Lazarus, R. A., Ecotin Is a Potent Inhibitor of the Contact System Proteases Factor Xiia and Plasma Kallikrein. Febs Letters 1995, 365, (2-3), 159-163. Kawabata, S. I.; Miura, T.; Morita, T.; Kato, H.; Fujikawa, K.; Iwanaga, S.; Takada, K.; Kimura, T.; Sakakibara, S., Highly Sensitive Peptide-4-Methylcoumaryl-7-Amide Substrates for Blood-Clotting Proteases and Trypsin. European Journal of Biochemistry 1988, 172, (1), 17-25; Stone, S. R.; Hofsteenge, J., Kinetics of the Inhibition of Thrombin by Hirudin.Biochemistry 1986, 25, (16), 4622-4628.) -
FIG. 1( a) is the simulation of the amplification process used in amplification example 1, with set initial concentration of the engineered prothrombin (1.4*10−6 M), thrombin (1.4*10−10 M), and hirudin (1*10−8 M), and varied concentration of input which is thrombin. Time of response for each concentration of input was defined as the time when concentration of thrombin reaches 80% of the initial concentration of prothrombin (if this time is larger than 10000 seconds, it was set to 10000 seconds). Rate of cleavage of engineered prothrombin by thrombin was taken to be the same as the rate of cleavage of factor V by thrombin. -
FIG. 1( b) is the simulation of the amplification process used in example 2, with set initial concentration of the factor XII (1×10−6 M), factor XIIa (1×10−10 M), ecotin (1×10−7 M), and Boc-Gln-Gly-Arg-MCA (fluorogenic substrate for factor XIIa), and varied concentration of input which is kallikrein. Time of response for each particular concentration of input was defined as the time when concentration of the fluorescent molecules reaches 80% of the initial concentration of the fluorogenic substrate. If this time is larger than 10000 seconds, it was set to 10000 seconds. -
FIG. 1( c) Simulation of the amplification process used in example 4, with set initial concentration of the factor XII (1×10−6 M), factor XIIa (1×10−10 M), prekallikrein (1×10−10 M), kallikrein (1×10−14 M), ecotin (1×10−7 M), and Boc-Gln-Gly-Arg-MCA (fluorogenic substrate for factor XIIa), and varied concentration of input which is kallikrein. Time of response for each particular concentration of input was defined as the time when concentration of the fluorescent molecules reaches 80% of the initial concentration of the fluorogenic substrate. If this time is larger than 10000 seconds, it was set to 10000 seconds. -
FIG. 15 is the experimental results showing how blood clotting time varied with size of patch of tissue factor, an input for the blood clotting network discussed in example 6. (Kastrup, C. J.; Runyon, M. K.; Shen, F.; Ismagilov, R. F., Modular chemical mechanism predicts spatiotemporal dynamics of initiation in the complex network of hemostasis. Proceedings of the National Academy of Sciences of the United States ofAmerica 2006, 103, (43), 15747-15752.) The patch size in these experiments correlated with local concentration of tissue factor. - Amplification process: This reaction network with positive feedback involves proteins in apoptosis. This network includes the production of caspase-9 from procaspase-9 catalyzed by cytochrome C and Apaf1, the dimerization of caspase-9, the production of caspase-3 from procaspase-3 catalyzed by caspase-9-dimer, the production of caspase-9 from procaspase-9 by catalyzed by either caspase-9 dimer or caspase-3.
- Inhibitory mechanism: Inhibitors or antibodies for caspase-3 and/or caspase-9 are used.
- Activation mechanism: Similar to examples 1-5, the analyte, bacterial phosphatase, may cleave tagged molecules and release them. These molecules may be caspase-3 and/or caspase-9, or inhibitors of the inhibitors used in the inhibitory mechanism. The specificity of this method may be designed to match expectation by changing the specificity of the cleavage of the tag by bacterial phosphatase. If detection of an enzyme different from phosphatase is needed, a different tag is used.
- Readout process: caspase-3 and/or caspase-9 enzymatically cleave fluorogenic substrates to give fluorescent signal.
- Using the techniques described in this patent, this method is predicted to be feasible with concentrations of enzyme precursors from 0.1 μM to 10 μM, be activated with concentration of input after concentrating techniques of as low as 1 nM, give response after 1-10 minutes, and give amplification gain of 3 to 5 orders of magnitude.
- Limulus amebocyte lysate (LAL) is known to coagulate when bacterial lipopolysaccharide (LPS) is present. One mechanism is the binding of LPS to an 82-kDa protein (termed LPS-binding protein (LBP)), which normally negatively regulates coagulation. (Roth, R. I.; Tobias, P. S., Lipopolysaccharide-Binding Proteins of Limulus Amebocyte Lysate. Infection and Immunity 1993, 61, (3), 1033-1039.)
- Amplification process: The clotting network of LAL.
- Inhibitory mechanism: A small excess of LBP.
- Activating mechanism: Generally, the input may be or promote the production of some substance that binds to LBP. The input may be bacterial LPS or bacterial phosphatase that may cleave tagged (and inactive) LPS.
- Readout process: Clotting or absorbance at 405 nm may be used.
- The variations below can be applied individually or in combinations with other variations to all of amplification examples 1-8 shown above.
- Variation 1:
- Negative contrast is used instead of positive contrast.
- Amplification processes: The processes used in examples 1-8 are used here.
- Inhibitory mechanism: There is no inhibitory mechanism.
- Activating mechanism: Inhibitory mechanism used in examples 1-8 are used as input to see the contrast.
- Readout process: The processes used in examples 1-8 are used here.
- Variation 2:
- An enzyme precursor (inactive form) and an enzyme (active form) do not have to be two totally different molecules. They only need to have different reactivity.
- The inactive form may have an inactive conformation while the active form has an active conformation. A conformation change may be facilitated by binding of a small molecule to an enzyme, an enzyme to and enzyme, a small molecule to a DNA or RNA molecule, an enzyme to a DNA or RNA molecule, or binding of more than two substances.
- The inactive form may be tagged with an inhibitor, thus being self-inhibitory. When the linker to the inhibitor is cleaved, the molecule is now active. Positive feedback can be incorporated in these variations because the active enzyme can catalyze the change of conformation or the cleavage of the self-inhibiting tag of another enzyme of the same kind or of different kind.
- Variation 3:
- Detection of molecules other than enzymes may be achieved as well. To the systems in examples 1-8 without or with any single or combination of variations, one or multiple steps is added. The analyte, which may not be an enzyme, promotes the activation of an enzyme that may cleave the tag from the substrate used in activating mechanisms in examples 1-8, through one or multiple reactions. For example, activation of enzymes may be done through change of conformation (a result of binding of some molecule to an enzyme), linking two inactive components to make an active substance, or activating another enzyme that may activate the enzyme of interest.
- Variation 4:
- The techniques described above with or without any variations may be used in combinations with amplification using materials and activation mechanism involving generation of high local concentration.
- Amplification process: The reaction of the purple complex of Co(III) and 2-(5-bromo-2-pyridylazo)-5[N-n-propyl-N-(3-sulfopropyl)amino]phenol (5-Br-PAPS) and oxone has Co2+ (aq) as the autocatalyst. (Endo, M.; Abe, S.; Deguchi, Y.; Yotsuyanagi, T., Kinetic determination of trace cobalt(II) by visual autocatalytic indication. Talanta 1998, 47, (2), 349-353; Endo, M.; Ishihara, M.; Yotsuyanagi, T., Autocatalytic decomposition of cobalt complexes as an indicator system for the determination of trace amounts of cobalt and effectors. Analyst 1996, 121, (4), 391-394; Tsukada, S.; Miki, H.; Lin, J. M.; Suzuki, T.; Yamada, M., Chemiluminescence from fluorescent organic compounds induced by cobalt(II) catalyzed decomposition of peroxomonosulfate. Analytica Chimica Acta 1998, 371, (2-3), 163-170.)
- Inhibitory mechanism: A ligand that can be used to capture Co2+. As a technical detail, the Co(III).(5-Br-PAPS) complex may be separated from oxone by immobilizing them into two different layers or keeping the mixture dry.
- Activating mechanism: The input, which may be an enzyme or a small molecule, may cleave or compete for the ligand that captures Co2+ discussed in the inhibitory mechanism. Alternatively, the input may also be a reducing agent that reduces Co3+ to Co2+ rapidly but reduces oxone more slowly.
- Readout process: The Co(III).(5-Br-PAPS) complex has a purple color that is lost when the reaction gets activated because of the conversion of Co(III) into Co(II) and the oxidation of the organic ligand.
- Amplification process: The reduction of aqueous Ag(I) is catalyzed by its product, Ag(0). Other metals (such as Pd, Au, and Pt) may also be used for the autocatalytic reduction of metal cations to lower oxidation states.
- Inhibitory mechanism: The reductant may be chemically protected. For example, the reductant may be based on hydroquinone, with the hydroxyl groups protected by a group that is removed by the process of interest. The metal cation may be captured by a ligand. The autocatalyst metal may be coated with small molecules, gel or polymer.
- Activating mechanism: The input (enzyme or small molecule) may deprotect the reductant by cleaving off the protective rings. The input may also destroy or compete for the ligand. The input may also remove the coating layer on the metal particle.
- Readout process: Visual readout may be achieved via aggregates (precipitates) of metal, specific indicator for different oxidation states of the metals, or general reduction-oxidation indicator.
- Amplification process: The reduction-oxidation reaction between chlorite and iodide has iodine as the autocatalyst. (Dateo, C. E.; Orban, M.; Dekepper, P.; Epstein, I. R., Systematic Design of Chemical Oscillators 0.5. Bistability and Oscillations in the Autocatalytic Chlorite Iodide Reaction in a Stirred-Flow Reactor. Journal of the
American Chemical Society 1982, 104, (2), 504-509.) - Inhibitory mechanism: A compound may be used to consume the autocatalyst, iodine, thus slowing down the reaction effectively to the degree that no significant output is visualized after a long time.
- Activating mechanism: The input may be iodine, or produce iodine through one or multiple reactions. The input may also be a compound that inhibits the consumption of iodine, or may produce such compound after one or many steps.
- Readout process: Starch may be used to give a strongly colored blue complex with the product iodine.
- Amplification process: The reduction-oxidation reaction between thiosulfate and chlorite is autocatalytic in both hydronium ion and chloride ion, (Runyon, M. K.; Johnson-Kerner, B. L.; Ismagilov, R. F., Minimal functional model of hemostasis in a biomimetic microfluidic system. Angewandte Chemie-
International Edition 2004, 43, (12), 1531-1536. - Horvath, A. K.; Nagypal, I.; Epstein, I. R., Kinetics and mechanism of the chlorine dioxide-tetrathionate reaction. Journal of Physical Chemistry A 2003, 107, (47), 10063-10068; Horvath, A. K.; Nagypal, I.; Epstein, I. R., Oscillatory photochemical decomposition of tetrathionate ion. Journal of the American Chemical Society 2002, 124, (37), 10956-10957; Nagypal, I.; Epstein, I. R., Systematic Design of Chemical Oscillators 0.37. Fluctuations and Stirring Rate Effects in the Chlorite Thiosulfate Reaction. Journal of Physical Chemistry 1986, 90, (23), 6285-6292.) and may be activated by Ag+ which is predicted to oxidize thiosulfate and release hydronium or chloride (preliminary result).
- Inhibitory mechanism: The amount of hydronium ion may be kept in check by using a pH buffer. Chloride anion may be sequestered by a cation that is a sufficiently weak oxidizer to not react with thiosulfate. Ag+ may be sequestered by ligands. Solids that produce an acidic environment or solids that are salts of Cl− or Ag+ may be coated with materials such as gel or polymer.
- Activating mechanism: The input may be acidic or promote the production of any acid through one or multiple steps. The input may also be chloride anion or promote the production of chloride anion, or compete with the cation that captures chloride anion, or react with the cation to disable its ability to capture chloride anion. The input may also be Ag+ or produce Ag+ by compete for or inactivate the ligands for Ag+. The input may also break the coating materials of the solid particles if such inhibitory mechanism is used.
- Readout process: A pH or reduction-oxidation indicator may be used.
- Using the techniques described in this patent and the reaction conditions previously described, (Kastrup, C. J.; Runyon, M. K.; Shen, F.; Ismagilov, R. F., Modular chemical mechanism predicts spatiotemporal dynamics of initiation in the complex network of hemostasis. Proceedings of the National Academy of Sciences of the United States of
America 2006, 103, (43), 15747-15752.) one can get response in 1-2 minutes. - Amplification process: The organic reactions developed by Ichimura and coworkers (Ichimura, K., Nonlinear organic reactions to proliferate acidic and basic molecules and their applications.
Chemical Record 2002, 2, (1), 46-55.) have acids as autocatalysts. - Inhibitory mechanism: The amount of hydronium ion may be kept in check by using a pH buffer or a weak base.
- Activating mechanism: The input may be acidic or promote the production of any acid through one or multiple steps.
- Readout process: A pH or reduction-oxidation indicator is used.
- The variations below can be applied individually or in combinations with other variations to all of amplification examples 9-13 shown above
- Variation 1:
- Negative contrast is used instead of positive contrast.
- Amplification processes: The processes used in examples 1-5 described above are used.
- Inhibitory mechanism: There is no inhibitory mechanism.
- Activating mechanism: Inhibitory mechanism used in examples 1-5 described above are used as input to see the contrast.
- Readout process: The processes used in examples 1-5 described above are used here.
- Variation 2:
- The techniques described above with or without any variation may be used in combinations amplification using materials and activation mechanism involving generation of high local concentration.
- Provided the analytes are particles that can be tagged with some activating molecules through various methods (such as antibodies, His-tag/Ni/NTA, biotin/avidin etc), a method can be used to detect small concentration of the analytes in which the amplification process may be any. The activating molecule is first concentrated on particles. Then stochastic confinement is performed to concentrate these particles into plugs. The concentrated activating molecules act as input for the amplification process. Because excess activating molecules are not concentrated on particles, even after stochastic confinement, the concentration is still not high enough to activate the amplification process.
- For example, the amplification process may be chosen as the one described in example 5 of
section 1 and inFIG. 13 , the activating molecules may be chosen to be InhA1, as shown inFIG. 16 . The particular example is predicted to be able to detect particles of concentration of as low as 1fM, which may hypothetically be amplified to 1 nM after stochastic confinement. To total time of detection is predicted to be 1-10 minutes. -
FIG. 16 illustrates combining amplification cascades with stochastic confinement enables sensitive detection of single particles or more. The general idea is described in the text. The protease shown here represents an activating molecule in general. (A and B) Particles are added to a container containing the activating molecules. (C) The particles bind to the activating molecules and are stochastically confined in plugs. (D) In plugs loaded with particles, the concentration of activating molecules is above the detection threshold and produces a threshold signal, while plugs without particles do not. (E and F) In solutions with excess but sub-threshold concentrations of activating molecules, stochastic confinement of particles into plugs (G) results in a few plugs containing a particle with multiple copies of the activating molecules attached and many plugs with a few copies of activating molecules. (H) Plugs containing a particle initiate the cascade, because stochastic confinement of the particles has concentrated the activating molecules in occupied plugs, whereas plugs without a particle remain at the sub-threshold protease concentration of the bulk solution. - The analytes are particles which bind to activating molecules. The reactions may be chosen from those described in
1 and 2. For example, if the system with example 2 insections section 1 is chosen, the activating molecule is kallikrein. - Amplification process: The enzyme precursor is factor XII that may be cleaved by factor XIIa to produce more factor XIIa in the presence of dextran sulfate or negatively charge surface in general.
- Suppose a sample containing low concentration of type-B particles (such as 100 CFU/mL) has a large excess of interfering type-A particles (such as 105 CFU/mL) that can bind much less activating molecules per particle (such as 100 fold) (with a specifically designed antibody or any other means), but much more collectively. Under bulk detection mechanisms, either with amplification or by classical methods for measuring enzyme concentrations, the activity due to the excess of type-A particles will dominate the response (
FIGS. 17 A and B). When the tagged particles are stochastically confined in plugs, only those containing type-B particles will have enough activating molecules to activate the amplification process. In general, any kind of particles which can bind to any of activating molecules described in 1 and 2 through antibodies or any other method may be detected using this method. For example, this technique may be use to detect B. anthracis from a sample containing a lot of interfering bacteria such as B. circulans and other kinds.sections -
FIG. 17 illustrates selective detection of particles by using stochastic confinement. (A and B) In a bulk solution containing both a high concentration of interfering type-A particles (such as the bacteria B. circulans) (small gray particles binding few activating molecules (such as kallikrein)) and a low concentration of target type-B particles (B. anthracis) (large gray particles binding many activating molecules), the activity of the excess type-A particles dominates. Therefore, solutions with excess type-A particles (A) and excess type-B particle with a low concentration of type-A particles (B) both trigger a detection response (dark gray) (C and D). When stochastically confined in plugs, the amount of activating molecule in each plug made from solution A remains below the detectible level, while the amount of activating molecules of plugs containing type-B particles from solution B results in readout of type-B particles (dark gray plug), not from interfering type-A particles (lighter gray plugs). - This technique is a variation of example 2 in
section 2. Ag particles are coated with tags to form Ag—(X—Y)n. This coated particle cannot bind with bacteria. However, the input cleaves or produces some substance that cleaves X—Y, exposing X on the surface of the particles. These particles now can be locally concentrated using techniques shown in section 4ii. - This technique is a variation of example 4 in
section 2. This system contains AgCl particles coated with an inert shell (such as Ca3(PO4)2) and protected ethylenediaminetetraacetic acid (EDTA) ligands (in the solution or in the particle), and thiosulfate and chlorite in the solution. The input deprotects EDTA, allowing it to complex with Ca2+, dissolving the inert shell, exposing AgCl to the thiosulfate/chlorite mixture and activates the amplification process. The threshold is set up by the thickness of the inert shell. To detect different kinds of input, the method to protect and deprotect EDTA may be customized. The major reaction in this amplification process was described previously. (Runyon, M. K.; Johnson-Kerner, B. L.; Ismagilov, R. F., Minimal functional model of hemostasis in a biomimetic microfluidic system. Angewandte Chemie-International Edition 2004, 43, (12), 1531-1536; Horvath, A. K.; Nagypal, I.; Epstein, I. R., Kinetics and mechanism of the chlorine dioxide-tetrathionate reaction. Journal of Physical Chemistry A 2003, 107, (47), 10063-10068; Horvath, A. K.; Nagypal, I.; Epstein, I. R., Oscillatory photochemical decomposition of tetrathionate ion. Journal of the American Chemical Society 2002, 124, (37), 10956-10957; Nagypal, I.; Epstein, I. R., Systematic Design of Chemical Oscillators 0.37. Fluctuations and Stirring Rate Effects in the Chlorite Thiosulfate Reaction. Journal of Physical Chemistry 1986, 90, (23), 6285-6292.)
Claims (22)
1. A method of detecting bacteria in a sample, comprising:
creating an array of plugs by introducing a first plug fluid into a flow of carrier fluid in a microchannel; wherein the majority of plugs in the array do not contain a bacterium;
wherein the first plug fluid is substantially immiscible with the carrier fluid and comprises a concentration of the sample diluted such that at most 2 bacteria are present in any plug; and
analyzing the array for the presence of bacteria.
2. The method of claim 1 , wherein the array is analyzed for a detectable signal produced by the bacteria, wherein the detectable signal is a substance produced by the bacteria or is produced when the bacteria consumes a substance in the plug.
3. The method of claim 2 , wherein the substance is selected from the group consisting of oxygen, carbon, a protein produced by the bacteria, a molecule produced by a bacterial enzymatic reaction, and a redox/potential sensitive indicator.
4-5. (canceled)
6. The method of claim 1 , wherein the sample is from human, soil or marine.
7. (canceled)
8. The method of claim 1 , wherein the bacteria are at a higher concentration in the plugs than in the sample.
9. The method of claim 1 , wherein the plugs contain different species of bacteria.
10. The method of claim 1 , further comprising introducing a plug fluid comprising media capable of supporting bacterial growth into the plug.
11. The method of claim 10 , wherein the detectable signal is produced by growth of the bacteria.
12. The method of claim 1 , wherein the plugs comprise a substance capable of inducing virulence in the bacteria.
13. The method of claim 1 , wherein the at least two plug comprise a substance capable of lysing the bacteria.
14. (canceled)
15. The method of claim 1 , further comprising assaying the bacteria detected for a biological activity.
16. The method of claim 1 , further comprising identifying the bacteria.
17. The method of claim 1 , further comprising splitting a plug that has been determined to contain bacteria into multiple plugs, each containing at least one of the bacteria.
18. The method of claim 1 , further comprising conducting a polymerase chain reaction on the contents of the at least two plugs prior to analyzing the at least two plugs for the detectable signal.
19. A method of detecting bacteria comprising:
flowing at least two plugs in a carrier fluid through a microchannel;
wherein each plug comprises a plug fluid substantially immiscible with the carrier fluid;
wherein a first plug comprises a means for detecting a first species of bacteria;
wherein a second plug comprises a means for detecting a second species of bacteria different from the first species of bacteria;
introducing a sample optionally comprising bacteria into the first and second plugs, wherein the bacteria produce a detectable signal; and
analyzing the plugs for the detectable signal.
20-28. (canceled)
29. A method of screening for antibiotic activity comprising:
flowing at least two plugs in a carrier fluid through a microchannel;
wherein each plug comprises a plug fluid immiscible with the carrier fluid and media capable of supporting bacterial growth;
wherein the first plug comprises a first antibiotic candidate;
wherein the second plug comprises a second antibiotic candidate;
introducing a sample which comprises bacteria into the first and second plugs; and
detecting the presence of bacterial growth.
30-44. (canceled)
45. A method of detecting bacteria in an aqueous sample, comprising:
dividing a sample into a plurality of subsamples in a microfluidic device,
where each subsample is separated from another by a fluorinated liquid, each subsample has a volume that is a nanoliter or less, the majority of the subsamples do not contain a bacterium, and each subsample has at most 2 bacteria; and
analyzing the volumes for the presence of bacteria.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/670,739 US20100227767A1 (en) | 2007-07-26 | 2008-07-28 | Stochastic confinement to detect, manipulate, and utilize molecules and organisms |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96242607P | 2007-07-26 | 2007-07-26 | |
| US5249008P | 2008-05-12 | 2008-05-12 | |
| US12/670,739 US20100227767A1 (en) | 2007-07-26 | 2008-07-28 | Stochastic confinement to detect, manipulate, and utilize molecules and organisms |
| PCT/US2008/071374 WO2009048673A2 (en) | 2007-07-26 | 2008-07-28 | Stochastic confinement to detect, manipulate, and utilize molecules and organisms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20100227767A1 true US20100227767A1 (en) | 2010-09-09 |
Family
ID=39882696
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/670,739 Abandoned US20100227767A1 (en) | 2007-07-26 | 2008-07-28 | Stochastic confinement to detect, manipulate, and utilize molecules and organisms |
| US12/670,725 Active 2031-03-17 US9090885B2 (en) | 2007-07-26 | 2008-07-28 | Co-incubating confined microbial communities |
| US14/746,494 Active US10202571B2 (en) | 2007-07-26 | 2015-06-22 | Co-incubating confined microbial communities |
| US16/236,248 Active 2030-05-23 US11661577B2 (en) | 2007-07-26 | 2018-12-28 | Co-incubating confined microbial communities |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US12/670,725 Active 2031-03-17 US9090885B2 (en) | 2007-07-26 | 2008-07-28 | Co-incubating confined microbial communities |
| US14/746,494 Active US10202571B2 (en) | 2007-07-26 | 2015-06-22 | Co-incubating confined microbial communities |
| US16/236,248 Active 2030-05-23 US11661577B2 (en) | 2007-07-26 | 2018-12-28 | Co-incubating confined microbial communities |
Country Status (2)
| Country | Link |
|---|---|
| US (4) | US20100227767A1 (en) |
| WO (2) | WO2009048673A2 (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110165037A1 (en) * | 2010-01-07 | 2011-07-07 | Ismagilov Rustem F | Interfaces that eliminate non-specific adsorption, and introduce specific interactions |
| US20130095511A1 (en) * | 2010-06-11 | 2013-04-18 | Markus Kostrzewa | Mass spectrometric measurement of b-lactamase resistances |
| US9222115B2 (en) | 2011-12-30 | 2015-12-29 | Abbott Molecular, Inc. | Channels with cross-sectional thermal gradients |
| US20170080426A1 (en) * | 2014-05-14 | 2017-03-23 | University Of Limerick | Device and method for testing compounds on living cells |
| WO2017130059A1 (en) | 2016-01-25 | 2017-08-03 | Bio-Rad Innovations | Digital microbiology |
| US9851345B1 (en) | 2016-10-12 | 2017-12-26 | Viasphere, Llc | Compositions and methods for disease diagnosis using single cell analysis |
| US20190010356A1 (en) * | 2017-07-10 | 2019-01-10 | Sinmat, Inc. | Hard abrasive particle-free polishing of hard materials |
| US10953404B1 (en) | 2020-04-24 | 2021-03-23 | Pattern Bioscience, Inc. | Apparatuses for contactless loading and imaging of microfluidic chips and related methods |
| US11268135B2 (en) | 2016-05-10 | 2022-03-08 | Pattern Bioscience, Inc. | Compositions and methods for identifying, quantifying, and/or characterizing an analyte |
| US11305284B2 (en) | 2018-11-26 | 2022-04-19 | Tokitae, LLC | Determining a bulk concentration of a target in a sample using a digital assay with compartments having nonuniform volumes |
| US11344890B2 (en) | 2018-10-22 | 2022-05-31 | Pattern Bioscience, Inc. | Vacuum-loaded, droplet-generating microfluidic chips and related methods |
| US11465148B2 (en) | 2018-04-16 | 2022-10-11 | Pattern Bioscience, Inc. | Methods and apparatus for forming 2-dimensional drop arrays |
| WO2022235284A1 (en) * | 2021-05-05 | 2022-11-10 | The University Of Chicago | Rapid enumeration of microorganisms |
| CN116948816A (en) * | 2023-06-06 | 2023-10-27 | 仲恺农业工程学院 | A superoxide dismutase resistance detection device and method |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100227767A1 (en) | 2007-07-26 | 2010-09-09 | Boedicker James Q | Stochastic confinement to detect, manipulate, and utilize molecules and organisms |
| ES2639183T3 (en) | 2007-09-19 | 2017-10-25 | The Charles Stark Draper Laboratory, Inc. | Microfluidic structures with circular cross section |
| US8622987B2 (en) | 2008-06-04 | 2014-01-07 | The University Of Chicago | Chemistrode, a plug-based microfluidic device and method for stimulation and sampling with high temporal, spatial, and chemical resolution |
| US8710836B2 (en) | 2008-12-10 | 2014-04-29 | Nanomr, Inc. | NMR, instrumentation, and flow meter/controller continuously detecting MR signals, from continuously flowing sample material |
| US9464319B2 (en) | 2009-03-24 | 2016-10-11 | California Institute Of Technology | Multivolume devices, kits and related methods for quantification of nucleic acids and other analytes |
| US10196700B2 (en) | 2009-03-24 | 2019-02-05 | University Of Chicago | Multivolume devices, kits and related methods for quantification and detection of nucleic acids and other analytes |
| US9447461B2 (en) | 2009-03-24 | 2016-09-20 | California Institute Of Technology | Analysis devices, kits, and related methods for digital quantification of nucleic acids and other analytes |
| CN104722342B (en) | 2009-03-24 | 2017-01-11 | 芝加哥大学 | Slip chip device and method |
| US20110082563A1 (en) * | 2009-10-05 | 2011-04-07 | The Charles Stark Draper Laboratory, Inc. | Microscale multiple-fluid-stream bioreactor for cell culture |
| US9476812B2 (en) | 2010-04-21 | 2016-10-25 | Dna Electronics, Inc. | Methods for isolating a target analyte from a heterogeneous sample |
| US9428547B2 (en) | 2010-04-21 | 2016-08-30 | Dna Electronics, Inc. | Compositions for isolating a target analyte from a heterogeneous sample |
| US8841104B2 (en) | 2010-04-21 | 2014-09-23 | Nanomr, Inc. | Methods for isolating a target analyte from a heterogeneous sample |
| US20110262989A1 (en) * | 2010-04-21 | 2011-10-27 | Nanomr, Inc. | Isolating a target analyte from a body fluid |
| US20110287407A1 (en) * | 2010-04-27 | 2011-11-24 | Diomics Corporation | Integrated methods and systems for processing a molecular profile |
| DK2668284T3 (en) * | 2011-01-28 | 2014-12-15 | Amyris Inc | Screening of colony micro encapsulated in gel |
| CN104428651B (en) | 2012-04-20 | 2019-01-11 | 达丽斯生物医学公司 | Fluidic devices and systems for sample preparation or autonomous analysis |
| WO2013159116A1 (en) | 2012-04-20 | 2013-10-24 | University Of Chicago | Fluidic devices for biospecimen preservation |
| US9803237B2 (en) | 2012-04-24 | 2017-10-31 | California Institute Of Technology | Slip-induced compartmentalization |
| JP2015525078A (en) * | 2012-06-15 | 2015-09-03 | マイクロヴァイ・バイオテック・インコーポレイテッド | Bioconversion process and equipment |
| US9804069B2 (en) | 2012-12-19 | 2017-10-31 | Dnae Group Holdings Limited | Methods for degrading nucleic acid |
| US10000557B2 (en) | 2012-12-19 | 2018-06-19 | Dnae Group Holdings Limited | Methods for raising antibodies |
| US9434940B2 (en) | 2012-12-19 | 2016-09-06 | Dna Electronics, Inc. | Methods for universal target capture |
| US9995742B2 (en) | 2012-12-19 | 2018-06-12 | Dnae Group Holdings Limited | Sample entry |
| US9551704B2 (en) | 2012-12-19 | 2017-01-24 | Dna Electronics, Inc. | Target detection |
| US9599610B2 (en) | 2012-12-19 | 2017-03-21 | Dnae Group Holdings Limited | Target capture system |
| FR3008421B1 (en) * | 2013-07-10 | 2015-12-25 | J Soufflet Ets | NOVEL PROCESS FOR THE CULTURE OF MICROORGANISMS BY CONTAINMENT IN MICRO-BIOREACTORS |
| WO2015009967A1 (en) | 2013-07-19 | 2015-01-22 | California Institute Of Technology | Digital assay for quantifying and concentrating analytes |
| WO2015013177A2 (en) * | 2013-07-25 | 2015-01-29 | Siemens Healthcare Diagnostics Inc. | Rapid detection of carbapenemase and beta-lactamase producing bacteria |
| AU2014318731A1 (en) * | 2013-09-11 | 2016-03-17 | Agenus Inc. | High throughput screening for biomolecules |
| WO2016057654A1 (en) * | 2014-10-07 | 2016-04-14 | Stc.Unm | Engineered stable microorganism/cell communities |
| DE102015106870B3 (en) * | 2014-11-10 | 2016-02-25 | Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie e. V. Hans-Knöll-Institut | System for incubation of microfluidic drops and method for providing homogeneous incubation conditions in a drop incubation unit |
| US20190241853A1 (en) | 2016-07-12 | 2019-08-08 | Micro Green Technologies Ltd. | Compositions comprising microalgae and methods of producing and using same |
| US11313000B2 (en) * | 2016-08-04 | 2022-04-26 | Duke University | Compositions and methods for measuring bacterial growth |
| CN106845128B (en) * | 2017-02-10 | 2023-05-30 | 长安大学 | Microalgae flotation efficiency prediction device and method based on microalgae surface characteristics |
| US11448645B2 (en) | 2017-03-03 | 2022-09-20 | Biomillenia Sas | Microparticle for cultivating and testing cells |
| CN119708265A (en) * | 2017-08-31 | 2025-03-28 | 辛格隆股份公司 | Methods and compositions for preparing bacteriocins and antimicrobial peptides |
| WO2019164734A2 (en) * | 2018-02-26 | 2019-08-29 | The Regents Of The University Of California | Method for detection and separation of enantiomers using vesicle-like nanostructures self-assembled from janus nanoparticles |
| EP3608395A1 (en) * | 2018-08-10 | 2020-02-12 | European Molecular Biology Laboratory | Directed evolution of a mutualistic community of organisms for the production of a nutrient or a nutraceutical |
| SG11202103556VA (en) | 2018-10-12 | 2021-05-28 | Univ Washington | System and method for removing uremic toxins from a patient's body |
| SG10201903862RA (en) * | 2019-04-29 | 2020-11-27 | Massachusetts Inst Technology | A device for seeding of dispersal cells |
| EP4041310A4 (en) | 2019-10-10 | 2024-05-15 | 1859, Inc. | Methods and systems for microfluidic screening |
| WO2021076508A1 (en) * | 2019-10-14 | 2021-04-22 | University Of Washington | Hydrogels for the entrapment of bacteria |
| KR20230056738A (en) | 2020-10-13 | 2023-04-27 | 바이오-라드 유럽 게엠베하 | Systems and methods for target detection applied in characterizing food quality and improving food safety |
| US11547995B2 (en) | 2020-10-19 | 2023-01-10 | Bio-Rad Laboratories, Inc. | System and method for rapid multiplexed sample processing with applications for nucleic acid amplification assays |
| WO2023047404A1 (en) * | 2021-09-27 | 2023-03-30 | Mybiotics Pharma Ltd. | Microbial compositions, methods of preparing same and use thereof |
| IL286748A (en) * | 2021-09-27 | 2023-04-01 | Mybiotics Pharma Ltd | Microbial compositions and methods of preparing same |
| US20250115528A1 (en) * | 2022-01-07 | 2025-04-10 | University Of Washington | Microbial-Embedded Hydrogel Beads and Methods of Use |
| WO2023183931A2 (en) * | 2022-03-24 | 2023-09-28 | Board Of Trustees Of Michigan State University | Hydrogen bioreactor |
Citations (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4853336A (en) * | 1982-11-15 | 1989-08-01 | Technicon Instruments Corporation | Single channel continuous flow system |
| US4963498A (en) * | 1985-08-05 | 1990-10-16 | Biotrack | Capillary flow device |
| US5185099A (en) * | 1988-04-20 | 1993-02-09 | Institut National De Recherche Chimique Appliquee | Visco-elastic, isotropic materials based on water, fluorinate sufactants and fluorinated oils, process for their preparation, and their use in various fields, such as optics, pharmacology and electrodynamics |
| US5725853A (en) * | 1994-10-18 | 1998-03-10 | Pioneer Hi-Bred International, Inc. | 4 strain direct-fed microbial |
| US5739036A (en) * | 1996-04-15 | 1998-04-14 | Dade International Inc. | Method for analysis |
| US5872010A (en) * | 1995-07-21 | 1999-02-16 | Northeastern University | Microscale fluid handling system |
| US5997636A (en) * | 1998-05-01 | 1999-12-07 | Instrumentation Technology Associates, Inc. | Method and apparatus for growing crystals |
| US6130098A (en) * | 1995-09-15 | 2000-10-10 | The Regents Of The University Of Michigan | Moving microdroplets |
| US6140053A (en) * | 1996-11-06 | 2000-10-31 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
| US6180372B1 (en) * | 1997-04-23 | 2001-01-30 | Bruker Daltonik Gmbh | Method and devices for extremely fast DNA replication by polymerase chain reactions (PCR) |
| US20010036669A1 (en) * | 2000-02-23 | 2001-11-01 | Paul Jedrzejewski | Microfluidic devices and methods |
| US20010048900A1 (en) * | 2000-05-24 | 2001-12-06 | Bardell Ronald L. | Jet vortex mixer |
| US20020008029A1 (en) * | 2000-02-11 | 2002-01-24 | Williams Stephen J. | Microfluidic device with sample injector and method |
| US20020012971A1 (en) * | 2000-03-20 | 2002-01-31 | Mehta Tammy Burd | PCR compatible nucleic acid sieving medium |
| US20020017464A1 (en) * | 1996-06-28 | 2002-02-14 | Parce J. Wallace | Electropipettor and compensation means for electrophoretic bias |
| US20020022261A1 (en) * | 1995-06-29 | 2002-02-21 | Anderson Rolfe C. | Miniaturized genetic analysis systems and methods |
| US20020058332A1 (en) * | 2000-09-15 | 2002-05-16 | California Institute Of Technology | Microfabricated crossflow devices and methods |
| US6409832B2 (en) * | 2000-03-31 | 2002-06-25 | Micronics, Inc. | Protein crystallization in microfluidic structures |
| US6432290B1 (en) * | 1999-11-26 | 2002-08-13 | The Governors Of The University Of Alberta | Apparatus and method for trapping bead based reagents within microfluidic analysis systems |
| US6451610B1 (en) * | 1999-04-14 | 2002-09-17 | International Technidyne Corporation | Method and apparatus for coagulation based assays |
| US20020160518A1 (en) * | 2001-04-03 | 2002-10-31 | Hayenga Jon W. | Microfluidic sedimentation |
| US6524456B1 (en) * | 1999-08-12 | 2003-02-25 | Ut-Battelle, Llc | Microfluidic devices for the controlled manipulation of small volumes |
| US20030064414A1 (en) * | 2001-03-30 | 2003-04-03 | Benecky Michael J. | Rapid assessment of coagulation activity in whole blood |
| US6544568B2 (en) * | 1998-12-15 | 2003-04-08 | Vsl Pharmaceuticals Inc. | Symbiotic functional food containing lactic acid bacteria |
| US20030075446A1 (en) * | 2001-10-19 | 2003-04-24 | Culbertson Christopher T. | Microfluidic systems and methods of transport and lysis of cells and analysis of cell lysate |
| US20030089605A1 (en) * | 2001-10-19 | 2003-05-15 | West Virginia University Research Corporation | Microfluidic system for proteome analysis |
| US6569631B1 (en) * | 1998-11-12 | 2003-05-27 | 3-Dimensional Pharmaceuticals, Inc. | Microplate thermal shift assay for ligand development using 5-(4″dimethylaminophenyl)-2-(4′-phenyl)oxazole derivative fluorescent dyes |
| US20030229376A1 (en) * | 1999-06-01 | 2003-12-11 | Biointeractions Ltd. | Coated surfaces for immobilizing negatively charged anticoagulating agents from blood fluid |
| US20040005582A1 (en) * | 2000-08-10 | 2004-01-08 | Nanobiodynamics, Incorporated | Biospecific desorption microflow systems and methods for studying biospecific interactions and their modulators |
| US20040037813A1 (en) * | 1999-02-25 | 2004-02-26 | Simpson David G. | Electroprocessed collagen and tissue engineering |
| US20040072357A1 (en) * | 2000-12-19 | 2004-04-15 | Matthias Stiene | Device for measuring blood coagulation and method thereof |
| US20040181131A1 (en) * | 2003-02-25 | 2004-09-16 | Maynard John D. | Determination of pH including hemoglobin correction |
| US20040224419A1 (en) * | 2003-05-06 | 2004-11-11 | Thrombodyne, Inc. | Systems and methods for measuring fluid properties |
| US20050084923A1 (en) * | 2001-09-14 | 2005-04-21 | Peter-Juergen Mueller | Methods for cultivating and analyzing microbial individual cell cultures |
| US20060051329A1 (en) * | 2004-08-27 | 2006-03-09 | The Regents Of The University Of California | Microfluidic device for the encapsulation of cells with low and high cell densities |
| US20060078888A1 (en) * | 2004-10-08 | 2006-04-13 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
| US20060094119A1 (en) * | 2004-10-29 | 2006-05-04 | Ismagilov Rustem F | Microfluidic system |
| US20060163385A1 (en) * | 2003-04-10 | 2006-07-27 | Link Darren R | Formation and control of fluidic species |
| US7129091B2 (en) * | 2002-05-09 | 2006-10-31 | University Of Chicago | Device and method for pressure-driven plug transport and reaction |
| US20070026439A1 (en) * | 2005-07-15 | 2007-02-01 | Applera Corporation | Fluid processing device and method |
| US20080003142A1 (en) * | 2006-05-11 | 2008-01-03 | Link Darren R | Microfluidic devices |
| US20080124726A1 (en) * | 2006-05-26 | 2008-05-29 | Althea Technologies, Inc. | Biochemical analysis of partitioned cells |
| US20090021728A1 (en) * | 2007-06-21 | 2009-01-22 | Gen-Probe Incorporated | Multi-Channel Optical Measurement Instrument |
| US20090060797A1 (en) * | 2002-12-30 | 2009-03-05 | The Regents Of The University Of California | Fluid control structures in microfluidic devices |
| US20100022414A1 (en) * | 2008-07-18 | 2010-01-28 | Raindance Technologies, Inc. | Droplet Libraries |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US610053A (en) * | 1898-08-30 | Alfred hodge | ||
| GB2097692B (en) | 1981-01-10 | 1985-05-22 | Shaw Stewart P D | Combining chemical reagents |
| US5994056A (en) | 1991-05-02 | 1999-11-30 | Roche Molecular Systems, Inc. | Homogeneous methods for nucleic acid amplification and detection |
| WO1996019585A1 (en) | 1994-12-20 | 1996-06-27 | Heidelberg Repatriation Hospital | Typing of microorganisms |
| WO1997029508A2 (en) | 1996-02-08 | 1997-08-14 | Perseptive Biosystems, Inc. | Interface between liquid flow and mass spectrometer |
| US5800690A (en) | 1996-07-03 | 1998-09-01 | Caliper Technologies Corporation | Variable control of electroosmotic and/or electrophoretic forces within a fluid-containing structure via electrical forces |
| ATE206633T1 (en) | 1996-07-15 | 2001-10-15 | Calcitech Ltd | PRODUCTION OF POWDER |
| JP2002503336A (en) | 1997-05-16 | 2002-01-29 | アルバータ リサーチ カウンシル | Micro-distribution system and method of using the same |
| US20050070005A1 (en) | 1997-06-16 | 2005-03-31 | Martin Keller | High throughput or capillary-based screening for a bioactivity or biomolecule |
| EP1111044A4 (en) | 1998-09-08 | 2003-06-04 | Takara Shuzo Co | DNA SYNTHESIS PROCESS |
| US6149787A (en) | 1998-10-14 | 2000-11-21 | Caliper Technologies Corp. | External material accession systems and methods |
| DE10027113A1 (en) | 1999-12-23 | 2001-09-27 | Andreas Hoeft | Method for determining microbial DNA / RNA, kit therefor and use of the method |
| EP1275005A1 (en) | 2000-04-06 | 2003-01-15 | Caliper Technologies Corporation | Methods and devices for achieving long incubation times in high-throughput systems |
| DE60121604T2 (en) | 2000-08-04 | 2007-06-21 | Caliper Life Sciences, Inc., Mountain View | CONTROL OF OPERATING CONDITIONS IN FLUIDIC SYSTEMS |
| WO2002025243A1 (en) | 2000-09-21 | 2002-03-28 | Dna Sciences, Inc. | Sample injector system and method |
| WO2002029101A2 (en) | 2000-09-30 | 2002-04-11 | Kairos Scientific Inc. | Methods for cloning, sequencing and expressing genes from complex microbial populations |
| SE0004297D0 (en) | 2000-11-23 | 2000-11-23 | Gyros Ab | Device for thermal cycling |
| US20020173033A1 (en) * | 2001-05-17 | 2002-11-21 | Kyle Hammerick | Device and method or three-dimensional spatial localization and functional interconnection of different types of cells |
| US7011957B2 (en) * | 2001-09-26 | 2006-03-14 | Northeastern University | Isolation and cultivation of microorganisms from natural environments and drug discovery based thereon |
| US7691333B2 (en) | 2001-11-30 | 2010-04-06 | Fluidigm Corporation | Microfluidic device and methods of using same |
| AU2002360499A1 (en) * | 2001-12-05 | 2003-06-17 | University Of Washington | Microfluidic device and surface decoration process for solid phase affinity binding assays |
| US7901939B2 (en) | 2002-05-09 | 2011-03-08 | University Of Chicago | Method for performing crystallization and reactions in pressure-driven fluid plugs |
| TW200519384A (en) | 2003-12-12 | 2005-06-16 | We Gene Technologies Inc | Sepsis detection chip and fabricating method thereof and method of detecting sepsis |
| WO2005056826A1 (en) | 2003-12-12 | 2005-06-23 | The University Of British Columbia | Transcription-patterned biological activity screening system |
| WO2005086784A2 (en) * | 2004-03-05 | 2005-09-22 | The Research Foundation Of State University Of New York | Method and apparatus for measuring changes in cell volume |
| US9477233B2 (en) | 2004-07-02 | 2016-10-25 | The University Of Chicago | Microfluidic system with a plurality of sequential T-junctions for performing reactions in microdroplets |
| EP1891201A4 (en) * | 2005-05-18 | 2011-11-09 | Cornell Res Foundation Inc | PHARMACOKINETIC CULTURE SYSTEM HAVING BIOLOGICAL BARRIERS |
| WO2007056561A2 (en) | 2005-11-09 | 2007-05-18 | Liquidia Technologies, Inc. | Medical device, materials, and methods |
| US20100227767A1 (en) | 2007-07-26 | 2010-09-09 | Boedicker James Q | Stochastic confinement to detect, manipulate, and utilize molecules and organisms |
-
2008
- 2008-07-28 US US12/670,739 patent/US20100227767A1/en not_active Abandoned
- 2008-07-28 WO PCT/US2008/071374 patent/WO2009048673A2/en active Application Filing
- 2008-07-28 WO PCT/US2008/071370 patent/WO2009015390A2/en active Application Filing
- 2008-07-28 US US12/670,725 patent/US9090885B2/en active Active
-
2015
- 2015-06-22 US US14/746,494 patent/US10202571B2/en active Active
-
2018
- 2018-12-28 US US16/236,248 patent/US11661577B2/en active Active
Patent Citations (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4853336A (en) * | 1982-11-15 | 1989-08-01 | Technicon Instruments Corporation | Single channel continuous flow system |
| US4963498A (en) * | 1985-08-05 | 1990-10-16 | Biotrack | Capillary flow device |
| US5185099A (en) * | 1988-04-20 | 1993-02-09 | Institut National De Recherche Chimique Appliquee | Visco-elastic, isotropic materials based on water, fluorinate sufactants and fluorinated oils, process for their preparation, and their use in various fields, such as optics, pharmacology and electrodynamics |
| US5725853A (en) * | 1994-10-18 | 1998-03-10 | Pioneer Hi-Bred International, Inc. | 4 strain direct-fed microbial |
| US20020022261A1 (en) * | 1995-06-29 | 2002-02-21 | Anderson Rolfe C. | Miniaturized genetic analysis systems and methods |
| US5872010A (en) * | 1995-07-21 | 1999-02-16 | Northeastern University | Microscale fluid handling system |
| US6130098A (en) * | 1995-09-15 | 2000-10-10 | The Regents Of The University Of Michigan | Moving microdroplets |
| US5739036A (en) * | 1996-04-15 | 1998-04-14 | Dade International Inc. | Method for analysis |
| US20020017464A1 (en) * | 1996-06-28 | 2002-02-14 | Parce J. Wallace | Electropipettor and compensation means for electrophoretic bias |
| US6140053A (en) * | 1996-11-06 | 2000-10-31 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
| US6180372B1 (en) * | 1997-04-23 | 2001-01-30 | Bruker Daltonik Gmbh | Method and devices for extremely fast DNA replication by polymerase chain reactions (PCR) |
| US5997636A (en) * | 1998-05-01 | 1999-12-07 | Instrumentation Technology Associates, Inc. | Method and apparatus for growing crystals |
| US6569631B1 (en) * | 1998-11-12 | 2003-05-27 | 3-Dimensional Pharmaceuticals, Inc. | Microplate thermal shift assay for ligand development using 5-(4″dimethylaminophenyl)-2-(4′-phenyl)oxazole derivative fluorescent dyes |
| US6544568B2 (en) * | 1998-12-15 | 2003-04-08 | Vsl Pharmaceuticals Inc. | Symbiotic functional food containing lactic acid bacteria |
| US20040037813A1 (en) * | 1999-02-25 | 2004-02-26 | Simpson David G. | Electroprocessed collagen and tissue engineering |
| US6451610B1 (en) * | 1999-04-14 | 2002-09-17 | International Technidyne Corporation | Method and apparatus for coagulation based assays |
| US20030229376A1 (en) * | 1999-06-01 | 2003-12-11 | Biointeractions Ltd. | Coated surfaces for immobilizing negatively charged anticoagulating agents from blood fluid |
| US6524456B1 (en) * | 1999-08-12 | 2003-02-25 | Ut-Battelle, Llc | Microfluidic devices for the controlled manipulation of small volumes |
| US6432290B1 (en) * | 1999-11-26 | 2002-08-13 | The Governors Of The University Of Alberta | Apparatus and method for trapping bead based reagents within microfluidic analysis systems |
| US20020008029A1 (en) * | 2000-02-11 | 2002-01-24 | Williams Stephen J. | Microfluidic device with sample injector and method |
| US20010036669A1 (en) * | 2000-02-23 | 2001-11-01 | Paul Jedrzejewski | Microfluidic devices and methods |
| US20020012971A1 (en) * | 2000-03-20 | 2002-01-31 | Mehta Tammy Burd | PCR compatible nucleic acid sieving medium |
| US6409832B2 (en) * | 2000-03-31 | 2002-06-25 | Micronics, Inc. | Protein crystallization in microfluidic structures |
| US20010048900A1 (en) * | 2000-05-24 | 2001-12-06 | Bardell Ronald L. | Jet vortex mixer |
| US20040005582A1 (en) * | 2000-08-10 | 2004-01-08 | Nanobiodynamics, Incorporated | Biospecific desorption microflow systems and methods for studying biospecific interactions and their modulators |
| US7294503B2 (en) * | 2000-09-15 | 2007-11-13 | California Institute Of Technology | Microfabricated crossflow devices and methods |
| US20020058332A1 (en) * | 2000-09-15 | 2002-05-16 | California Institute Of Technology | Microfabricated crossflow devices and methods |
| US20040072357A1 (en) * | 2000-12-19 | 2004-04-15 | Matthias Stiene | Device for measuring blood coagulation and method thereof |
| US20030064414A1 (en) * | 2001-03-30 | 2003-04-03 | Benecky Michael J. | Rapid assessment of coagulation activity in whole blood |
| US20020160518A1 (en) * | 2001-04-03 | 2002-10-31 | Hayenga Jon W. | Microfluidic sedimentation |
| US20050084923A1 (en) * | 2001-09-14 | 2005-04-21 | Peter-Juergen Mueller | Methods for cultivating and analyzing microbial individual cell cultures |
| US20030089605A1 (en) * | 2001-10-19 | 2003-05-15 | West Virginia University Research Corporation | Microfluidic system for proteome analysis |
| US20030075446A1 (en) * | 2001-10-19 | 2003-04-24 | Culbertson Christopher T. | Microfluidic systems and methods of transport and lysis of cells and analysis of cell lysate |
| US7129091B2 (en) * | 2002-05-09 | 2006-10-31 | University Of Chicago | Device and method for pressure-driven plug transport and reaction |
| US20090060797A1 (en) * | 2002-12-30 | 2009-03-05 | The Regents Of The University Of California | Fluid control structures in microfluidic devices |
| US20040181131A1 (en) * | 2003-02-25 | 2004-09-16 | Maynard John D. | Determination of pH including hemoglobin correction |
| US20060163385A1 (en) * | 2003-04-10 | 2006-07-27 | Link Darren R | Formation and control of fluidic species |
| US20040224419A1 (en) * | 2003-05-06 | 2004-11-11 | Thrombodyne, Inc. | Systems and methods for measuring fluid properties |
| US20060051329A1 (en) * | 2004-08-27 | 2006-03-09 | The Regents Of The University Of California | Microfluidic device for the encapsulation of cells with low and high cell densities |
| US20060078888A1 (en) * | 2004-10-08 | 2006-04-13 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
| US20060094119A1 (en) * | 2004-10-29 | 2006-05-04 | Ismagilov Rustem F | Microfluidic system |
| US20070026439A1 (en) * | 2005-07-15 | 2007-02-01 | Applera Corporation | Fluid processing device and method |
| US20080003142A1 (en) * | 2006-05-11 | 2008-01-03 | Link Darren R | Microfluidic devices |
| US20080014589A1 (en) * | 2006-05-11 | 2008-01-17 | Link Darren R | Microfluidic devices and methods of use thereof |
| US20080124726A1 (en) * | 2006-05-26 | 2008-05-29 | Althea Technologies, Inc. | Biochemical analysis of partitioned cells |
| US20090021728A1 (en) * | 2007-06-21 | 2009-01-22 | Gen-Probe Incorporated | Multi-Channel Optical Measurement Instrument |
| US20100022414A1 (en) * | 2008-07-18 | 2010-01-28 | Raindance Technologies, Inc. | Droplet Libraries |
Non-Patent Citations (1)
| Title |
|---|
| Huebner A. Quantitative Detection of Protein Expression... Chemical Communications Vol. 12, pages 1218-1220, 28 March 2007. * |
Cited By (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110165037A1 (en) * | 2010-01-07 | 2011-07-07 | Ismagilov Rustem F | Interfaces that eliminate non-specific adsorption, and introduce specific interactions |
| US12435352B2 (en) * | 2010-06-11 | 2025-10-07 | Bruker Daltonics GmbH & Co. KG | Mass spectrometric measurement of β-lactamase resistances |
| US20130095511A1 (en) * | 2010-06-11 | 2013-04-18 | Markus Kostrzewa | Mass spectrometric measurement of b-lactamase resistances |
| US9222115B2 (en) | 2011-12-30 | 2015-12-29 | Abbott Molecular, Inc. | Channels with cross-sectional thermal gradients |
| US10052632B2 (en) | 2011-12-30 | 2018-08-21 | Abbott Molecular Inc. | Channels with cross-sectional thermal gradients |
| US20170080426A1 (en) * | 2014-05-14 | 2017-03-23 | University Of Limerick | Device and method for testing compounds on living cells |
| WO2017130059A1 (en) | 2016-01-25 | 2017-08-03 | Bio-Rad Innovations | Digital microbiology |
| US11952610B2 (en) | 2016-01-25 | 2024-04-09 | Bio-Rad Europe Gmbh | Digital microbiology |
| EP3408403A1 (en) * | 2016-01-25 | 2018-12-05 | Bio-Rad Europe GmbH | Digital microbiology |
| US11268124B2 (en) | 2016-01-25 | 2022-03-08 | Bio-Rad Europe Gmbh | Digital microbiology |
| US11268135B2 (en) | 2016-05-10 | 2022-03-08 | Pattern Bioscience, Inc. | Compositions and methods for identifying, quantifying, and/or characterizing an analyte |
| US10401349B2 (en) | 2016-10-12 | 2019-09-03 | Klaris Corporation | Compositions and methods for disease diagnosis using single cell analysis |
| US10488404B2 (en) | 2016-10-12 | 2019-11-26 | Klaris Corporation | Compositions and methods for disease diagnosis using single cell analysis |
| US9851345B1 (en) | 2016-10-12 | 2017-12-26 | Viasphere, Llc | Compositions and methods for disease diagnosis using single cell analysis |
| US10488406B2 (en) | 2016-10-12 | 2019-11-26 | Klaris Corporation | Compositions and methods for disease diagnosis using single cell analysis |
| US11061018B2 (en) | 2016-10-12 | 2021-07-13 | Pattern Bioscience, Inc. | Compositions and methods for disease diagnosis using single cell analysis |
| US11959910B2 (en) | 2016-10-12 | 2024-04-16 | Pattern Bioscience, Inc. | Compositions and methods for disease diagnosis using single cell analysis |
| US10488405B2 (en) | 2016-10-12 | 2019-11-26 | Klaris Corporation | Compositions and methods for disease diagnosis using single cell analysis |
| US20210324238A1 (en) * | 2017-07-10 | 2021-10-21 | Entegris, Inc. | Hard abrasive particle-free polishing of hard materials |
| US11820918B2 (en) * | 2017-07-10 | 2023-11-21 | Entegris, Inc. | Hard abrasive particle-free polishing of hard materials |
| US20190010356A1 (en) * | 2017-07-10 | 2019-01-10 | Sinmat, Inc. | Hard abrasive particle-free polishing of hard materials |
| US11078380B2 (en) * | 2017-07-10 | 2021-08-03 | Entegris, Inc. | Hard abrasive particle-free polishing of hard materials |
| CN111094482A (en) * | 2017-07-10 | 2020-05-01 | 辛麦特有限公司 | Hard abrasive particle-free polishing of hard materials |
| US12036556B2 (en) | 2018-04-16 | 2024-07-16 | Pattern Bioscience, Inc. | Methods and apparatus for forming 2-dimensional drop arrays |
| US11465148B2 (en) | 2018-04-16 | 2022-10-11 | Pattern Bioscience, Inc. | Methods and apparatus for forming 2-dimensional drop arrays |
| US11344890B2 (en) | 2018-10-22 | 2022-05-31 | Pattern Bioscience, Inc. | Vacuum-loaded, droplet-generating microfluidic chips and related methods |
| US11305284B2 (en) | 2018-11-26 | 2022-04-19 | Tokitae, LLC | Determining a bulk concentration of a target in a sample using a digital assay with compartments having nonuniform volumes |
| US12128415B2 (en) | 2020-04-24 | 2024-10-29 | Pattern Bioscience, Inc. | Apparatuses for contactless loading and imaging of microfluidic chips and related methods |
| US10953404B1 (en) | 2020-04-24 | 2021-03-23 | Pattern Bioscience, Inc. | Apparatuses for contactless loading and imaging of microfluidic chips and related methods |
| WO2022235284A1 (en) * | 2021-05-05 | 2022-11-10 | The University Of Chicago | Rapid enumeration of microorganisms |
| CN116948816A (en) * | 2023-06-06 | 2023-10-27 | 仲恺农业工程学院 | A superoxide dismutase resistance detection device and method |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009048673A3 (en) | 2009-10-22 |
| US20100317085A1 (en) | 2010-12-16 |
| WO2009015390A2 (en) | 2009-01-29 |
| WO2009015390A3 (en) | 2009-04-23 |
| US20160145558A1 (en) | 2016-05-26 |
| US11661577B2 (en) | 2023-05-30 |
| US9090885B2 (en) | 2015-07-28 |
| US20190218497A1 (en) | 2019-07-18 |
| US10202571B2 (en) | 2019-02-12 |
| WO2009048673A2 (en) | 2009-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100227767A1 (en) | Stochastic confinement to detect, manipulate, and utilize molecules and organisms | |
| Sun et al. | A simple and rapid colorimetric bacteria detection method based on bacterial inhibition of glucose oxidase-catalyzed reaction | |
| Kirsch et al. | Biosensor technology: recent advances in threat agent detection and medicine | |
| He et al. | Laser-patterned paper-based sensors for rapid point-of-care detection and antibiotic-resistance testing of bacterial infections | |
| Fernandes et al. | A bacteriophage detection tool for viability assessment of Salmonella cells | |
| Chen et al. | An optical biosensor using immunomagnetic separation, urease catalysis and pH indication for rapid and sensitive detection of Listeria monocytogenes | |
| US10620200B2 (en) | Methods and compositions for hybrid microfluidic devices integrated with nano-biosensors | |
| O’Brien et al. | The electrochemical detection of bioterrorism agents: a review of the detection, diagnostics, and implementation of sensors in biosafety programs for Class A bioweapons | |
| Shanker et al. | Nanotechnology and detection of microbial pathogens | |
| CA2811493C (en) | Method for separating target molecules or particles from fibrinogen-containing samples including blood components | |
| Wu et al. | Trace detection of specific viable bacteria using tetracysteine-tagged bacteriophages | |
| Wijesinghe et al. | FRET-based single-molecule detection of pathogen protein IsdA using computationally selected aptamers | |
| Sivakumar et al. | Quercetin-mediated silver nanoparticle formation for the colorimetric detection of infectious pathogens coupled with loop-mediated isothermal amplification | |
| Pham et al. | Electrochemical aptasensor for pathogenic bacteria detection | |
| Latka et al. | Optimization of propidium monoazide qPCR (viability-qPCR) to quantify the killing by the gardnerella-specific endolysin PM-477, directly in vaginal samples from women with bacterial vaginosis | |
| Yang et al. | Employment of the phage cocktail as a species-specific recognition agent for wide-spectrum detection of bacterial strains | |
| Singh et al. | Wastewater-borne viruses and bacteria, surveillance and biosensors at the interface of academia and field deployment | |
| Choinière et al. | Binding strategies for capturing and growing Escherichia coli on surfaces of biosensing devices | |
| Trinh et al. | Nucleic acid amplification-based microfluidic approaches for antimicrobial susceptibility testing | |
| Bokhari | Exploitation of microbial forensics and nanotechnology for the monitoring of emerging pathogens | |
| Starodub et al. | Efficiency of instrumental analytical approaches at the control of bacterial infections in water, foods and feeds | |
| WO2012154734A1 (en) | System for detecting and enumerating biological particles | |
| Tekintas et al. | Nanozymes-based detection of clinically important pathogens | |
| Rani et al. | Detection and removal of pathogenic bacteria from wastewater using various nanoparticles | |
| Suaifan et al. | Magnetic Nanobead Paper-Based Biosensors for Colorimetric Detection of Candida albicans |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: THE UNIVERSITY OF CHICAGO, ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ISMAGILOV, RUSTEM;BOEDICKER, JAMES;KIM, HYUN JUNG;AND OTHERS;SIGNING DATES FROM 20100617 TO 20100721;REEL/FRAME:024732/0676 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |